<SEC-DOCUMENT>0001193125-19-125776.txt : 20190429
<SEC-HEADER>0001193125-19-125776.hdr.sgml : 20190429
<ACCEPTANCE-DATETIME>20190429172904
ACCESSION NUMBER:		0001193125-19-125776
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20190625
FILED AS OF DATE:		20190429
DATE AS OF CHANGE:		20190429
EFFECTIVENESS DATE:		20190429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		19777290

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d734420ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant
&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744;
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>EyePoint Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g734420g33q91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">480 Pleasant Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Watertown, MA 02472 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">United States
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My Fellow Stockholders, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is my pleasure to invite you to the annual meeting of stockholders of EyePoint Pharmaceuticals, Inc., or the Company, which will be held on
Tuesday, June&nbsp;25, 2019 at 9:00 a.m. U.S. Eastern Time at EyePoint&#146;s Corporate Headquarters, 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472, in order to vote on the proposals disclosed in the accompanying proxy statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calendar year 2018 was transformational for our Company as we executed on our strategy to become a fully-integrated, specialty
biopharmaceutical company with two products commercially launched for the treatment of ocular diseases. As part of our Company transition, in March 2018 we rebranded to EyePoint Pharmaceuticals, Inc. to highlight our progression from a research and
development driven clinical-stage organization into an emerging, commercial-stage specialty pharmaceutical company focused on advancing our innovative ophthalmic products for serious eye disorders. We also changed our fiscal <FONT
STYLE="white-space:nowrap">year-end</FONT> date from June&nbsp;30 to December 31. As a result, you will see references throughout the accompanying proxy statement to the Company&#146;s <FONT STYLE="white-space:nowrap">six-month</FONT> transition
period ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercially available product portfolio includes DEXYCU<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (dexamethasone intraocular suspension) 9%, which was added to our portfolio through the acquisition of Icon Bioscience, Inc. in March 2018, and utilizes our proprietary Verisome<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>sustained release technology. DEXYCU is a U.S. Food and Drug Administration, or FDA, approved ophthalmic product indicated for the treatment
of postoperative inflammation, and is administered as a single dose following surgery. Cataract surgery is the most common surgical procedure performed in the U.S., with approximately 4.8&nbsp;million surgeries completed in 2018 alone. The current
standard of care to treat inflammation post-cataract surgery is to administer steroid drops titrated over three to four weeks. This treatment regimen can be burdensome to cataract surgery patients, who tend to be elderly and can suffer from other
medical conditions such as mild cognitive impairment or osteoarthritis in the hands, making compliance difficult. DEXYCU has the potential to address the limitations of the current standard of care for patients by providing a convenient,
long-lasting, single-dose injection immediately following cataract surgery. Reimbursement for DEXYCU has been secured by The Centers for Medicare and Medicaid Services, or CMS, through its issuance of a specific and permanent <FONT
STYLE="white-space:nowrap">J-code.</FONT> The Company retains transitional pass-through status for DEXYCU from CMS for three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
second commercial product is YUTIQ<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (fluocinolone acetonide intravitreal implant) 0.18 mg, a three-year intravitreal micro-insert for the treatment of chronic
<FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis affecting the posterior segment of the eye, the third leading cause of blindness in the U.S. YUTIQ is derived from our proprietary
DURASERT<SUP STYLE="font-size:85%; vertical-align:top">TM </SUP>sustained-release technology platform that has been licensed previously to several companies, including Alimera Sciences and Bausch&nbsp;&amp; Lomb, which have developed or marketed
products utilizing the DURASERT technology. We believe YUTIQ addresses the high unmet need for treatment options that last longer than the current standard of care and that offer the ease of physician office administration. YUTIQ provides patients
with a therapeutic alternative that delivers a consistent micro dosing for up to a three-year period. Extended and consistent drug delivery is an important element to the treatment of posterior segment uveitis as it helps prevent inflammatory
uveitis eye flares, which can lead to blindness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since launching both products in the first quarter of 2019, our <FONT
STYLE="white-space:nowrap">44-person</FONT> salesforce (10 for YUTIQ and 34 for DEXYCU) have been successfully trained and are active across the U.S. targeting high-volume surgery </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
centers and cataract surgeons for DEXYCU and uveitis and retinal specialists for YUTIQ. The DEXYCU launch has been strategically staged to ensure both appropriate initial training for the
physicians and other members of the ambulatory surgical centers and adherence to best practices when administering drugs or new medical devices in the surgical suite. Our sales efforts have been supported by our robust medical education initiatives
and medical science liaison team that continues to expand our presence at key congresses, as well as to proactively plan publications for continued data flow to the greater medical community. We are pleased by the increased interest for both of our
products from the greater ophthalmology community of physicians and patients and look forward to providing further progress updates throughout 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From a corporate standpoint, we made several critical management and Board of Directors appointments to ensure the success of our
commercialization planning and ongoing product launches. Key new hires in 2018 included David Price, Chief Financial Officer, Dr.&nbsp;John&nbsp;J. Weet, Senior Vice President of Regulatory Affairs&nbsp;&amp; Quality, Ron Honig, Esq., Senior Vice
President, General Counsel&nbsp;&amp; Company Secretary, and other professionals in sales, marketing, manufacturing and medical affairs positions to support our launch efforts. We have also strengthened our Board of Directors with the appointment of
Dr.&nbsp;G&ouml;ran Ando, the former Chairman of the Board of Novo Nordisk A/S, who was also named our Chairman of the Board in September 2018 to help guide the Company through this next phase of growth. We were also privileged to welcome Ron
Eastman, Managing Director of EW Healthcare Partners, Dr.&nbsp;John Landis, a former executive at Schering-Plough Corporation and Dr.&nbsp;David Guyer, Executive Chairman of IVERIC bio, Inc. (formerly known as Ophthotech Corporation), as additional
members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am tremendously proud of the accomplishments our Company and team have made this year. A special thank you is
warranted to our dedicated employees who have helped lead our organization through a transformational year and the momentous milestones for our pipeline of ophthalmic products. It is only through the combined efforts of all of us that we can bring
to market innovative ophthalmology products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, I would also like to thank you, our stockholders, for your continued support
through our major transition into a specialty pharmaceutical company. We plan to build on this momentum as we enter a new period of growth. I look forward to keeping you updated on our progress and milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In connection with this annual meeting, all stockholders are cordially invited to attend the meeting in person. Whether or not you expect
to attend the meeting, we urge you to submit your voting instructions as soon as possible so that your shares can be voted at the meeting in accordance with your instructions. For specific instructions on voting, please refer to the instructions on
the stockholder meeting notice. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Instead of mailing a printed copy of our proxy materials (including our Transition Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018) to each stockholder of record, we have decided to provide access to these materials via the Internet. This delivery method reduces the amount of paper necessary
to produce these materials, as well as the costs associated with printing and mailing these materials to all stockholders. Accordingly, on or about May&nbsp;10, 2019, we will have commenced the mailing of a Notice of Internet Availability of Proxy
Materials, or the Notice, to all stockholders of record as of April&nbsp;26, 2019. As explained in greater detail in the Notice, all stockholders may access our proxy materials on our website or may request a printed set of our proxy materials. In
addition, the Notice and website provide information on how to request to receive all future proxy materials in printed form or electronically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be Held on June&nbsp;25, 2019: This proxy
statement and our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 are available on the following websites: www.edocumentview.com/EYPT for street holders and
www.envisionreports.com/EYPT for registered holders. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Whether or not you plan to attend the meeting, your vote is very important
and we encourage you to vote promptly and affirmatively for the proposals. As a Delaware corporation and under our bylaws, a</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>minimum of <FONT STYLE="white-space:nowrap">one-third</FONT> of our outstanding shares of common stock must be present in person or represented by proxy at the meeting in order for the meeting
to be considered valid.</B> You may vote your shares online, by telephone or by mailing a completed proxy card if you elect to receive the proxy materials by mail. Instructions regarding each method of voting are provided on the stockholder meeting
notice. If you hold your shares through an account with a brokerage firm, bank or other nominee, please follow the instructions you receive from them to vote your shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g734420g08i61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nancy Lurker </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and
Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter to stockholders includes &#147;forward-looking statements&#148; within the meaning of the &#147;safe
harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements. Among the factors that could cause actual
results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: our ability to
achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the
U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the regulatory approval and successful release of our YUTIQ line extension shorter-acting
treatment for <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis affecting the posterior segment of the eye; potential <FONT STYLE="white-space:nowrap">off-label</FONT> sales of ILUVIEN for
<FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful
commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera&#146;s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME;
Alimera&#146;s ability to commercialize ILUVIEN for <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis affecting the posterior segment of the eye in its licensed territories; potential declines in Retisert royalties; our ability to
market and sell products; the success of current and future license agreements; termination or breach of current license agreements; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects
of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of
key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other
factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors,
including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider
any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in such statements will not be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g734420g33q91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD JUNE&nbsp;25, 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that the 2019 Annual Meeting of Stockholders, or the Annual Meeting, of EyePoint Pharmaceuticals, Inc., or the Company, will be held on
Tuesday, June&nbsp;25, 2019, at 9:00 a.m., local time, at the Company&#146;s Corporate Headquarters, 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472, for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect nine directors to the Company&#146;s Board of Directors, each to serve until the Company&#146;s 2020
Annual Meeting of Stockholders or until such person&#146;s successor is duly elected and qualified. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan to increase the
number of shares authorized for issuance thereunder by 11,000,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the
accompanying proxy statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our
named executive officers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the meeting or any adjournment or postponement of
the Annual Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors recommends that stockholders vote <B><U>FOR ALL</U></B> on Proposal
No.&nbsp;1, <B><U>FOR</U></B> Proposal Nos. 2, 3, 4 and 6 and <B><U>1 YEAR</U></B> on Proposal No.&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders of record at the close of
business on April&nbsp;26, 2019, the record date of the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement of the meeting. A list of stockholders as of the record date will be available
for stockholder inspection at the Annual Meeting and at the Company&#146;s executive offices at 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472 during normal business hours from April&nbsp;26, 2019 to the date of the Annual Meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important notice regarding the availability of proxy materials for the Annual Meeting to be held on June</B><B></B><B>&nbsp;25, 2019</B>. Our 2019
Proxy Statement and Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered
holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement includes further details with respect to the proposals to be considered at the Annual Meeting. This notice of
Annual Meeting and the accompanying proxy statement contain important information and should be read in their entirety. If you are in doubt as to how you should vote at the Annual Meeting, you should seek advice from your legal counsel, accountant
or other professional adviser prior to voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:54%; text-indent:-2%">


<IMG SRC="g734420g85m10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ron Honig </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SVP, General Counsel and Company Secretary </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown, Massachusetts </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_1">QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_2">DIRECTORS AND EXECUTIVE OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_3">CORPORATE GOVERNANCE AND BOARD MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_4">STOCK OWNERSHIP</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_5">EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_6">PROPOSAL 1: ELECTION OF NINE DIRECTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_7">PROPOSAL 2: AMENDMENT TO 2016 LONG-TERM INCENTIVE PLAN TO INCREASE THE NUMBER
 OF SHARES AUTHORIZED FOR ISSUANCE</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_8">PROPOSAL 3: ADOPTION OF EMPLOYEE STOCK PURCHASE PLAN</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_9">PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_10">PROPOSAL 5: ADVISORY VOTE ON FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE
 COMPENSATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_11">PROPOSAL 6: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
 FIRM</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_12">INFORMATION ABOUT STOCKHOLDER PROPOSALS AND DIRECTOR
NOMINATIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_13">DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN
ADDRESS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_14">AVAILABILITY OF TRANSITION REPORT ON FORM <FONT
STYLE="white-space:nowrap">10-K</FONT></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_15">OTHER BUSINESS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_16">ANNEX A: AMENDMENT NO. 1 TO EYEPOINT PHARMACEUTICALS,&nbsp;
INC. 2016 LONG TERM INCENTIVE PLAN AND EYEPOINT PHARMACEUTICALS, INC. 2016 LONG TERM INCENTIVE PLAN</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc734420_17">ANNEX B. EYEPOINT PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this
proxy statement, the words &#147;EyePoint,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;ours,&#148; &#147;us&#148; and similar terms refer to EyePoint Pharmaceuticals, Inc. and its consolidated subsidiaries, unless the
context indicates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Notice of 2019 Annual Meeting of Stockholders and Proxy Statement and our accompanying Transition Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> are being distributed and made available on or about May&nbsp;10, 2019. </I></B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g734420g33q91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_1"></A>QUESTIONS AND ANSWERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE PROXY
MATERIALS AND VOTING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Materials </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why am I receiving these proxy materials? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors (Board) has made these proxy materials available to you on the Internet, or, upon your request, has delivered a printed or email copy of
these proxy materials to you, in connection with its solicitation of proxies for use at our 2019 Annual Meeting of Stockholders (Annual Meeting), which will take place on June&nbsp;25, 2019 at 9:00 a.m., local time, at the Company&#146;s Corporate
Headquarters, 480 Pleasant Street, Suite A210, Watertown, MA 02472. We began sending the Notice of Internet Availability of Proxy Materials (Notice) on or about May&nbsp;10, 2019. You received proxy materials because you owned shares of EyePoint
common stock at the close of business on April&nbsp;26, 2019 (the Record Date), and that entitles you to vote at the Annual Meeting. These proxy materials describe the matters on which our Board of Directors would like you to vote and contain
information that we are required to provide to you under the rules of the U.S. Securities and Exchange Commission (SEC) when we solicit your proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE&nbsp;25, 2019. Our 2019 Proxy Statement and
Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is included in the proxy materials? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy
materials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Notice of 2019 Annual Meeting of Stockholders and Proxy Statement (Proxy Statement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended
December&nbsp;31, 2018 (Transition Report); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if you requested a printed or email copy of these proxy materials, the proxy or voting instruction card that
accompanied these materials. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What information is contained in this Proxy Statement and our Transition Report on Form <FONT
STYLE="white-space:nowrap">10-K?</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Proxy Statement relates to the proposals to be voted on at the Annual Meeting, the
voting process, the compensation of our directors and certain of our executive officers, corporate governance matters, and certain other required information. Our Transition Report contains information about our business, our audited financial
statements and other important information that we are required to disclose under the rules of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice in the mail
regarding the Internet availability of proxy materials instead of a full set of proxy materials? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with SEC rules, we may furnish proxy
materials, including this Proxy Statement and our Transition Report, to our stockholders by providing access to such documents on the Internet instead of mailing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
printed copies. Most stockholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice will instruct you as to how you may access and review all of
the proxy materials on the Internet. The Notice also instructs you as to how you may submit your proxy or voting instructions on the Internet. If you would like to receive a paper or email copy of the proxy materials, you should follow the
instructions in the Notice for requesting such materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I access the proxy materials over the Internet? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notice and, if you requested to receive a printed or email copy of these proxy materials, the proxy or voting instruction card that accompanied these
materials, contains instructions on how to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">view the proxy materials for the Annual Meeting on the Internet and vote your shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instruct us to send our future proxy materials to you electronically by email. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proxy materials are also available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Choosing to receive your future proxy materials by email will save us the cost of printing and mailing documents to you. If you choose to receive future proxy
materials by email, you will receive an email next year with instructions containing a link to those materials and a link to the proxy voting site. Your election to receive proxy materials by email will remain in effect until you revoke it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What items of business will be voted on at the
Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The items of business scheduled to be voted on at the Annual Meeting are: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal&nbsp;No.&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To elect nine members of our Board of Directors, each to serve until our 2020&nbsp;Annual Meeting of Stockholders or until such person&#146;s successor is duly elected and qualified.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To approve an amendment to our 2016 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance by 11,000,000.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To approve the adoption of our 2019 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Proposal No.&nbsp;4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To approve, on an advisory basis, the compensation paid to our named executive officers, as described in this proxy statement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers. </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;6:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the <I>&#147;Proposals&#148;</I> section of this Proxy Statement for information on these proposals. We will also consider
any other business that is properly brought before the Annual Meeting or any adjournments or postponements thereof. See <I>&#147;What happens if additional matters are presented at the Annual Meeting?&#148;</I> below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How does the Board of Directors recommend that I vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board recommends that you vote your shares as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Board<BR>Recommendation</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The election of nine members of our Board of Directors, each to serve until our 2020 Annual Meeting of Stockholders or until such person&#146;s successor is duly elected and qualified.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>FOR ALL</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The approval of an amendment to our 2016 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance by 11,000,000.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>FOR</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;3:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The approval of the adoption of our 2019 Employee Stock Purchase Plan.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>FOR</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal&nbsp;No.&nbsp;4:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The&nbsp;approval,&nbsp;on&nbsp;an&nbsp;advisory&nbsp;basis,&nbsp;of&nbsp;the&nbsp;compensation&nbsp;paid&nbsp;to&nbsp;our named&nbsp;executive&nbsp;officers,&nbsp;as&nbsp;described&nbsp;in&nbsp;this&nbsp;proxy&nbsp;statement.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>FOR</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;5:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>1 YEAR</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposal No.&nbsp;6:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>FOR</U></B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the <I>&#147;Proposals&#148;</I> section of this Proxy Statement for information on these proposals and
our Board&#146;s recommendations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if additional matters are presented at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the six items of business described in this Proxy Statement, we are not aware of any other business to be acted upon at the Annual Meeting. If you
grant a proxy, the persons named as proxy holders, Nancy S. Lurker, President and Chief Executive Officer, and Ron I. Honig, Senior Vice President, General Counsel and Company Secretary, or either of them, will have the discretion to vote your
shares on any additional matters properly presented for a vote at the Annual Meeting or any adjournments or postponements thereof. If, for any reason, any of the director nominees is not available as a candidate for director, the persons named as
proxy holders will vote your proxy for such other candidate or candidates as may be nominated by our Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were 106,105,728 shares of common stock issued and outstanding as of the close of business on the Record Date. Each share of our common stock
that you own as of the Record Date entitles you to one vote on each matter presented at the Annual Meeting. Cumulative voting for directors is not permitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the difference between holding shares as a &#147;stockholder of record&#148; as compared to as a &#147;beneficial owner&#148;? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of our stockholders hold their shares as a beneficial owner through a broker, bank, trust or other nominee rather than directly in their own name. As
summarized below, there are some distinctions between shares held of record and those owned beneficially. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Stockholder of Record:</B> If your shares are registered directly in your name with our transfer agent,
Computershare Trust Company N.A., you are considered, with respect to those shares, the stockholder of record. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote in person at the Annual Meeting. If
you do not wish to vote in person or you will not be attending the Annual Meeting, you may vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of the these proxy
materials, you can also vote by telephone or mail by following the instructions contained in the proxy card that accompanied these materials See <I>&#147;How can I vote my shares without attending the Annual Meeting?&#148;</I> below.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Beneficial Owner:</B> If your shares are held through a broker, bank, trust or other nominee, like the
majority of our stockholders, you are considered the beneficial owner of shares held in street name, and the Notice was forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for
purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to direct your broker, bank, trustee, or other nominee how to vote the shares in your account. Since a beneficial owner is not the stockholder of record, you may
not vote your shares in person at the Annual Meeting unless you obtain a &#147;legal proxy&#148; from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares at the Annual Meeting. If you do not
wish to vote in person or you will not be attending the Annual Meeting, you may vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of these proxy materials, you can also
vote by telephone or by mail by following the instructions on the voting instruction card provided to you by your broker, bank, trustee, or other nominee. See <I>&#147;How can I vote my shares without attending the Annual Meeting?&#148;</I> below.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I vote my shares in person at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote your shares held in your name as the stockholder of record in person at the Annual Meeting. You may vote your shares held beneficially in street
name in person at the Annual Meeting only if you obtain a legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting, we recommend that you also
submit your proxy or voting instructions as described below so that your vote will be counted if you later decide not to attend the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I vote my shares without attending the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct how your shares are voted without attending the
Annual Meeting. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Stockholder of Record:</B> If you are a stockholder of record, you may vote by proxy. You can vote by proxy
over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of these proxy materials, you can also vote by telephone or mail by following the instructions on the proxy card that accompanied
these materials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Beneficial Owner:</B> If you hold shares beneficially in street name, you may also vote by proxy over the
Internet by following the instructions provided in the Notice, or, if you requested to receive a printed or email copy of these proxy materials, you can also vote by telephone or mail by following the instructions on the voting instruction card
provided to you by your broker, bank, trustee, or other nominee. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote or revoke my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are the stockholder of record, you may change your vote at any time prior to the taking of the vote at the Annual Meeting by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">granting a new proxy bearing a later date by following the instructions provided in the Notice or, if you
requested to receive a printed or email copy of these proxy materials, the proxy card that accompanied these materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing a written notice of revocation to our Company Secretary at 480 Pleasant Street, Suite A210, Watertown,
MA 02472, which notice must be received by our Company Secretary before the Annual Meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending the Annual Meeting and voting in person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold shares beneficially in street name, you may change your vote by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submitting new voting instructions to your broker, bank, trustee, or other nominee by following the instructions
provided in the voting instruction card that accompanied these proxy materials; or, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if you have obtained a valid legal proxy from your broker, bank, trustee, or other nominee giving you the right
to vote your shares, by attending the Annual Meeting and voting in person using the valid legal proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that for both stockholders
of record and beneficial owners, attendance at the Annual Meeting will not cause your previously granted proxy or voting instructions to be revoked unless you specifically so request or vote in person at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Is my vote confidential? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxy instructions, ballots,
and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within our Company or to third parties, except: (1)&nbsp;as necessary to meet applicable
legal requirements, (2)&nbsp;to allow for the tabulation of votes and certification of the vote, and (3)&nbsp;to facilitate a successful proxy solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is a &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;?</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held by a broker, bank, trust or other nominee and you do not provide your broker, bank, trustee or other nominee with
voting instructions, your shares may constitute &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;.</FONT> Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur on a matter when the broker, bank, trustee or other nominee is not
permitted under applicable stock exchange rules to vote on that matter without instructions from the beneficial owner and instructions are not given. These matters are referred to as <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT>
matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposal Nos. 1 to 5 are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters, while Proposal No.&nbsp;6 to ratify
the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2019 is considered a &#147;routine&#148; matter. Therefore, if you are a beneficial owner of shares held in
street name and do not provide voting instructions, your shares will not be voted on Proposal Nos. 1 to 5, and a broker <FONT STYLE="white-space:nowrap">non-vote</FONT> will occur on this matter. In tabulating the voting result for any particular
proposal, shares that constitute broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are not considered voting power present with respect to that proposal. Thus, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not affect the
outcome of any matter being voted on at the Annual Meeting, assuming that a quorum is obtained. Because Proposal No.&nbsp;6 is a &#147;routine&#148; matter, a broker, bank, trustee or other nominee will be permitted to exercise its discretion on
this proposal, which means there will be no broker <FONT STYLE="white-space:nowrap">non-votes</FONT> on this matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many shares must be present
or represented to conduct business at the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;quorum&#148; is necessary to conduct business at the Annual Meeting. A quorum is
established if the holders of <FONT STYLE="white-space:nowrap">one-third</FONT> of all shares issued and outstanding and entitled to vote at the Annual Meeting are present at the Annual Meeting, either in person, by means of remote communication in
a manner, if any, authorized by the Board of Directors in its sole discretion or represented by proxy. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted as present for purposes of determining a quorum at the
Annual Meeting. If a quorum is not present, the Annual Meeting will be adjourned until a quorum is obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are the voting requirements to
approve the proposals discussed in this Proxy Statement? </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;1: Election of nine directors to the Board.</B> Votes may be cast: <U>FOR
ALL</U> nominees, <U>WITHHOLD ALL</U> nominees or <U>FOR ALL EXCEPT</U> those nominees noted by you on the appropriate portion of your proxy or voting instructions. A plurality of the votes of the shares present in person or represented by proxy at
the Annual Meeting is required to elect director nominees, and as such, the nine nominees who receive the greatest number of votes cast by stockholders entitled to vote on the matter will be elected. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of this proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;2: Approve an amendment to the EyePoint Pharmaceuticals, Inc. 2016 Long-Term
Incentive Plan (2016 Plan) to increase the number of shares reserved under the 2016 Plan by 11,000,000 shares. </B>Votes may be cast: <U>FOR</U>, <U>AGAINST</U> or <U>ABSTAIN</U>. The approval of this Proposal No.&nbsp;2 requires the affirmative
vote of a majority of the votes properly cast on the matter. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of this proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;3: Approve the adoption of the EyePoint Pharmaceuticals, Inc. 2019 Employee
Stock Purchase Plan. </B>Votes may be cast: <U>FOR</U>, <U>AGAINST</U> or <U>ABSTAIN</U>. The approval of this Proposal No.&nbsp;3 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of this proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;4</B>: <B>Approve, on an advisory basis, the compensation paid to our named
executive officers as disclosed in this proxy statement. </B>Votes may be cast: <U>FOR</U>, <U>AGAINST</U> or <U>ABSTAIN</U>. The approval of this Proposal No.&nbsp;4 requires the affirmative vote of a majority of the votes properly cast on the
matter. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of this proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;5</B>: <B>Vote, on an advisory basis, on the frequency of advisory stockholder
votes on the compensation paid to our named executive officers. </B>Votes may be cast: <U>1 YEAR</U>, <U>2 YEARS</U>, <U>3</U> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<U>YEARS</U> or <U>ABSTAIN</U>. The approval of this Proposal No.&nbsp;5 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of this proposal. As stockholders have several voting choices with respect to this proposal, it is possible that no single choice will receive a majority
vote. In light of the foregoing, the Board of Directors will consider the outcome of the vote when determining the frequency of future advisory votes on executive compensation. Moreover, because this vote is
<FONT STYLE="white-space:nowrap">non-binding,</FONT> the Board may determine the frequency of future advisory votes on executive compensation in its discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;6: Ratification of the appointment of Deloitte</B><B></B><B>&nbsp;&amp; Touche
LLP as our independent registered public accounting firm for the fiscal year ending December</B><B></B><B>&nbsp;31, 2019</B>. Votes may be cast: <U>FOR</U>, <U>AGAINST</U> or <U>ABSTAIN</U>. The approval of this Proposal No.&nbsp;6 requires the
affirmative vote of a majority of the votes properly cast on the matter. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not occur in connection with this proposal because brokers, banks, trustees and other nominees have discretionary
voting authority to vote shares on the ratification of independent registered public accounting firms under stock exchange rules without specific instructions from the beneficial owner of such shares. Abstentions will have no effect on the outcome
of this proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who will bear the cost of soliciting votes for the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay the entire cost of preparing, assembling, printing, mailing and distributing these proxy materials and soliciting votes. Our directors, officers
and employees may solicit proxies or votes in person, by telephone or by electronic communication. We will not pay our directors, officers or employees any additional compensation for these services. We will ask brokers, banks, trustees and other
nominees to forward the proxy materials to their principals and to obtain authority to execute proxies and will reimburse them for certain costs in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who will count the votes? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Votes will be counted by the
inspector of election appointed for the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where can I find the voting results of the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will announce preliminary voting results at the Annual Meeting and disclose the final voting results in a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that we will file with the SEC within four business days of the Annual Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the Annual Meeting </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I attend the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are entitled to
attend the Annual Meeting only if you were an EyePoint Pharmaceuticals, Inc. stockholder as of the Record Date (April 26, 2019), or you hold a valid legal proxy from a stockholder of record for attending or voting at the Annual Meeting. You must
present valid government-issued photo identification, such as a driver&#146;s license or passport, for admittance. If you are not a stockholder of record but hold shares as a beneficial owner in street name, you must also provide proof of beneficial
ownership as of the Record Date, such as your most recent account statement prior to April&nbsp;26, 2019, a copy of the voting instruction card provided by your broker, bank, trustee, or other nominee, or other similar evidence of ownership. If you
do not provide photo identification or comply with the other procedures outlined above, you will not be admitted to the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please let us
know if you plan to attend the Annual Meeting by indicating your plans when prompted if you vote by Internet or telephone or, if you vote by mail, by marking the appropriate box on your proxy or voting instruction card. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Meeting will begin promptly at 9:00 a.m., local time. <FONT STYLE="white-space:nowrap">Check-in</FONT> will begin at 8:30 a.m., local time, and you
should allow ample time for the <FONT STYLE="white-space:nowrap">check-in</FONT> procedures. The Corporate Headquarters of EyePoint Pharmaceuticals, Inc. are located at 480 Pleasant Street, Suite A210, Watertown, MA 02472. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc734420_2"></A>DIRECTORS AND EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors consists of ten
(10)&nbsp;directors. The term of each director expires each year at our Annual Meeting of Stockholders. Each director also continues to serve as a director until his or her successor is duly elected and qualified, or until he or she sooner dies,
resigns, or is removed. Michael Rogers will not stand for <FONT STYLE="white-space:nowrap">re-election</FONT> at our 2019 Annual Meeting but will continue to serve as a director until the expiration of his term at the 2019 Annual Meeting. The size
of the Board of Directors will be reduced to nine (9)&nbsp;as of the 2019 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age, director service
period and position of each of our current directors as of April&nbsp;26, 2019 other than Michael Rogers, who will not stand for <FONT STYLE="white-space:nowrap">re-election</FONT> at our 2019 Annual Meeting: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director&nbsp;Since</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#246;ran Ando, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Lurker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Mazzo, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Godshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2012</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Duker, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald W. Eastman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John B. Landis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Guyer, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2019</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below for each current director standing for election at the 2019 Annual Meeting is a list of Board Committee
memberships and a description of his or her business experience, qualifications, education and skills that led our Board to conclude that such individual should serve as a member of our Board: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G&ouml;ran Ando, M.D. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board and member
of the Science Committee and the Governance and Nominating Committee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;G&ouml;ran Ando has had a distinguished career in the global pharmaceutical
industry that has spanned nearly four decades. He began his career at Pfizer, Inc., where he held several senior clinical positions both in the U.S. and in Europe. Dr.&nbsp;Ando also served as President of the Astra Research Centre. He held various
senior appointments at GlaxoSmithKline plc, including Research and Development Director for Glaxo Group Research. Dr.&nbsp;Ando then joined Pharmacia AB in 1995 as Executive Vice President and Deputy Chief Executive Officer to lead Research and
Development with additional responsibilities for manufacturing, information technology, business development and M&amp;A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia&nbsp;&amp; Upjohn, 17 new drugs were
approved by the FDA prior to Pharmacia&#146;s acquisition by Pfizer for $60&nbsp;billion. Dr.&nbsp;Ando is the retired Chairman of Novo Nordisk A/S and previously served as the Chief Executive Officer of Cell Tech Group PLC. He has also served as
Chairman of the Board for several European-based biopharmaceutical companies and he currently serves as a Board member of biopharmaceutical companies in Europe, U.S. and Singapore. He is a Senior Advisor at EW Healthcare Partners. Dr.&nbsp;Ando
received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Link&ouml;ping University in Sweden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe
Dr.&nbsp;Ando is qualified to serve as Chair of our Board because his strong record of leadership as an executive officer and director in the life sciences industry affords him a deep understanding of the industry and corporate setting in which we
operate and allows him to impart his substantial expertise in the fields of manufacturing, information technology, business development and commercialization to the Board and our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Lurker </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;and Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Lurker has
been our President and Chief Executive Officer since September 2016. From 2008 to 2015, Ms.&nbsp;Lurker served as President and Chief Executive Officer and a director of PDI, Inc., a Nasdaq-listed healthcare commercialization company now named
Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms.&nbsp;Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. From 2003 to 2006, she served as President and
Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. From 1998 to 2003, Ms.&nbsp;Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia
Corporation (Pharmacia), now a part of Pfizer, Inc. She also served as a member of Pharmacia&#146;s U.S. executive management committee. Previously, Ms.&nbsp;Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative
to Senior Director, Worldwide Cardiovascular Franchise Management. Since April 2018, Ms.&nbsp;Lurker has served as a member of the board of directors of Aquestive Therapeutics, a Nasdaq-listed company. Ms.&nbsp;Lurker also serves as chair of the
board of directors of X4 Pharmaceuticals, Inc. and as a member of the board of directors of the Cancer Treatment Centers of America, both privately held companies. Ms.&nbsp;Lurker previously served as a member of the boards of directors of publicly
held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 and Mallinckrodt Pharmaceuticals, plc from 2013 to 2016, in addition to serving as a director of PDI, Inc. from 2008 to 2015. Ms.&nbsp;Lurker received a B.S. in Biology from Seattle Pacific
University and an M.B.A. from the University of Evansville. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&nbsp;Lurker is qualified to serve on our Board because of her role as our
President and Chief Executive Officer, as well as her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies and successfully implementing innovative U.S. and global drug launches,
which provide her with valuable expertise and perspective on our corporate strategy, management, operations and governance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David J. Mazzo, Ph.D.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Compensation Committee and member of the Audit Committee and the Science Committee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mazzo has been the Chief Executive Officer and a director of Caladrius Biosciences, Inc., a Nasdaq Stock Market LLC, or Nasdaq, listed company, since
January 2015. Caladrius is a cell therapeutics development company with a focus on applications in cardiovascular and autoimmune diseases. Prior to joining Caladrius, Dr.&nbsp;Mazzo served from August 2008 to October 2014 as Chief Executive Officer
and as a member of the board of directors of Regado Biosciences, Inc., a Nasdaq-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute <FONT STYLE="white-space:nowrap">and&nbsp;sub-acute</FONT>
cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr.&nbsp;Mazzo was President, Chief Executive Officer and a director of &AElig;terna Zentaris, Inc., a publicly held international biopharmaceutical company <FONT
STYLE="white-space:nowrap">co-listed</FONT> on Nasdaq and the Toronto Stock Exchange. From 2003 until 2007, Dr.&nbsp;Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was
the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr.&nbsp;Mazzo has also held senior management and executive positions in research and development and/or directorships with the Essex Chimie European subsidiary at Schering-Plough
Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck&nbsp;&amp; Co., Inc.; Hoechst Marion Roussel, Inc., the U.S. subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational
pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulene SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the board of directors of Avanir Pharmaceuticals,
Inc., a specialty pharmaceutical company, from 2005 until Avanir was sold to Otsuka Holdings in 2015. Dr.&nbsp;Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition,
Dr.&nbsp;Mazzo received his M.S. in chemistry and his Ph.D. degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Mazzo is qualified to serve on our Board because his extensive experience as an
executive officer and director in the life sciences industry, his understanding of the strategic and regulatory environment in which we conduct our business, his lengthy track record in global product development, his Ph.D. in analytical chemistry
and his broad scientific and managerial background provide him expertise in the oversight of companies in this sector and the ability to guide such companies through varying operating climates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Douglas Godshall </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Governance and
Nominating Committee and member of the Compensation Committee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Godshall has served since May 2017 as President and Chief Executive Officer of
Shockwave Medical, a privately held company which is creating and commercializing interventional devices designed to better address patients with problematic cardiovascular calcification. Previously, he served as the Chief Executive Officer of
HeartWare International, Inc., a Nasdaq-listed company, and its predecessor HeartWare Limited, a medical device company focused on heart failure, from September&nbsp;2006 until August 2016 and as director from October 2006 until August 2016.
HeartWare was acquired by Medtronic PLC in August 2016. Prior to joining HeartWare Limited, Mr.&nbsp;Godshall served in various executive and managerial positions at Boston Scientific Corporation, where he had been employed since 1990, including as
a member of Boston Scientific&#146;s Operating Committee. From January&nbsp;2005 he served as President, Vascular Surgery, and for the prior five years as Vice President, Business Development, focused on acquisition strategies for the cardiology,
electrophysiology, neuroradiology and vascular surgery divisions. Mr.&nbsp;Godshall has a Bachelor of Arts in Business from Lafayette College and Master of Business Administration from Northeastern University. Mr.&nbsp;Godshall has served on the
board of directors of the Medical Device Manufacturers Association, a national trade association, since May 2014. Mr.&nbsp;Godshall previously served on the board of directors of Vital Therapies, Inc., a public company traded on Nasdaq, that
develops cell-based therapies for the treatment of liver disease, from May 2013 to October 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Godshall is qualified to serve on
our Board because his managerial experience at public, life sciences companies provides him insights as a successful life sciences entrepreneur <FONT STYLE="white-space:nowrap">with&nbsp;in-depth&nbsp;knowledge</FONT> of medical product strategy and
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jay Duker, M.D. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the
Science Committee and member of the Governance and Nominating Committee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Duker is the Director of the New England Eye Center, where he has served
in various capacities since 1992. He is also Professor and Chairman of Ophthalmology at Tufts Medical Center and Tufts University School of Medicine. He has published more than 200 journal articles related to ophthalmology and <FONT
STYLE="white-space:nowrap">is&nbsp;co-author&nbsp;of</FONT> Yanoff and Duker&#146;s Ophthalmology, a best-selling ophthalmic text. Dr.&nbsp;Duker <FONT STYLE="white-space:nowrap">is&nbsp;co-founder&nbsp;of</FONT> three companies, including Hemera
Biosciences, Inc., a privately held company seeking to develop anti-compliment gene-based therapies for the treatment of dry and <FONT STYLE="white-space:nowrap">wet&nbsp;age-related&nbsp;macular</FONT> degeneration. Dr.&nbsp;Duker serves as a
director of Hemera and Sesen Bio, a Nasdaq-listed biopharmaceutical company developing protein therapeutics to treat bladder cancer. Dr.&nbsp;Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas
Jefferson University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Duker is qualified to serve on our Board because his extensive clinical and academic experience and expertise
in ophthalmology coupled with his leadership <FONT STYLE="white-space:nowrap">as&nbsp;co-founder&nbsp;of</FONT> other life sciences companies provide him with valuable clinical, scientific and commercial insight to bring to our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kristine Peterson </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of the Audit Committee and the
Governance and Nominating Committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Peterson has over 30 years of healthcare industry experience. She most recently served from 2009 to
2016 as Chief Executive Officer of Valeritas, Inc., a medical technology company focused on innovative drug delivery systems, and as a strategic advisor to Valeritas until August 2017. Prior to that, Ms.&nbsp;Peterson served as Company Group Chair
of Johnson&nbsp;&amp; Johnson&#146;s biotech groups from 2006 to 2009, and as Executive Vice President of Johnson&nbsp;&amp; Johnson&#146;s global strategic marketing organization from 2004 to 2006. Prior to that, she served as Senior Vice
President, Commercial Operations for Biovail Corporation, a pharmaceutical company, and President of Biovail Pharmaceuticals from 2003 to 2004. Ms.&nbsp;Peterson began her career at Bristol-Myers Squibb, holding assignments of increasing
responsibility spanning marketing, sales and general management, including running a cardiovascular / metabolic business unit and a generics division. Ms.&nbsp;Peterson is also a director of Paratek Pharmaceuticals, Inc., Immunogen, Inc. Amarin
Corporation plc and Enanta Pharmaceuticals, Inc., and within the past five years also served as a director of Valeritas, Inc. Ms.&nbsp;Peterson earned a B.S. and M.B.A. from the University of Illinois at Champaign Urbana. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&nbsp;Peterson is qualified to serve on our Board because of her extensive executive management and sales and marketing experience in both
large, multinational pharmaceutical and smaller biotechnology companies, in particular as it relates to later-stage development and commercialization, as well as her other public company board experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ronald W. Eastman </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of the Compensation Committee
and the Governance and Nominating Committee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Eastman joined Essex Woodlands (EW) in 2006 as a Partner and was appointed Managing Director in
2008. Mr.&nbsp;Eastman led and served on the Board of Directors of EW&#146;s growth equity investment in ProteinSimple (acquired by <FONT STYLE="white-space:nowrap">Bio-Techne).</FONT> He currently serves on the Board of Directors of EW portfolio
companies Elusys Therapeutics, Inc., Suneva Medical, Inc. and Symphogen A/S. Mr.&nbsp;Eastman has over 40 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home
Products (now Pfizer), where Mr.&nbsp;Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr.&nbsp;Eastman led the company&#146;s growth from a
venture-backed <FONT STYLE="white-space:nowrap">start-up</FONT> to a publicly traded pioneer in the fields of regenerative medicine and cancer. Most recently, at Rinat, a private biotech company spun out of Genentech with the support of EW in late
2001, Mr.&nbsp;Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006. Mr.&nbsp;Eastman has a Bachelor of
Arts degree from Williams College and a Master of Business Administration degree from Columbia University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Eastman is qualified to
serve on the Board because he brings to the Board knowledge and experience in both the healthcare and finance fields, as well as executive leadership, based on his work in life science-related venture capital. Mr.&nbsp;Eastman also brings corporate
governance expertise through his service on public company boards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John Landis, Ph.D. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of the Science Committee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Landis served as a
director for Bioanalytical Systems, Inc. from 2009 to 2017, serving as the chairman of its board of directors from 2011 until his departure in 2017. Dr.&nbsp;Landis previously served as Senior Vice President, Pharmaceutical Sciences of
Schering-Plough Corporation, a pharmaceutical company, from September 2003 until his retirement in October 2008. In that role, Dr.&nbsp;Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry,
biotechnology, quality assurance, clinical supplies and devices. Prior to that, Dr.&nbsp;Landis served as Senior Vice President, Preclinical Development at Pharmacia Corporation from 1997 until 2003 and led the global preclinical functions of
toxicology, drug metabolism and pharmacokinetics, pharmaceutical sciences, analytical chemistry and laboratory animal care. Dr.&nbsp;Landis also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
served as Vice President, Central Nervous System Psychiatry, Critical Care and Inflammation Development for Pharmacia&nbsp;&amp; Upjohn from 1995 through 1997. Prior to that, Dr.&nbsp;Landis was
employed by The Upjohn Company, where he held positions of increasing responsibility in the areas of analytical research, quality assurance and quality control. He is a current member of Purdue University&#146;s Chemistry Leadership Council and
Dean&#146;s Leadership Council for the School of Science and serves on the Advisory Board of South West Michigan Life Science Venture Capital and NanoMed Scientific and on the board of directors of Metabolic Solutions Development Company. Over his
career, Dr.&nbsp;Landis served on several other boards of directors, academic advisory panels and professional boards. Dr.&nbsp;Landis earned Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from
Kent State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Landis is qualified to serve on the Board because his substantial and varied experience working within medical
communities ranging from academia to the pharmaceutical industry position him to provide a practical and balanced perspective to the Board. Dr.&nbsp;Landis also brings to the Board executive experience in clinical research and his service on other
public company boards affords him a deep understanding of the role of the Board and its oversight of corporate governance and business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David
Guyer, M.D. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of the Science Committee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Guyer currently serves as Executive Chairman of IVERIC bio, Inc. (formerly Ophthotech Corporation), a publicly-traded biopharmaceutical company
specializing in gene therapy treatments for ocular diseases, which he <FONT STYLE="white-space:nowrap">co-founded,</FONT> and for which he served as Chief Executive Officer from April 2013 until January 2017. Before founding Ophthotech,
Dr.&nbsp;Guyer served as a partner and venture partner at SV Life Science Advisers, a venture capital firm focused on healthcare, from 2006 to 2013. Dr.&nbsp;Guyer <FONT STYLE="white-space:nowrap">co-founded</FONT> Eyetech Pharmaceuticals, Inc. and
served as its Chief Executive Officer and as a member of its Board of Directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Eyetech Pharmaceuticals,
Dr.&nbsp;Guyer was a Professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. He currently serves on the Board of Directors of Oxurion NV, a publicly-traded biotechnology company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Guyer received a B.S. from Yale University and an M.D. from Johns Hopkins Medical School. Dr.&nbsp;Guyer completed his ophthalmology residency at
Wilmer Ophthamological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Guyer is qualified to serve on the Board because of his extensive executive leadership experience, his extensive experience in
ophthalmology, his extensive experience in the life sciences industry as an entrepreneur and venture capital investor, and his service on the board of directors of other life sciences companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our executive officers holds
office until the first meeting of our Board following the next annual meeting of stockholders and until such officer&#146;s respective successor is chosen and qualified, unless a shorter period shall have been specified by the terms of such
officer&#146;s election or appointment. The following table sets forth information about our executive officers: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Lurker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dario Paggiarino, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice Presdient and Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leonard S. Ross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Accounting Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Lurker </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please refer to&nbsp;the section entitled &#147;<I>Directors, Executive Officers and Corporate Governance &#150; Directors</I>&#148; above for
Ms.&nbsp;Lurker&#146;s biographical information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Price has served as our Chief Financial Officer since August 2018. Mr.&nbsp;Price brings to EyePoint more than 25 years of financial experience in the
healthcare, investment banking and accounting industries. He has extensive experience in executing debt and equity capital financings, business development deals, restructurings and oversight of all financial functions in both domestic and
international markets for public and private commercial companies. Most recently, he served as Chief Financial Officer of Concordia International Corporation, a publicly traded, revenue generating, generic pharmaceutical company. Prior to Concordia,
he was the Chief Financial Officer at Bioventus, a global, commercial medical device company, where he was responsible for the creation of an independent business unit following the company&#146;s spinout from Smith&nbsp;&amp; Nephew. In this role,
he led a $175&nbsp;million debt financing and $210&nbsp;million public debt raise. In addition, Mr.&nbsp;Price served as Chief Financial Officer of Cornerstone Therapeutics Inc., a publicly-traded, commercial specialty pharmaceutical company, where
he orchestrated and executed the reverse merger of Cornerstone BioPharma with Critical Therapeutics to form Cornerstone Therapeutics Inc. Mr.&nbsp;Price also served as Chief Financial Officer of EDGAR Online, Inc., a financial data, technology and
business process outsourcing company. In addition to his corporate experience, Mr.&nbsp;Price previously served as a managing director in the healthcare and pharmaceutical services sector at both Jefferies&nbsp;&amp; Company and Bear
Stearns&nbsp;&amp; Co. Mr.&nbsp;Price began his career in public accounting at Arthur Andersen and PriceWaterhouseCoopers, and earned a B.A. in Accounting from Lancaster University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dario Paggiarino, M.D. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Paggiarino has served as
our Senior Vice President and Chief Medical Officer since April 2019, and was previously Vice President, Chief Medical Officer since August 2016. Prior to that, Dr.&nbsp;Paggiarino served since April 2013 as Senior Vice President and Chief
Development Officer of Lpath, Inc., a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies that target bioactive signaling lipids to treat a wide range of human diseases.&nbsp;Dr.&nbsp;Paggiarino
served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis from 2011 to 2013. He served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&amp;D, a division of Pfizer,
Inc., from 2001 to 2011. Earlier in his career, he held research and development positions of increasing responsibility at Angelini Pharmaceuticals, Inc., an affiliate of Angelini S.p.A, a privately-owned company, ultimately serving as president,
and later joined Pharmacia Global R&amp;D, a division of Pharmacia Corporation, where he was clinical program director of ophthalmology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leonard S.
Ross </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ross has served as our Vice President, Finance and Chief Accounting Officer since July 2017, and was previously Vice President, Finance
since November 2009 and before that our Corporate Controller from October&nbsp;2006. From 2001 through April 2006, Mr.&nbsp;Ross served as Corporate Controller for NMT Medical, Inc., a medical device company. From 1990 to 1999, Mr.&nbsp;Ross was
employed by JetForm Corporation, a developer of workflow software solutions, where he served in various capacities, including Vice President, Finance and Vice President, International Operations. Mr.&nbsp;Ross received a B.S. in Chemical Engineering
from Tufts University, an M.B.A. from the Amos Tuck School at Dartmouth College and an M.S. in Taxation from Bentley College. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements between Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Eastman was appointed to the Board as the designee of EW Healthcare Partners, L.P., or EWHP, and EW Healthcare
<FONT STYLE="white-space:nowrap">Partners-A,</FONT> L.P., or <FONT STYLE="white-space:nowrap">EWHP-A,</FONT> pursuant to the terms of that certain Securities Purchase Agreement, dated March&nbsp;28, 2018, by and among us, EWHP and <FONT
STYLE="white-space:nowrap">EWHP-A,</FONT> or the First Tranche Securities Purchase Agreement. Mr.&nbsp;Eastman is a Managing Director of EW Healthcare Partners, which is an affiliate of both EWHP and <FONT STYLE="white-space:nowrap">EWHP-A.</FONT>
Per the terms of the First Tranche Securities Purchase Agreement, EWHP and <FONT STYLE="white-space:nowrap">EWHP-A</FONT> have the right, subject to certain customary limitations and restrictions, to nominate one individual to our Board for so long
as they beneficially own shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ando was appointed to the Board as the designee of EWHP and
<FONT STYLE="white-space:nowrap">EWHP-A,</FONT> pursuant to the terms of that certain Second Tranche Securities Purchase Agreement, dated March&nbsp;28, 2018, by and among us, EWHP, <FONT STYLE="white-space:nowrap">EWHP-A</FONT> and the other
accredited investors signatory thereto, or the Second Tranche Securities Purchase Agreement. Dr.&nbsp;Ando is Senior Advisor to EW Healthcare Partners, which is an affiliate of both EWHP and <FONT STYLE="white-space:nowrap">EWHP-A.</FONT> Per the
terms of the Second Tranche Securities Agreement, EWHP and <FONT STYLE="white-space:nowrap">EWHP-A</FONT> will have the right, subject to certain customary limitations and restrictions, to nominate one additional individual to our Board for so long
as they beneficially own shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as disclosed above, there is no arrangement or understanding between any of our executive
officers or directors and any other person, pursuant to which such person was selected to serve as an executive officer or director, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc734420_3"></A>CORPORATE GOVERNANCE AND BOARD MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has unanimously
determined that Dr.&nbsp;Mazzo, Mr.&nbsp;Rogers, Mr.&nbsp;Godshall, Dr.&nbsp;Duker, Ms.&nbsp;Peterson, Mr.&nbsp;Eastman, Dr.&nbsp;Ando, Dr.&nbsp;Landis and Dr.&nbsp;Guyer are independent under applicable standards of the SEC and Nasdaq.
Ms.&nbsp;Lurker serves as our President and Chief Executive Officer. Each of the Audit Committee, the Compensation Committee, the Governance and Nominating Committee and the Science Committee is comprised entirely of independent directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure, Processes and Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has chosen to
separate the roles of Board Chair and Chief Executive Officer and believes that such a separation of roles is in our best interests and the best interests of our stockholders. Dr.&nbsp;Ando&#146;s extensive experience in the life sciences industry
in both senior management and board of director positions coupled with his perspective as an independent director provide effective leadership for our Board and support for our executive team. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board&#146;s Role in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is
management&#146;s responsibility to manage risk and bring to the Board&#146;s attention risks that are material to the Company. The Board has oversight responsibility for the systems established to report and monitor the most significant risks
applicable to us. The Board administers its risk oversight role directly and through its committee structure. The Board reviews strategic and financial risks and exposures associated with our long-term strategy, development and commercialization of
products and product candidates and other matters that may present material risk to our operations, strategy and prospects. The Audit Committee reviews risks associated with financial and accounting matters, including financial reporting,
accounting, disclosure and internal control over financial reporting. The Compensation Committee reviews risks related to executive compensation and the design of compensation programs, plans and arrangements. The Governance and Nominating Committee
manages risks associated with corporate governance, <FONT STYLE="white-space:nowrap">non-financial</FONT> compliance (including healthcare and related regulatory matters and information technology (including cybersecurity) matters) and Board
composition and procedures. The Science Committee supports the Board&#146;s oversight of risks related to our research and development, or R&amp;D, organization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Sessions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive sessions of our independent
directors are held at each regularly scheduled meeting of our Board and at other times they deem necessary. Our Board&#146;s policy is to hold executive sessions both with and without the presence of management. Our Board committees also generally
meet in executive session at the end of each committee meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive and Director Compensation Processes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agenda for each meeting of the Compensation Committee is usually developed by the chair of the Compensation Committee in consultation with our Chief
Executive Officer. The Compensation Committee meets regularly in executive session. From time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make
presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. No officer may participate in, or be present during, any deliberations or determinations of the
Compensation Committee regarding the compensation for such officer or employee. Our Chief Executive Officer provides recommendations to our Compensation Committee with respect to executive and employee compensation, other than her own compensation.
The Compensation Committee takes into consideration Ms.&nbsp;Lurker&#146;s input in granting annual bonuses or equity awards and setting compensation levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The charter of the Compensation Committee grants the Compensation Committee full access to all of our books,
records, facilities and personnel, as well as the authority to obtain, at our expense, advice and assistance from internal and external legal, accounting or other advisors and consultants and other external resources that the Compensation Committee
considers necessary or appropriate in the performance of its duties. In particular, the Compensation Committee has the authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the
authority to approve the consultant&#146;s reasonable fees and other retention terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2018, the Compensation Committee retained Radford, an Aon
company, as its independent consultant to assist in evaluating our executive compensation programs and practices and to make recommendations regarding compensation for the six-month transition period ended December 31, 2018. During this process,
Radford: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepared competitive market data for the compensation of our executive management team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluated the continued appropriateness of and made recommendations regarding our peer group;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analyzed our short term and long-term incentive plan designs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed equity retention and our equity burn rate and dilution levels relative to the market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessed our compensation practices and levels against those of our peer group companies and the broader
marketplace; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">made recommendations regarding base salary, target bonus percentage and long-term incentive compensation for each
Named Executive Officer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">updated the Compensation Committee on compensation trends and regulatory developments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Radford, Aon or their affiliates provides other services to us. The Compensation Committee assessed the independence of Radford pursuant to SEC rules
and concluded that no conflict of interest existed that would prevent Radford from independently representing the Compensation Committee. The Compensation Committee has sole responsibility for the selection, engagement, removal and compensation of
its compensation consultant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee may form and delegate any or all of its duties or responsibilities to a subcommittee of the
Compensation Committee, to the extent consistent with our Certificate of Incorporation, bylaws and applicable laws and rules of markets in which our securities then trade. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has four standing committees:
the Audit Committee, the Compensation Committee, the Governance and Nominating Committee and the Science Committee. Each standing committee has a written charter. Each of the Audit Committee, the Compensation Committee and the Governance and
Nominating Committee is comprised entirely of independent directors. The Science Committee is currently comprised entirely of independent directors; however it may in the future include members of our R&amp;D organization and other members of
executive management in accordance with its charter. While each committee has designated responsibilities, the committees act on behalf of the entire Board and regularly report on their activities to the entire Board. Details concerning the role and
structure of the Board and each Board committee are contained in the Corporate Governance Guidelines and the committee charters, available on the &#147;Investor&#148; section of our website at www.eyepointpharma.com under &#147;Corporate
Governance.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit
Committee is responsible for assisting the Board with oversight of our accounting and financial reporting processes, including but not limited to (i)&nbsp;our audit program; (ii)&nbsp;the integrity of our financial statements; (iii)&nbsp;the review
and assessment of the qualifications and independence of our independent registered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public accounting firm; and (iv)&nbsp;the preparation of reports required of the Audit Committee under the rules of the Securities and Exchange Commission, or SEC. More specifically, the Audit
Committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, overseeing and, if necessary, replacing the independent registered public accounting firm, including
evaluating the effectiveness and independence of the firm at least annually, approving <FONT STYLE="white-space:nowrap">or&nbsp;pre-approving&nbsp;all</FONT> audit <FONT STYLE="white-space:nowrap">and&nbsp;non-audit&nbsp;services</FONT> provided by
the firm and establishing hiring policies for employees or former employees of the firm, and also including resolving any disagreements between management and the firm regarding financial reporting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with the independent registered public accounting firm the scope of, plans for and any difficulties
with audits and the adequacy of staffing and compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with the independent registered public accounting firm matters required to be communicated to audit
committees in accordance with Public Company Accounting Oversight Board, or PCAOB, Auditing Standard No.&nbsp;1301, <I>Communications With Audit Committees</I>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and the independent registered public accounting firm our internal controls, financial
and critical accounting policies (including effects of alternate United States generally accepted accounting principles, or GAAP, methods <FONT STYLE="white-space:nowrap">and&nbsp;off-balance&nbsp;sheet</FONT> structures, if any) and significant
judgments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and the independent registered public accounting firm our annual and quarterly
financial statements and financial disclosure, and preparing the Audit Committee report for inclusion in our annual proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, or establishing standards for, the substance and presentation of information included in earnings
press releases and other earnings guidance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing material pending legal proceedings and other contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing appropriate control processes for accounting, disclosures and reporting, review and approval of
intercompany, related party and significant unusual transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for receipt, retention and treatment of complaints, including the confidential and
anonymous submission of concerns by employees regarding accounting, internal accounting controls or auditing matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving from management a report of any significant deficiencies and material weaknesses in the design or
operation of our internal controls, and any fraud involving management or other employees who have a significant role in our internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">presenting to the Board annually an evaluation of the Audit Committee&#146;s performance and charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing such other activities as the Board or the Audit Committee deem appropriate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Audit Committee are Mr.&nbsp;Rogers (chair), Ms.&nbsp;Peterson and Dr.&nbsp;Mazzo, each of whom was a member of the Audit Committee during
the fiscal year ended June&nbsp;30, 2018 and the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018. Mr.&nbsp;Rogers will not be standing for <FONT STYLE="white-space:nowrap">re-election</FONT> at the
2019 Annual Meeting and will be replaced as Audit Committee chair by Dr.&nbsp;Guyer following the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has determined that all
members of the Audit Committee are independent for purposes of service on the Audit Committee as provided in SEC and Nasdaq rules, as applicable. The Board also has determined that Mr.&nbsp;Rogers, Dr.&nbsp;Mazzo, Ms.&nbsp;Peterson and
Dr.&nbsp;Guyer are audit committee financial experts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee met six times during the fiscal year ended June&nbsp;30, 2018. The Audit
Committee met two times during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee is responsible for (i)&nbsp;discharging the Board&#146;s responsibilities relating to executive compensation, (ii)&nbsp;overseeing
our compensation and employee benefits plans and practices, including incentive, equity-based and other compensatory plans in which executive officers and key employees participate and (iii)&nbsp;producing a report on executive compensation as
required by the SEC. More specifically, the Compensation Committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and periodically reviewing compensation policies and practices applicable to executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving the compensation of the CEO and other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervising, administering and evaluating incentive, equity-based and other compensatory plans of our company in
which executive officers and key employees participate, including approving guidelines and size of grants and awards, making grants and awards, interpreting and promulgating rules relating to the plans, modifying or canceling grants or awards,
designating employees eligible to participate and imposing limitations and conditions on grants or awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the Board regarding any executive and equity compensation plans and such
other compensation and benefit plans that are subject to Board approval and, where appropriate or required, to stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving any <FONT STYLE="white-space:nowrap">tax-qualified,</FONT>
<FONT STYLE="white-space:nowrap">non-discriminatory</FONT> employee benefit plans (and any parallel nonqualified plans) for which stockholder approval is not sought and pursuant to which options or stock may be acquired by our officers, directors,
employees or consultants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any employment agreements, severance arrangements, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements or special or supplemental employee benefits, and any material amendments to any of the foregoing, applicable to executive officers and our other employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making individual determinations and granting any shares, stock options or other equity-based awards under all
equity-based compensation plans that are outside approved guidelines for such grants, and exercising such power and authority as may be required or permitted under such plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually evaluating the performance of the Compensation Committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and reassessing the charter of the Compensation Committee and, if appropriate, recommending
changes to the Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually evaluating the adequacy of directors&#146; compensation and the composition of such compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the Compensation Discussion&nbsp;&amp; Analysis to be included in our annual proxy statement or Annual
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> issuing a Compensation Committee report thereon as required by the SEC to be included in our annual proxy statement or Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;filed</FONT> with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing significant risks or exposures facing us and discussing the relationship, if any, between these risks
and our compensation policies and practices, as well as appropriate means through compensation policy to mitigate these risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and recommending to the Board, as applicable, for approval of, (i)&nbsp;the frequency with
which we conduct stockholder advisory votes on executive compensation (Say on Pay Vote) and (ii)&nbsp;any proposals related to the Say on Pay Vote to be included in our annual proxy statement, in each case as applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing such other duties and responsibilities as may be assigned to the Compensation Committee by the Board
or as designated in plan documents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forming and delegating authority to subcommittees, comprised of one or more members of the Compensation
Committee, when the Compensation Committee deems appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Compensation Committee are Dr.&nbsp;Mazzo (chair), Mr.&nbsp;Rogers, Mr.&nbsp;Godshall and
Mr.&nbsp;Eastman, each of whom was a member of the Compensation Committee during the fiscal year ended June&nbsp;30, 2018 and the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018. Mr.&nbsp;Rogers will
not be standing for <FONT STYLE="white-space:nowrap">re-election</FONT> at the 2019 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has determined that all current and
transition period members of the Compensation Committee are independent for purposes of service on the Compensation Committee as provided in SEC and Nasdaq rules, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee met four times during the fiscal year ended June&nbsp;30, 2018. The Compensation Committee met two times during the <FONT
STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The processes and procedures followed by our
Compensation Committee in considering and determining executive and director compensation are described above under &#147;Corporate Governance and Board Matters&#151;Board Leadership Structure, Processes and Role in Risk Oversight&#151;Executive and
Director Compensation Processes.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance and Nominating Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Governance and Nominating Committee is responsible for (i)&nbsp;identifying and recommending to the Board individuals qualified to serve as directors,
(ii)&nbsp;advising the Board with respect to Board composition and procedures, (iii)&nbsp;overseeing the evaluation of the Board and (iv)&nbsp;developing and maintaining our corporate governance and compliance policies. The Governance and Nominating
Committee has periodically engaged third parties to identify and evaluate candidates qualified to serve as our directors and may continue to do so in the future. More specifically, the Governance and Nominating Committee&#146;s responsibilities
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting and interviewing candidates for Board membership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the background and qualifications of individuals being considered as director candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the Board guidelines and criteria to determine the qualifications of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the Board the director nominees for election by the stockholders or appointment by the Board to
fill any vacancies pursuant to <FONT STYLE="white-space:nowrap">our&nbsp;By-Laws;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and considering candidates for election submitted by stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the suitability for continued service as a director of each Board member when his or her term expires,
and recommending whether or not the director should <FONT STYLE="white-space:nowrap">be&nbsp;re-nominated;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the independence (within the meaning of the Nasdaq listing requirements) of Board members and the
overall Board composition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing periodically the size of the Board and to recommend to the Board any appropriate changes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations on the frequency and structure of Board meetings and on the practices of the Board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the Board the directors to be appointed to each committee of the Board, including the Governance
and Nominating Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the Board the director to serve as chair of the Board and the directors to serve as chair of each
committee of the Board, including the Governance and Nominating Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our corporate governance policies, including information related to the operations of the committees of
the Board, director independence, the director nominations process and the documents, policies and procedures in our corporate governance framework, identifying best practices and discussing with management the results of such review;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing policies, if any, with respect to risk assessment and risk management and periodically discussing our
plans or processes to monitor, control and minimize corporate risks and exposures (including with respect to information technology and cybersecurity) with our external legal counsel, insurance advisors and the independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing all <FONT STYLE="white-space:nowrap">non-financial</FONT> compliance activities and matters, including
the design and implementation of appropriate compliance programs, policies and procedures and the management of matters involving significant legal or regulatory compliance exposure or material reports or inquiries from government or regulatory
agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing an annual self-evaluation of the Board and its committees to determine whether the Board and its
committees are functioning effectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing such other duties and responsibilities as may be assigned to the Governance and Nominating Committee
by the Board or as designated in plan documents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forming and delegating authority to subcommittees, comprised of one or more members of the Governance and
Nominating Committee, when the Governance and Nominating Committee deems appropriate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Governance and Nominating
Committee are Mr.&nbsp;Godshall (chair), Dr.&nbsp;Ando, Dr.&nbsp;Duker, Ms.&nbsp;Peterson and Mr.&nbsp;Eastman. Each of Mr.&nbsp;Godshall, Dr.&nbsp;Duker, Ms.&nbsp;Peterson and Mr.&nbsp;Eastman was a member of the committee during the fiscal year
ended June&nbsp;30, 2018 and for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018. Dr.&nbsp;Ando joined the committee on February&nbsp;21, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has determined that all current and transition period members of the Governance and Nominating Committee are independent for purposes of service on
the Governance and Nominating Committee as provided in SEC and Nasdaq rules, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Governance and Nominating Committee met five times during
the fiscal year ended June&nbsp;30, 2018. The Governance and Nominating Committee met two times during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Science Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Science Committee is responsible
for reviewing the science, clinical and regulatory strategy underlying our research and development programs and making recommendations to the Board on key strategic and tactical issues relating to our research and development activities. More
specifically, the Science Committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the science and clinical and regulatory strategy underlying the major research and development
programs, including publication strategies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our significant medical affairs strategies and initiatives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the annual research and development budget and allocation of resources to discovery and development
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the capacity and skill set of the research development organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the implications for the research and development organization of significant business development
transactions, including mergers, acquisitions, licensing and collaborative agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the progress toward achievement of key research and development milestones; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and overseeing our intellectual property strategies and initiatives; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the interactions of the research and development organization with health care providers and regulatory
bodies, especially with regard to the reporting of adverse events and/or unexpected negative data observed in the preclinical and clinical studies conducted by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current members of the Science Committee are Dr.&nbsp;Duker (chair), Dr.&nbsp;Mazzo, Dr.&nbsp;Ando, Dr.&nbsp;Landis and Dr.&nbsp;Guyer. Each of
Dr.&nbsp;Duker, Dr.&nbsp;Mazzo and Dr.&nbsp;Ando was a member of the committee during the fiscal year ended June&nbsp;30, 2018 and for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018.
Dr.&nbsp;Landis joined the committee on October&nbsp;25, 2018 and Dr.&nbsp;Guyer joined the committee on January&nbsp;25, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Science Committee met
three times during the fiscal year ended June&nbsp;30, 2018. The Science Committee met two times during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attendance at Board and Committee Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board met
ten times during the fiscal year ended June&nbsp;30, 2018 and the Board met three times during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018. Except as described below, each of the
directors who served during the fiscal year ended June&nbsp;30, 2018 and the six-month transition period ended December&nbsp;31, 2018 and are standing for election attended at least 75% of the aggregate of the total number of meetings of the Board
and of the committees on which he or she served (during the period that each such director served). During the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018, Mr.&nbsp;Eastman attended approximately
60% of the aggregate of the total number of meetings of the Board and of the committees on which he served during such transition period. In accordance with our policy that encourages each director to attend Annual Meetings, each director who was
serving as a director as of the 2017 Annual Meeting, which was our most recently held annual meeting, attended the 2017 Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder
Nominations for Director </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Governance and Nominating Committee will consider written stockholder recommendations for candidates for the Board, which
recommendations should be delivered or mailed, postage prepaid, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Company Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EyePoint Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">480 Pleasant Street, Suite A210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">United
States </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholder recommendations must include certain relevant information concerning the candidate, the stockholder making the recommendation and any
beneficial owner on whose behalf the recommendation is made. The required information is set forth in our Stockholder Nomination Policy, available on the &#147;Investor&#148; section of our website at www.eyepointpharma.com under &#147;Corporate
Governance &#150; Governance Overview.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Governance and Nominating Committee will evaluate candidates for director who are recommended by
stockholders on the same basis as candidates recommended by other sources. Considerations include the Governance and Nominating Committee&#146;s discretionary assessment of the skills represented and required on the Board, and an evaluation of
candidates against the standards and qualifications set forth in our Corporate Governance Guidelines and criteria approved by the Board from time to time. We do not have a formal policy with respect to diversity, although we seek to have a Board
that reflects a range of talents, ages, skills, viewpoints, professional experience, educational backgrounds, expertise, genders and ethnicities. The Governance and Nominating Committee will determine whether to interview any candidate in its sole
discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications with Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders and other interested parties may communicate directly with the Board, the independent directors, the Chairman of the Board, any other group of
directors or any individual director. The required information is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in our Policy Regarding Stockholder Communications With Directors, available on the &#147;Investor&#148; section of our website at www.eyepointpharma.com under &#147;Corporate
Governance &#150; Governance Overview&#148;. Any such written communications should be addressed to the relevant group or individual and sent to the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Name(s) of Director(s), Group of Directors or Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">c/o Company Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EyePoint
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">480 Pleasant Street, Suite A210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">United
States </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Company Secretary will forward such communications to the relevant group or individual at or prior to the next meeting of the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of
Business Conduct applicable to each of our officers, directors and employees, and consultants and contractors to, us and our subsidiaries, including our principal executive officer and principal financial officer. The Code of Business Conduct is a
set of policies on key integrity issues that requires our representatives to act ethically and legally. It includes policies with respect to conflicts of interest, compliance with laws, insider trading, corporate opportunities, competition and fair
dealing, discrimination and harassment, health and safety, record-keeping, confidentiality, protection and proper use of assets, payments to government personnel and reports to and communications with the SEC and the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to disclose any future amendments to, or waivers from, the Code of Business Conduct that affect our directors or senior financial and executive
officers within four business days of the amendment or waiver by posting such information on the &#147;Investor&#148; section of our website at www.eyepointpharma.com under &#147;Corporate Governance&#151;Governance Overview.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee Report </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As more fully described in its
charter, the Audit Committee oversees our financial reporting process on behalf of the Board. Our management is responsible for our financial reporting process, including assuring that we develop and maintain adequate financial controls and
procedures, and assess compliance therewith. Our independent registered public accounting firm, Deloitte&nbsp;&amp; Touche LLP, or Deloitte, is responsible for performing an audit of the effectiveness of our internal control over financial reporting
in conjunction with an audit of our consolidated financial statements in accordance with standards of the Public Company Accounting Oversight Board (United States), or PCAOB, and issuing its opinion on the financial statements and the effectiveness
of internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The committee reviewed and discussed our audited consolidated financial statements for the fiscal year
ended June&nbsp;30, 2018 and the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018 with our management and Deloitte. The committee also reviewed and discussed with Deloitte our audited consolidated
financial statements and the matters required by PCAOB Auditing Standard No.&nbsp;1301, <I>Communications with Audit Committees.</I> The committee met with Deloitte, with and without management present, to discuss the results of their examinations,
other areas of oversight relating to the financial reporting and audit process that the Audit Committee determined appropriate, their evaluation of our internal controls and the overall quality of our financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The committee discussed with Deloitte the firm&#146;s independence and received from Deloitte and reviewed the written disclosures and the letter required by
PCAOB Ethics and Independence Rule 3526 (Communication with Audit Committees Concerning Independence). The committee considered whether Deloitte&#146;s provision of <FONT STYLE="white-space:nowrap">non-audit</FONT> services to us is compatible with
Deloitte&#146;s independence and concluded that Deloitte is independent from our company and our management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the above-referenced reviews and discussions with our management and Deloitte, the Audit Committee
recommended to the Board that our audited consolidated financial statements be included in each of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2018 and our Transition Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018, each for filing with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Submitted by the members of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Audit Committee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Michael Rogers (Chair) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kristine Peterson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">David Mazzo </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy Regarding Transactions with Related Persons </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
maintain a written &#147;Policy Regarding Related Person Transactions.&#148; Under this policy, the Audit Committee or, in time sensitive instances, the chair of the Audit Committee, has responsibility for reviewing and approving or ratifying any
transaction in which we and any of our directors, director nominees, executive officers or 5% stockholders and their immediate family members are participants, or in which such persons have a direct or indirect material interest, as provided under
SEC rules. In reviewing transactions, the committee or the chair considers all of the relevant facts and circumstances, and approves only those transactions that the committee or the chair in good faith determines to be in, or not inconsistent with,
the best interests of us and our stockholders. Except as disclosed below, there were no such related-person transactions since January&nbsp;1, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions with Related Persons </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Financings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;28, 2018, we entered into (i)&nbsp;the First Tranche Securities Purchase Agreement with two related parties, EWHP and <FONT
STYLE="white-space:nowrap">EWHP-A,</FONT> which we collectively refer to as the First Tranche Investors, pursuant to which we offered and sold to such investors an aggregate of 8,606,324 shares of our common stock, or the First Tranche Transaction,
and (ii)&nbsp;the Second Tranche Securities Purchase Agreement with the First Tranche Investors and certain other accredited investors signatory thereto, which we collectively refer to as the Second Tranche Investors, pursuant to which we agreed to
offer and sell, subject to the approval of our stockholders, an aggregate of up to approximately $25.5&nbsp;million of units, which we refer to individually each as a Unit and collectively as the Units, with each Unit consisting of (a)&nbsp;one
share of our common stock and (b)&nbsp;one warrant to purchase a share of our common stock. We refer to the issuance of the Units pursuant to the Second Tranche Securities Purchase Agreement as the Second Tranche Transaction. Our stockholders
approved the sale and issuance of the Units on June&nbsp;22, 2018 and we sold 20,184,224 Units to the Second Tranche Investors upon the closing of the Second Tranche Transaction on June&nbsp;25, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of our common stock sold to the First Tranche Investors pursuant to the First Tranche Securities Purchase Agreement were sold at a purchase price
of $1.10 per share, which was the consolidated closing bid price of our common stock on the Nasdaq Global Market immediately preceding the execution of the First Tranche Securities Purchase Agreement. Each Unit sold upon the closing of the Second
Tranche Transaction was sold at a purchase price of $1.265 per Unit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the warrants issued in the Second Tranche Transaction, which we refer to
individually as a Second Tranche Warrant and collectively as the Second Tranche Warrants, were exercisable at any time on or prior to the close of business on September&nbsp;28, 2018 (which was the 15th business day following the date on which the
holders of the Second Tranche Warrants received written notice from us that the Centers for Medicare&nbsp;&amp; Medicaid Services had announced that a new <FONT STYLE="white-space:nowrap">C-Code</FONT> has been established for DEXYCU). As of
September&nbsp;28, 2018, the Second Tranche Investors exercised all of the outstanding Second Tranche Warrants and we issued an aggregate of 20,184,224 shares of our common stock at an exercise price of $1.43 per share to the Second Tranche
Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the First Tranche Securities Purchase Agreement and the Second Tranche Securities Purchase Agreement, we issued to EWHP an
aggregate 24,485,283 shares of our common stock and 16,211,822 Second Tranche Warrants for aggregate gross proceeds of $29,608,762. Pursuant to the First Tranche Securities Purchase Agreement and the Second Tranche Securities Purchase Agreement, we
issued to EWHP-A an aggregate 985,107 shares of our common stock and 652,244 Second Tranche Warrants for aggregate gross proceeds of $1,191,238. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the First Tranche Transaction, we entered into a Registration Rights Agreement with the First Tranche Investors, or the First Tranche Registration Rights Agreement, effective as of the closing of the First
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tranche Transaction. Pursuant to the First Tranche Registration Rights Agreement, the First Tranche Investors required us to register their shares of common stock for resale on a registration
statement filed with the SEC and such investors have the right to &#147;piggyback&#148; on certain of our registrations. The registration rights will terminate with respect to each First Tranche Investor on the date on which such investor ceases to
beneficially own shares of our common stock or can sell all of its registrable shares without limitation pursuant to Rule 144 of the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Second Tranche Transaction, we entered into that certain Second Registration Rights Agreement with the Second Tranche
Investors, or the Second Tranche Registration Rights Agreement. Pursuant to the Second Tranche Registration Rights Agreement, we were required, within 30 days of the closing of the Second Tranche Transaction, to file a shelf registration statement
with the SEC registering for resale the securities issued to the Second Tranche Investors in the Second Tranche Transaction and any securities issued pursuant to the First Tranche Securities Purchase Agreement that have not already been registered.
We filed a registration statement registering for resale these securities on July&nbsp;25, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We amended the Second Tranche Registration Rights
Agreement, which amendment extended the date by which we were required to have a registration statement registering for resale the securities issued to the Second Tranche Investors in the Second Tranche Transaction and any securities issued pursuant
to the First Tranche Securities Purchase Agreement that had not already been registered declared effective by the SEC. Per the terms of the amended Second Tranche Registration Rights Agreement, the registration statement registering for resale the
securities issued to the Second Tranche Investors in the Second Tranche Transaction and any securities issued pursuant to the First Tranche Securities Purchase Agreement that have not already been registered were to be declared effective on or
before November&nbsp;5, 2018. The Second Tranche Registration Rights Agreement was declared effective on November&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The brother of James
Barry, a former member of our Board, served as a managing director of the First Tranche Investors at the time of the closing of the First Tranche Transaction. Dr.&nbsp;Barry&#146;s brother was not involved in either the First Tranche Transaction or
the Second Tranche Transaction nor did he receive any direct financial benefit from the closing of the First Tranche Transaction or the Second Tranche Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two of our directors, Mr.&nbsp;Eastman and Dr.&nbsp;Ando, were appointed to the Board by the First Tranche Investors pursuant to the terms of the First
Tranche Securities Purchase Agreement and the Second Tranche Securities Purchase Agreement, respectively. Mr.&nbsp;Eastman is a Managing Director of EW Healthcare Partners, which is an affiliate of the First Tranche Investors and Dr.&nbsp;Ando is a
Senior Advisor to EW Healthcare Partners, which is an affiliate of the First Tranche Investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lease Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective June&nbsp;11, 2018, we leased 1,381 square feet of incremental office space in Basking Ridge, New Jersey from Caladrius Biosciences Inc. David J.
Mazzo, a member of our Board, is the President and Chief Executive Officer and a member of the board of directors of Caladrius Biosciences Inc. The lease term extends through May 2022. Base rent of $2,884 per month increases by $0.50 per square foot
each year beginning June&nbsp;1, 2019. During the period from inception through June&nbsp;30, 2018 and for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018, we incurred $1,923 and $17,304,
respectively, of rent expense for this facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the
director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity.
The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establishes certain presumptions that are favorable to the director or executive
officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of our directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc734420_4"></A>STOCK OWNERSHIP
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Ownership of Directors, Officers and Principal Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on April&nbsp;26, 2019, there were 106,105,728 shares of our common stock issued and outstanding and entitled to vote. On
April&nbsp;26, 2019, the closing price of our common stock as reported on the Nasdaq Global Market was $1.77 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
certain information relating to the beneficial ownership of our common stock as of April&nbsp;26, 2019 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding
shares of common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our Named Executive Officers (as defined below); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC as indicated in the footnotes to the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each of the beneficial owners listed below is: c/o EyePoint Pharmaceuticals, Inc., 480&nbsp;Pleasant Street, Suite
A210, Watertown, MA 02472, United States. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Number&nbsp;of<BR>Shares Beneficially<BR>Owned<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater Than 5% Stockholder:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EW Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,903,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 Waterway Avenue, Suite 225</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Woodlands, TX 77380</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#246;ran Ando</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Lurker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Mazzo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Godshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Eastman<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,903,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Duker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Landis<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Guyer<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Price<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dario Paggiarino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current directors and executive</B> <B></B><B></B><B>officers as a group (13
persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>44,743,920</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents holdings of less than 1% of our outstanding common stock </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects sole voting and investment power, except as indicated below. Includes shares of common stock that each
of the following persons had the right to acquire on April&nbsp;26, 2019 or within sixty (60)&nbsp;days thereafter through the exercise of stock options or for the issuance of common shares underlying restricted stock units
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and deferred stock units: Dr.&nbsp;Ando (26,666), Ms.&nbsp;Lurker (730,000), Dr.&nbsp;Mazzo (374,166), Mr.&nbsp;Rogers (275,834), Mr.&nbsp;Godshall (225,834), Dr.&nbsp;Duker (72,500),
Ms.&nbsp;Peterson (66,667) and Dr.&nbsp;Paggiarino (206,033). Also included in the shares beneficially owned by all current directors and executive officers as a group is 69,452 common shares owned by Mr.&nbsp;Ross and 288,366 shares of common stock
that Mr.&nbsp;Ross had the right to acquire on April&nbsp;26, 2019 or within sixty (60)&nbsp;days thereafter through the exercise of stock options or for the issuance of common shares underlying restricted stock units. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based, in part, on information provided on a Schedule 13D/A filed jointly on February&nbsp;13, 2019 by EWHP, <FONT
STYLE="white-space:nowrap">EWHP-A,</FONT> Essex Woodlands Fund <FONT STYLE="white-space:nowrap">IX-GP,</FONT> L.P., a Delaware limited partnership, or Essex IX Fund GP, Essex Woodlands IX, LLC, a Delaware limited liability company, or Essex IX
General Partner, Martin P. Sutter, an individual, R. Scott Barry, an individual, Ronald W. Eastman, an individual, and Petri Vainio, an individual, each of which serve as a Manager and collectively as the Managers. Essex IX Fund GP is the general
partner of each of EWHP and <FONT STYLE="white-space:nowrap">EWHP-A,</FONT> and Essex IX General Partner is the general partner of Essex IX Fund GP. The Managers are each managers of Essex IX General Partner. EWHP and
<FONT STYLE="white-space:nowrap">EWHP-A</FONT> have the sole voting and investment power with respect to their respective shares of common stock. Each of the Managers may be deemed to have shared voting and dispositive power with respect to the
shares of common stock registered hereunder. Each of Essex IX Fund GP, Essex IX General Partner and the Managers, including Mr.&nbsp;Eastman, disclaims beneficial ownership of the shares held by EWHP and
<FONT STYLE="white-space:nowrap">EWHP-A,</FONT> except to the extent of any pecuniary interests therein. The principal address of EWHP, <FONT STYLE="white-space:nowrap">EWHP-A,</FONT> Essex IX Fund GP, Essex IX General Partner and each of the
Managers is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 40,283,255 shares of common stock held by EWHP and 1,620,701 shares of common stock held by <FONT
STYLE="white-space:nowrap">EWHP-A.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Landis joined our Board on October&nbsp;25, 2018. Dr.&nbsp;Landis did not hold any shares of our
common stock as of April&nbsp;26, 2019, nor did Dr.&nbsp;Landis have the right to acquire beneficial ownership of any shares of our common stock within sixty (60)&nbsp;days of April&nbsp;26, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Guyer joined our Board on January&nbsp;25, 2019. Dr.&nbsp;Guyer did not hold any shares of our common
stock as of April&nbsp;26, 2019, nor did Dr.&nbsp;Guyer have the right to acquire beneficial ownership of any shares of our common stock within sixty (60)&nbsp;days of April&nbsp;26, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Price joined the Company as Chief Financial Officer on August&nbsp;1, 2018. Mr.&nbsp;Price did not
hold any shares of common stock as of April&nbsp;26, 2019, nor did Mr.&nbsp;Price have the right to acquire beneficial ownership of any shares of our common stock within sixty (60)&nbsp;days of April&nbsp;26, 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
provides information about the securities authorized for issuance under the Company&#146;s equity compensation plans as of December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>to be issued upon<BR>exercise of<BR>outstanding options,<BR>warrants and rights<BR>(a) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-average<BR>exercise price of<BR>outstanding&nbsp;options,<BR>warrants and rights<BR>(b)<SUP STYLE="font-size:85%; vertical-align:top">(4)
</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of securities<BR>remaining available<BR>for future issuance<BR>under equity<BR>compensation plans<BR>(excluding
securities<BR>reflected&nbsp;in&nbsp;Column&nbsp;a)<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,575,008</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,305,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation plans not approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>9,635,008</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,305,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of outstanding stock options, performance-based stock units, restricted stock units and deferred stock
units to purchase 8,575,008 awards pursuant to our 2008 Equity Incentive Plan, as amended, or the 2008 Plan, and our 2016 Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Board has not established any specific number of shares that could be issued without stockholder approval.
Inducement grants to new key employees are determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. Other than possible inducement grants, we expect all equity awards will be made under
stockholder-approved plans. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In August 2018, we issued 610,000 inducement equity awards outside of the 2016 Plan in accordance with Nasdaq
Listing Rule 5635(c)(4). The inducement equity awards were approved by the Compensation Committee of the Board and were made as an inducement material to David Price&#146;s acceptance of employment with us in accordance with Nasdaq Listing Rule
5635(c)(4). Mr.&nbsp;Price is our Chief Financial Officer. Mr.&nbsp;Price&#146;s inducement awards consisted of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option award to purchase a total of 385,000 shares of common stock and
performance stock units, or PSUs, entitling Mr.&nbsp;Price to receive up to 225,000 shares of common stock based on the achievement of prescribed performance metrics determined by the Compensation Committee. The stock option to purchase 385,000
shares of common stock is scheduled to vest ratably on each of the first, second and third anniversaries of the date of grant, subject to the terms of grant. The performance metrics associated with the PSU award are subject to measurement during the
<FONT STYLE="white-space:nowrap">3-year</FONT> period ending June&nbsp;30, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2018, we issued 100,000
inducement equity awards outside of the 2016 Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was approved by the Compensation Committee of the Board and was made as an inducement material to John Weet&#146;s
acceptance of employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). Dr.&nbsp;Weet is our SVP, Regulatory Affairs&nbsp;&amp; Quality. Dr.&nbsp;Weet&#146;s inducement award consisted of a
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option award to purchase a total of 100,000 shares of common stock. The stock option to purchase 100,000 shares of common stock is scheduled to vest ratably on each of the first, second and
third anniversaries of the date of grant, subject to the terms of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In November 2018, we issued 350,000 inducement equity awards
outside of the 2016 Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was approved by the Compensation Committee of the Board and was made as an inducement material to Ron Honig&#146;s acceptance of employment with
us in accordance with Nasdaq Listing Rule 5635(c)(4). Mr.&nbsp;Honig is our SVP, General Counsel and Company Secretary. Mr.&nbsp;Honig&#146;s inducement award consisted of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option award to
purchase a total of 350,000 shares of common stock. The stock option to purchase 350,000 shares of common stock is scheduled to vest ratably on each of the first, second and third anniversaries of the date of grant, subject to the terms of grant.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) Performance-based stock units, restricted stock units and deferred stock units are not included in the weighted-average exercise price
calculation because there is no exercise price associated with stock units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires our directors, executive officers and persons who
beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Directors, officers and greater than
10% stockholders are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based solely upon a review of Forms
3, 4 and 5 furnished to us during each of the fiscal year ended June&nbsp;30, 2018 and the six-month transition period ended December&nbsp;31, 2018, we believe that the directors, executive officers and greater than 10% beneficial owners have
complied with all applicable filing requirements during each of the fiscal year ended June&nbsp;30, 2018 and the six-month transition period ended December&nbsp;31, 2018 except that the Statements of Changes of Beneficial Ownership of Securities on
Form 4 filed by Essex Woodlands Healthcare Partners on April&nbsp;2, 2018 and July&nbsp;3, 2018, James Barry on May&nbsp;14, 2018 and each of David J. Mazzo, Douglas Godshall, Michael Rogers, Jay Duker and Kristine Peterson on June&nbsp;26, 2018,
respectively, were not filed before the end of the second business day following the day on which the transaction resulting in a change in beneficial ownership had been consummated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc734420_5"></A>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018 are Nancy Lurker, our
President and Chief Executive Officer, David Price, our Chief Financial Officer, and Dario Paggiarino, our SVP and Chief Medical Officer, who we collectively refer to as our Named Executive Officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and
footnotes provide information regarding the compensation of our Named Executive Officers for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018 (2018TP) and the fiscal years ended
June&nbsp;30,&nbsp;2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Executive Name and Principal<BR>Position </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nancy Lurker</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>2018TP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief</I> <I>Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,316</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>David Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>2018TP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">779,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Dario Paggiarino</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>2018TP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>SVP and Chief</I> <I></I><I></I><I>Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,904</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,100</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,194,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts represent the discretionary annual bonuses paid to the Named Executive Officer for the <FONT
STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018 and for fiscal year 2018 in excess of the respective amounts earned by the executive based upon achievement of the applicable corporate and individual
performance goals for each such period. The Compensation Committee determined to award an overall corporate performance achievement score of 110% <FONT STYLE="white-space:nowrap">(pro-rated</FONT> to 55% for the
<FONT STYLE="white-space:nowrap">six-month</FONT> transition period), which was greater than the score of 100% <FONT STYLE="white-space:nowrap">(pro-rated</FONT> to 50%) that resulted from the achievement of the applicable corporate goals, in
recognition of the transformational accomplishments made by the Company during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period. A similar 10% additional bonus amount <FONT STYLE="white-space:nowrap">(pro-rated</FONT> to 5%)
was applied to the 25% weighting of the individual performance achievement score of 125% for Mr.&nbsp;Price and Dr.&nbsp;Paggiarino. For fiscal 2018, the Compensation Committee determined to award an overall corporate performance achievement score
of 125%, which was greater than the score that resulted from the achievement of the applicable corporate goals (109%), in recognition of the significant transformation of the Company during fiscal 2018. In accordance with SEC guidance, these excess
amounts are included in the &#147;Bonus&#148; column of the &#147;Summary Compensation Table.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts represent the aggregate grant date fair value of restricted stock unit awards and performance
stock unit awards granted during the applicable fiscal year period computed in accordance with FASB ASC Topic 718. For a more detailed discussion of the valuation model and assumptions used to calculate the fair value of each stock award, refer to
Note 12 of the consolidated financial statements included in our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 filed on March&nbsp;18, 2019. The grant date fair value was
measured at the date of stockholder approval for stock awards granted to Ms.&nbsp;Lurker prior to our May&nbsp;7, 2018 delisting from the Australian Securities Exchange (ASX), which approval was required by ASX Listing Rules, and at the date of
Compensation Committee approval in the case of all other stock awards to our Named Executive Officers. The grant date fair value of the performance stock units awarded to Mr.&nbsp;Price on August&nbsp;1, 2018 as an inducement to his hire as Chief
Financial Officer is zero, which represents the probable outcome of the achievement of the applicable performance conditions as of the grant date in accordance with FASB ASC Topic 718. The maximum number of such performance stock units that would be
earned upon satisfaction of the applicable service and performance-based vesting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
conditions is 225,000. Assuming that the highest level of performance conditions will be achieved over the <FONT STYLE="white-space:nowrap">3-year</FONT> measurement period, the value of the
award would be $499,500 based on the $2.22 closing price of our common stock on the date of grant. Mr.&nbsp;Price&#146;s inducement award was made outside of our 2016 Plan, but is subject to the terms and conditions of the 2016 Plan.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts represent the aggregate grant date fair value of option awards granted during the applicable
fiscal year period computed in accordance with FASB ASC Topic 718. The grant date fair value of the option awards is estimated using the Black-Scholes option pricing model. For a more detailed discussion of the assumptions used to calculate the fair
value of each option award, refer to Note 12 of the consolidated financial statements included in our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 filed on March&nbsp;18,
2019. The grant date fair value was measured at the date of stockholder approval in the case of Ms.&nbsp;Lurker for option awards granted prior to our May&nbsp;7, 2018 delisting from ASX, which approval was required under ASX Listing Rules, and at
the date of Compensation Committee approval in the case of all other option awards to our Named Executive Officers. The option award granted to Ms.&nbsp;Lurker in fiscal 2017 was an inducement grant in connection with her hire as President and Chief
Executive Officer on September&nbsp;15, 2016, which was granted outside of our 2008 Plan, but is subject to the terms and conditions of the 2008 Plan. The option award granted to Mr.&nbsp;Price during the 2018 transition period was an inducement
grant in connection with his hire as Chief Financial Officer on August&nbsp;1, 2018, which was granted outside of the 2016 Plan but is subject to the terms and conditions of the 2016 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts represent the amount of the annual performance bonus earned by the Named Executive Officer for
the 2018 transition period and fiscal years 2018 and 2017, as applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts consist of 401(k) employer matching contributions, payment of group term life insurance premiums
and, in the case of Ms.&nbsp;Lurker for 2017, payment of $5,000 of her personal legal fees associated with the negotiation of her employment agreement with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount includes the grant date fair value of 115,000 performance stock units (PSUs) that were granted to
Ms.&nbsp;Lurker on June&nbsp;27, 2017, which were subject to stockholder approval under the then applicable ASX listing rules. Accordingly, the grant date fair value of this award was measured in fiscal 2018 following the December&nbsp;15, 2017
annual meeting of stockholders, at which time the first performance condition was determined to be probable of achievement. As a result, the grant date fair value for Ms.&nbsp;Lurker&#146;s PSUs of $43,316 at December&nbsp;15, 2017 has been included
as a component of the total stock awards value for Ms.&nbsp;Lurker for fiscal 2018 in the above table. The maximum number of performance stock units that would be earned by Ms.&nbsp;Lurker upon satisfaction of the applicable service and
performance-based vesting conditions is 115,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount also includes the grant date fair value of the service-based restricted stock units that were
granted to Ms.&nbsp;Lurker on June&nbsp;27, 2017, which were subject to stockholder approval under the then applicable ASX listing rules. Accordingly, the grant date fair value of this award was measured in fiscal 2018 following the
December&nbsp;15, 2017 annual meeting of stockholders and has been included as a component of the total stock awards value for Ms.&nbsp;Lurker for fiscal 2018 in the above table. The grant date fair value of this award ($135,600) was equal to the
closing price of our common stock on the stockholder approval date ($1.13) multiplied by the number of service-based restricted stock units (120,000). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount also includes the grant date fair value of the service-based restricted stock units granted to
Ms.&nbsp;Lurker on June&nbsp;14, 2018 ($275,400), which is equal to the closing price of our common stock on the grant date ($2.04) multiplied by the number of restricted stock units granted to Ms.&nbsp;Lurker (135,000). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount includes the grant date fair value of the 500,000 market-based performance stock units granted to
Ms.&nbsp;Lurker as an inducement award in fiscal 2017, which vest based upon a relative percentile rank of the <FONT STYLE="white-space:nowrap">3-year</FONT> change in the closing price of our common stock compared to that of the companies that make
up the Nasdaq Biotechnology Index. The grant date fair value was estimated using a Monte Carlo valuation model and represents the probable outcome of the achievement of the applicable performance conditions as of the grant date. The number of
market-based performance stock units to be earned by Ms.&nbsp;Lurker will range from 0 to 500,000, dependent upon the level of performance achieved. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount includes the grant date fair value of the service-based restricted stock units granted to
Dr.&nbsp;Paggiarino on June&nbsp;14, 2018, which is equal to the closing price of our common stock on the grant date ($2.04) multiplied by the number of restricted stock units granted (42,600). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents the grant date fair value of the service-based restricted stock units granted to
Dr.&nbsp;Paggiarino on June&nbsp;27, 2017, which was equal to the closing price of our common stock on the grant date ($1.77) multiplied by the number of restricted stock units granted (30,000). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Transition Period Base Salaries </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of
July&nbsp;1, 2018, the annual base salaries for Ms.&nbsp;Lurker and Dr.&nbsp;Paggiarino were each increased by 3% to $562,277 and $408,447, respectively. Mr.&nbsp;Price&#146;s employment as our Chief Financial Officer commenced on August&nbsp;1,
2018 with an annual base salary of $425,000. For the fiscal year ending December&nbsp;31, 2019, the Compensation Committee approved salary increases of 3.5% for each of our Named Executive Officers, with effect from April&nbsp;1, 2019, resulting in
an annual base salary of $581,957 for Ms.&nbsp;Lurker, $439,875 for Mr.&nbsp;Price and $425,000 for Dr.&nbsp;Paggiarino, which also reflected an incremental adjustment in connection with his promotion to SVP and Chief Medical Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Transition Period <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our executive officers is eligible to receive an annual performance bonus based on the achievement of corporate goals, as determined by our Board of
Directors, and individual performance goals, as recommended by our Chief Executive Officer and approved by the Compensation Committee. The performance bonus for our Chief Executive Officer is weighted 100% for achievement of our corporate goals,
whereas the performance bonus for our other named executive officers is weighted 75% for corporate goal achievement and 25% for individual goal achievement. The annual target bonus as a percentage of base salary was established at 55% for
Ms.&nbsp;Lurker and 40% for each of Mr.&nbsp;Price and Dr.&nbsp;Paggiarino. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate goals were established for the year ending June&nbsp;30, 2019
before the Board&#146;s decision to change the Company&#146;s fiscal year end from June&nbsp;30 to December 31. For the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ending December&nbsp;31, 2018, the Compensation Committee
applied its judgement to extrapolate the Company&#146;s goal achievement for the remainder of the original twelve-month performance period, with primary focus on the Company&#146;s <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> and
launch readiness activities for its YUTIQ and DEXYCU products, both of which were launched in the first quarter of calendar 2019. The Compensation Committee approved a corporate performance score of 100% as recommended by our Chief Executive
Officer, and approved an additional 10%, for a total of 110%, based on its assessment of the transformational accomplishments of the Company during the transition period, with the resulting aggregate score prorated at 50%, or a total score of 55%,
for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period. Each of Mr.&nbsp;Price and Dr.&nbsp;Paggiarino were given an individual performance score of 125%, similarly adjusted and prorated. Actual bonus amounts earned with respect
to the 100% corporate goal achievement and the 125% individual performance scores applicable to Mr.&nbsp;Price and Dr.&nbsp;Paggiarino for the 2018 Transition Period (2018TP) are reflected in the
<FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column of the Summary Compensation Table above. The incremental discretionary incentive compensation amounts approved by the Compensation Committee are
reflected in the &#147;Bonus&#148; column of the Summary Compensation Table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Transition Period Equity Award Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment as our Chief Financial Officer on August&nbsp;1, 2018, Mr.&nbsp;Price was granted two equity awards, both of which were
granted as inducements material to his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). These consisted of (i)&nbsp;an option to purchase 385,000 shares of our common stock with an exercise price of $2.22,
which was equal to the closing price of our common stock on the date of grant, vesting in three equal annual installments commencing on the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anniversary of the date of grant; and (ii) 225,000 performance-based restricted stock units (PSUs), which vest as described below in this paragraph. 150,000 of the PSUs, or the Revenue PSUs,
become earned based upon the achievement of defined amounts of the Company&#146;s cumulative product revenues over a three-year performance period beginning on July&nbsp;1, 2018 and ending on June&nbsp;30, 2021. The number of Revenue PSUs that
become earned, if any, will vest on the later of (x)&nbsp;the date the Compensation Committee determines the level of achievement of the applicable product revenue target and (y)&nbsp;August&nbsp;1, 2021, subject, in each case, to
Mr.&nbsp;Price&#146;s continued employment through August&nbsp;1, 2021. 75,000 of the PSUs, or the Transaction PSUs, become earned and vested based upon the cumulative net present value of any merger or acquisition transactions, asset <FONT
STYLE="white-space:nowrap">in-licenses,</FONT> asset <FONT STYLE="white-space:nowrap">out-licenses,</FONT> collaborations or other commercial transactions consummated by the Company during the period commencing on August&nbsp;1, 2018 and ending on
August&nbsp;1, 2021, measured as of the date of each such transaction, subject to Mr.&nbsp;Price&#146;s continue employment through the closing date of the applicable transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No equity awards were made to our other Named Executive Officers during the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;21, 2019, the Compensation Committee approved the following option grants to our Named Executive Officers:
930,000 options to Ms.&nbsp;Lurker, 300,000 options to Mr.&nbsp;Price and 370,000 options to Dr.&nbsp;Paggiarino. The exercise price of these options is $2.65 per share, the closing price of the Company&#146;s common stock on the date of
Compensation Committee approval, and the options will vest on a monthly basis over a <FONT STYLE="white-space:nowrap">4-year</FONT> period. In addition, the Compensation Committee approved a supplemental award of 411,523 restricted stock units
(RSUs) to Ms.&nbsp;Lurker, with pro rata annual vesting over 3 years. Each of these equity awards is subject to the approval of Annual Meeting Proposal No.&nbsp;2, as discussed further below, to amend our 2016 Plan to increase by 11,000,000 the
number of shares of common stock authorized for issuance under the 2016 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution 401(k) retirement plan, or 401(k) Plan, for all employees in the United States, including our Named Executive Officers.
Employees are eligible to participate in the 401(k) Plan in the month following their date of hire. Under the terms of the 401(k) Plan, participating employees may defer up to 100% of their <FONT STYLE="white-space:nowrap">pre-tax</FONT> salary
provided that such deferral is not in excess of the applicable statutory limits within any calendar year. The Company matches 100% of employee contributions up to a maximum of 5% of salary and bonus compensation, subject to annual Internal Revenue
Service limits. Employee contributions and our company matching contributions to the 401(k) Plan vest immediately. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers are eligible to participate in our health and welfare programs to the same extent as all full-time employees generally
and are entitled to 20 days of annual paid time off in accordance with our vacation policy. We also provide our Named Executive Officers and other employees with group term life insurance and short and long-term disability (LTD) insurance at our
expense. Under the terms of the group LTD policy, premiums paid by the Company are included in the employee&#146;s taxable income, provided that any benefits payable to an employee under the LTD policy are not subject to income tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nancy Lurker, who became our
President and Chief Executive Officer on September&nbsp;15, 2016, is employed under an employment agreement with us that provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company performance goals,
discretionary equity incentives and severance payments as described further below under<I>&nbsp;Additional Narrative Disclosure&#151;Termination-Based Compensation</I>. In addition, as an inducement to her hire, Ms.&nbsp;Lurker was awarded
restricted stock units that are eligible to vest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based on our total stockholder return relative to the total stockholder returns of the companies that comprise the Nasdaq Biotechnology Index, in each case, over a three-year performance period
ending on September&nbsp;14, 2019, and stock options that are eligible to vest in equal annual installments on each of the first four anniversaries of the grant date based on Ms.&nbsp;Lurker&#146;s continued service with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Price, who became our Chief Financial Officer on August&nbsp;1, 2018, is employed under an employment agreement that provides for a minimum base salary,
a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives and severance payments as described further below under <I>Additional Narrative Disclosure&#151;Termination-Based
Compensation</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dario Paggiarino, who initially became our Vice President, Chief Medical Officer on August&nbsp;1, 2016, is employed under an
employment agreement with us that provides for a base salary, a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives and severance payments as described further below
under<I>&nbsp;Additional Narrative Disclosure&#151;Termination-Based Compensation</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2018 Transition <FONT
STYLE="white-space:nowrap">Period-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and footnotes provide information concerning outstanding equity awards for our Named
Executive Officers as of December&nbsp;31,&nbsp;2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:36pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Securities<BR>Underlying<BR>Unexercised&nbsp;Options (#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares or<BR>units of<BR>stock that<BR>have not<BR>vested (#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;value<BR>of shares or<BR>units of stock<BR>that have not<BR>vested
</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>incentive<BR>plan&nbsp;awards:<BR>number of<BR>unearned<BR>shares, units<BR>or&nbsp;other&nbsp;rights<BR>that have not<BR>vested
(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>incentive<BR>plan&nbsp;awards:<BR>market or<BR>payout value<BR>of unearned<BR>shares, units<BR>or&nbsp;other&nbsp;rights<BR>that have
not<BR>yet vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Lurker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/14/28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>385,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/01/28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dario Paggiarino</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/01/26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/14/28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,100</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Lurker&#146;s unexercisable options vest and become exercisable as follows: 425,000 in two equal
annual installments commencing September&nbsp;15, 2019, 160,000 in two equal annual installments commencing June&nbsp;27, 2019 and 540,000 in three equal annual installments commencing June&nbsp;14, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Price&#146;s unexercisable options vest and become exercisable as follows: 385,000 in three equal
annual installments commencing August&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Paggiarino&#146;s unexercisable options vest and become exercisable as follows: 115,000 in two equal
annual installments commencing August&nbsp;1, 2019, 40,000 in two equal annual installments commencing June&nbsp;27, 2019 and 170,500 in three equal annual installments commencing June&nbsp;14, 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Lurker&#146;s restricted stock units vest as follows: 80,000 in two equal annual installments
commencing June&nbsp;27, 2019, 135,000 in three equal annual installments commencing June&nbsp;14, 2019, 19,167 on March&nbsp;19, 2019 and 38,333 on October&nbsp;12, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Paggiarino&#146;s restricted stock units vest as follows: 20,000 in two equal annual installments
commencing June&nbsp;27, 2019, 42,600 in three equal annual installments commencing June&nbsp;14, 2019, 4,167 on March&nbsp;19, 2019 and 8,333 on October&nbsp;12, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the number of performance stock units that Ms.&nbsp;Lurker would earn if the threshold level of
performance is achieved. The actual number of performance stock units that will vest on September&nbsp;14, 2019, if any, will be determined based upon a relative percentile rank of <FONT STYLE="white-space:nowrap">the&nbsp;3-year&nbsp;change</FONT>
in the closing price of our common stock compared to that of the companies that make up the Nasdaq Biotechnology Index. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the number of performance stock units that Mr.&nbsp;Price would earn if the threshold level of
performance is achieved. The actual number of performance stock units that vest will be determined based on (1)&nbsp;the Company&#146;s cumulative product revenues for the <FONT STYLE="white-space:nowrap">3-year</FONT> period ending June&nbsp;30,
2021 and (ii)&nbsp;the net present value of any merger or acquisition transactions, asset <FONT STYLE="white-space:nowrap">in-licenses,</FONT> asset <FONT STYLE="white-space:nowrap">out-licenses,</FONT> collaborations or other commercial
transactions closed by the Company during the <FONT STYLE="white-space:nowrap">3-year</FONT> period ending August&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market price of unvested and unearned stock awards is calculated based on the closing price of our common
stock at December&nbsp;31, 2018 of $1.89, as reported on the Nasdaq Global Market. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Narrative Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nancy Lurker </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of Ms.&nbsp;Lurker&#146;s employment by us without &#147;cause,&#148; or by Ms.&nbsp;Lurker with &#147;good cause&#148; (as such terms are defined
in her employment agreement), would require us to pay severance to Ms.&nbsp;Lurker. Upon any such termination (other than in connection with a &#147;change of control&#148; (as defined in Ms.&nbsp;Lurker&#146;s employment agreement)),
Ms.&nbsp;Lurker would be entitled to receive (i)&nbsp;base salary continuation for a period of 12 months from the date of termination, payable in accordance with our normal payroll practices, (ii)&nbsp;one times her annual target bonus, payable in
equal installments during the period of base salary continuation under clause (i)&nbsp;above, and (iii)&nbsp;provided that Ms.&nbsp;Lurker timely elects COBRA continuation coverage for herself and her eligible dependents, a monthly amount that
equals the portion of the monthly health premiums paid by us on behalf of her and her eligible dependents immediately preceding the date that her employment terminates until the earlier of the last day of the period of Ms.&nbsp;Lurker&#146;s base
salary continuation or the date that Ms.&nbsp;Lurker and her eligible dependents become ineligible for COBRA continuation coverage pursuant to applicable law or plan terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to <FONT STYLE="white-space:nowrap">Ms.&nbsp;Lurker&#146;s&nbsp;sign-on&nbsp;equity</FONT> grant of 850,000 stock options, any unvested portion
of the options held by Ms.&nbsp;Lurker immediately prior to her employment termination by us without cause or by Ms.&nbsp;Lurker with good cause that would have vested as of the second anniversary of her employment termination will vest upon any
such termination, and such options would remain exercisable until the earlier of (1)&nbsp;three months thereafter and (2)&nbsp;the applicable option expiration date. Pursuant to the applicable award agreements, (x)&nbsp;with respect to all other
stock options held by Ms.&nbsp;Lurker, any unvested portion that would have vested as of the first anniversary following the date of her termination by us without cause or by Ms.&nbsp;Lurker with good cause will vest upon any such termination, and
such options would remain exercisable until the earlier of (i)&nbsp;three months thereafter and (ii)&nbsp;the applicable option expiration date; and (y)&nbsp;with respect to any unvested time-based restricted stock units held by Ms.&nbsp;Lurker that
would have vested as of the first anniversary following the date of her termination of employment by us without cause or by Ms.&nbsp;Lurker with good cause, such units would vest upon any such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any such termination that occurs within 60 days prior to, or within 18 months following a change of control, Ms.&nbsp;Lurker would be entitled
to receive (i)&nbsp;base salary continuation for a period of 18 months, payable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in accordance with our normal payroll practices, (ii)&nbsp;1.5 times her annual target bonus, payable in equal installments during the period of base salary continuation under clause
(i)&nbsp;above, and (iii)&nbsp;provided that Ms.&nbsp;Lurker timely elects COBRA continuation coverage for herself and her eligible dependents, a monthly amount that equals the portion of the monthly health premiums paid by us on behalf of her and
her eligible dependents immediately preceding the date that her employment terminates until the earlier of the last day of the period of Ms.&nbsp;Lurker&#146;s base salary continuation or the date that Ms.&nbsp;Lurker and her eligible dependents
become ineligible for COBRA continuation coverage pursuant to applicable law or plan terms. In addition, upon any such termination following a change of control, any unvested portion of Ms.&nbsp;Lurker&#146;s options and any unvested time-based
restricted stock units would vest and the options would become exercisable upon such termination, and such options would remain exercisable until the earlier of (i)&nbsp;one year thereafter and (ii)&nbsp;the applicable option expiration date,
provided, however, that with respect to Ms.&nbsp;Lurker&#146;s <FONT STYLE="white-space:nowrap">sign-on</FONT> equity grant of 850,000 stock options, pursuant to the applicable award agreement, such termination must occur within 24 months following
a change of control. Termination by us for cause or by Ms.&nbsp;Lurker without good cause would not require us to pay any severance to Ms.&nbsp;Lurker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to <FONT STYLE="white-space:nowrap">Ms.&nbsp;Lurker&#146;s&nbsp;sign-on&nbsp;equity</FONT> grant of 500,000 performance stock units, in the event
of a termination of Ms.&nbsp;Lurker&#146;s employment by us without cause or by Ms.&nbsp;Lurker with good cause, <FONT STYLE="white-space:nowrap">a&nbsp;pro-rated&nbsp;portion</FONT> of the performance stock units, based on the number of days
elapsed between September&nbsp;15, 2016 and Ms.&nbsp;Lurker&#146;s termination date divided by 1,095 days (the <FONT STYLE="white-space:nowrap">original&nbsp;3-year&nbsp;performance</FONT> period) would remain outstanding and eligible to be earned
based on our total stockholder return, or TSR, relative to the companies that comprise the Nasdaq Biotechnology Index, with Ms.&nbsp;Lurker&#146;s termination date serving as the last day of the performance period. In the event that a change of
control occurs before the end of the three-year performance period, the performance stock units will be eligible to vest on the date of the change of control based on our TSR relative to the companies that comprise the Nasdaq Biotechnology Index,
with performance measured as of the change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Lurker&#146;s right to receive the severance payments and benefits described above under
her employment agreement is conditioned upon her execution <FONT STYLE="white-space:nowrap">and&nbsp;non-revocation&nbsp;of</FONT> a separation agreement containing a general release of claims. Ms.&nbsp;Lurker&#146;s employment agreement contains
certain restrictive covenants, <FONT STYLE="white-space:nowrap">including&nbsp;non-disclosure&nbsp;of</FONT> confidential information, assignment of rights to intellectual property,
<FONT STYLE="white-space:nowrap">a&nbsp;non-competition&nbsp;covenant</FONT> that runs for 12 months following her termination of employment for any reason, <FONT STYLE="white-space:nowrap">a&nbsp;non-solicitation&nbsp;covenant</FONT> with respect
to certain of our customers, vendors, suppliers and business partners that runs for 12 months following her termination of employment for any reason and <FONT STYLE="white-space:nowrap">a&nbsp;non-solicitation&nbsp;covenant</FONT> with respect to
our employees and independent contractors that runs for 12 months following her termination of employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>David Price </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Mr.&nbsp;Price&#146;s employment is terminated by the Company without &#147;cause&#148; or by Mr.&nbsp;Price for &#147;good cause&#148; (as such terms are
defined in his employment agreement), Mr.&nbsp;Price will be entitled to (a)&nbsp;his base salary for the period of 12 months from the date of termination; provided, however, that if such termination occurs within 12 months following his
August&nbsp;1, 2018 start date (a &#147;One Year Termination&#148;), Mr.&nbsp;Price will instead be entitled to his base salary for the period of 6 months from the date of termination; (b) 100% of his target bonus, or 50% of his target bonus in the
event of a One Year Termination, in either case, payable in equal installments during the period of base salary continuation payable in clause (a); and (c)&nbsp;reimbursements equal to the portion of the monthly health premiums paid by the Company
on Mr.&nbsp;Price&#146;s behalf and that of his eligible dependents immediately preceding the date that Mr.&nbsp;Price&#146;s employment terminates until the earlier of (i)&nbsp;the last day of the period of base salary continuation under clause
(a)&nbsp;and (ii) that date that Mr.&nbsp;Price and his eligible dependents become ineligible for COBRA coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable award
agreements, (x)&nbsp;with respect to all options held by Mr. Price, any unvested portion that would have vested as of the first anniversary following the date of his termination of employment by us without cause or by Mr. Price with good cause would
vest upon any such termination, and such options would remain exercisable until the earlier of (1)&nbsp;three months thereafter and (2)&nbsp;the applicable option expiration date; and (y)&nbsp;with respect to any unvested time-based restricted stock
units held by Mr. Price that would have vested as of the first anniversary following the date of his termination of employment by us without cause or by Mr. Price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with good cause, such units would vest upon any such termination. Upon a &#147;change of control&#148; (as such term is defined in his employment agreement), any options to purchase shares of the
Company&#146;s common stock or shares of restricted stock of the Company held by Mr.&nbsp;Price that are not fully vested at the time of the change of control will immediately accelerate and vest in full, provided that Mr.&nbsp;Price is employed by
the Company on the date of the change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the payments set forth in the preceding paragraph, upon the termination of
Mr.&nbsp;Price&#146;s employment for any reason, Mr.&nbsp;Price will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment. The payments and benefits set forth
above are subject to Mr.&nbsp;Price&#146;s execution of a release of claims. Pursuant to a Confidential Information, <FONT STYLE="white-space:nowrap">Non-Disclosure,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicitation,</FONT> <FONT
STYLE="white-space:nowrap">Non-Compete,</FONT> and Rights to Intellectual Property Agreement entered into by Mr.&nbsp;Price in connection with his appointment as our Chief Financial Officer, Mr.&nbsp;Price is subject to certain restrictive
covenants, including <FONT STYLE="white-space:nowrap">non-disclosure&nbsp;of</FONT> confidential information, assignment of rights to intellectual property, <FONT STYLE="white-space:nowrap">a&nbsp;non-competition&nbsp;covenant</FONT> that runs for
12 months following his termination of employment for any reason, <FONT STYLE="white-space:nowrap">a&nbsp;non-solicitation&nbsp;covenant</FONT> with respect to certain of our customers, vendors, suppliers and business partners that runs for 12
months following his termination of employment for any reason and <FONT STYLE="white-space:nowrap">a&nbsp;non-solicitation&nbsp;covenant</FONT> with respect to our employees and independent contractors that runs for 12 months following his
termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the 225,000 PSUs granted to Mr.&nbsp;Price in connection with his appointment as our Chief Financial Officer,
the award agreement evidencing the grant of such PSUs generally provides that Mr.&nbsp;Price (i)&nbsp;will forfeit all unvested Revenue PSUs in the event his employment terminates for any reason prior to August&nbsp;1, 2021, and (ii)&nbsp;will
forfeit all unvested Transaction PSUs in the event his employment terminates for any reason at any time. In the event a &#147;change of control&#148; (as defined in the award agreement evidencing the grant of such PSUs) occurs during the applicable
performance period (with respect to the Revenue PSUs) or prior to August&nbsp;1, 2021 (with respect to the Transaction PSUs), the Compensation Committee will determine the number of PSUs that are earned, if any, in connection with such change of
control, based upon the achievement of the applicable performance objectives determined as of the date of such change of control. Any earned PSUs will vest on the date of the change of control, subject to Mr.&nbsp;Price&#146;s continued employment
through such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dario Paggiarino </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we terminate
Dr.&nbsp;Paggiarino&#146;s employment without &#147;cause,&#148; or if Dr.&nbsp;Paggiarino terminates his employment with us for &#147;good cause&#148; (as such terms are defined in his employment agreement), we are obligated to (i)&nbsp;pay
Dr.&nbsp;Paggiarino&#146;s base salary for a period of 12 months, payable in accordance with our then-current payroll practices, (ii)&nbsp;pay Dr.&nbsp;Paggiarino an amount equal to his annual target bonus, payable in equal installments during the
period of base salary continuation under clause (i)&nbsp;above, and (iii)&nbsp;provided that Dr.&nbsp;Paggiarino timely elects COBRA continuation coverage for himself and his eligible dependents, pay Dr.&nbsp;Paggiarino a monthly amount that equals
the portion of the monthly health premiums paid by us on behalf of him and his eligible dependents immediately preceding the date that his employment terminates until the earlier of the last day of the period of Dr.&nbsp;Paggiarino&#146;s base
salary continuation or the date that Dr.&nbsp;Paggiarino and his eligible dependents become ineligible for COBRA continuation coverage pursuant to applicable law or plan terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable award agreements, (x)&nbsp;with respect to all options held by Dr.&nbsp;Paggiarino, any unvested portion that would have vested as
of the first anniversary following the date of his termination of employment by us without cause or by Dr.&nbsp;Paggiarino with good cause would vest upon any such termination, and such options would remain exercisable until the earlier of
(1)&nbsp;three months thereafter and (2)&nbsp;the applicable option expiration date; and (y)&nbsp;with respect to any unvested time-based restricted stock units held by Dr.&nbsp;Paggiarino that would have vested as of the first anniversary following
the date of his termination of employment by us without cause or by Dr.&nbsp;Paggiarino with good cause, such units would vest upon any such termination. In addition, upon any such termination within 24&nbsp;months of a change of control,
(i)&nbsp;any unvested portion of Dr.&nbsp;Paggiarino&#146;s options would vest and become exercisable upon such termination, and such options would remain exercisable until the earlier of (A)&nbsp;one year thereafter and (B)&nbsp;the applicable
option expiration date and (ii)&nbsp;any unvested portion of Dr.&nbsp;Paggiarino&#146;s time-based restricted stock units would vest upon any such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the severance benefits described above, Dr.&nbsp;Paggiarino&#146;s employment agreement provides that if we terminate his employment without
cause or if Dr.&nbsp;Paggiarino terminates his employment with us for good </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cause, following, in each case, a change of control, as defined in Dr.&nbsp;Paggiarino&#146;s employment agreement, any stock options or restricted stock held by Dr.&nbsp;Paggiarino at the time
of such change of control and assumed or substituted in connection with such change of control, will, following his termination as described above, accelerate and vest in full and such options will remain exercisable until the earlier of the first
anniversary of Dr.&nbsp;Paggiarino&#146;s termination (or three months following such termination in the case of incentive stock options) and the last day of any applicable option term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Paggiarino&#146;s right to receive the severance payments and benefits described above under his employment agreement is conditioned upon his
execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a separation agreement containing a general release of claims. Dr.&nbsp;Paggiarino&#146;s employment agreement contains certain restrictive covenants, including <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> of confidential information, assignment of rights to intellectual property, a <FONT STYLE="white-space:nowrap">non-competition</FONT> covenant that runs for 12 months following his termination of
employment for any reason, a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenant with respect to certain of our customers, vendors, suppliers and business partners that runs for 12 months following his termination of employment for any
reason and a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DIRECTOR COMPENSATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition Period Compensation
Summary </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and footnotes provide information regarding the compensation paid to our non-executive directors for the <FONT
STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31,&nbsp;2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;
($)<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt">(1)(2)</FONT></SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#246;ran Ando<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Mazzo<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Rogers<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Godshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Duker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Eastman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Landis<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in these columns reflect the grant date fair value as determined in accordance with FASB ASC Topic
718. The underlying valuation assumptions for equity awards are further disclosed in Note 12 of the audited financial statements filed with our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following table shows the aggregate number of outstanding shares underlying outstanding options and
unvested deferred stock units held by our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors as of December&nbsp;31, 2018: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding<BR>Option&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding<BR>Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#246;ran Ando</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Mazzo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Godshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Duker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Eastman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Landis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On October&nbsp;11, 2018, in consultation with our compensation consultant, the Compensation Committee awarded
Dr.&nbsp;Ando an option to purchase 15,000 shares of common stock to reflect Dr.&nbsp;Ando assuming the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
role of Board chair. This incremental new director award will vest in equal installments over three years from the date of grant. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;6, 2018, the Compensation Committee awarded Dr.&nbsp;Mazzo an additional grant of 1,667
options to purchase common stock and 417 deferred stock units, each with <FONT STYLE="white-space:nowrap">one-year</FONT> cliff vesting, in connection with Dr.&nbsp;Mazzo ceasing to serve as Board chair. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Rogers will not stand for <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board at the 2019
Annual Meeting. As a result, his term will expire at the completion of the 2019 Annual Meeting. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Landis received a new director option grant to purchase 80,000 shares on October&nbsp;25, 2018.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elements of <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rates of compensation to <FONT STYLE="white-space:nowrap">our&nbsp;non-executive&nbsp;directors</FONT> in effect for the
<FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018, and continuing until otherwise modified in the future, were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual retainer of $60,000 for the Board chair and $40,000 for each other Board member; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual retainer of $20,000 for the chair and $8,000 for each member of the Audit Committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual retainer of $15,000 for the chair and $7,500 for each member of the Compensation Committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual retainer of $10,000 for the chair and $5,000 for each member of the Governance and Nominating Committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual retainer of $8,000 for the chair and $4,000 for each member of the Science Committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event a director attends more than twelve committee meetings, meeting attendance fees of $1,000 for each
Board and committee meeting attended thereafter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initial grant of an option to purchase 80,000 shares for a new director, which vests in three equal annual
installments commencing on the first anniversary of the date of grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annual grants of options to purchase 50,000 shares for the Board chair and 40,000 shares for other <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors, other than Mr.&nbsp;Eastman, subject to allowable allocations between stock options and deferred stock units utilizing relative values between each instrument determined in consultation with
the Company&#146;s compensation consultant. Annual grants vest on the first anniversary of the date of grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;21,
2019, the Compensation Committee approved the following annual equity awards consisting solely of stock options as described above. Each of these equity awards is subject to the approval of Annual Meeting Proposal No.&nbsp;2, as discussed further
below, to amend our 2016 Plan to increase by 11,000,000 the number of shares of common stock authorized for issuance under the 2016 Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#246;ran Ando</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Mazzo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Godshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Duker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Landis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Lurker receives no additional compensation for serving as a director. Mr.&nbsp;Eastman does not receive compensation
for his serving as a director, although he is entitled to seek reimbursement for reasonable expenses incurred in connection with his service on the Board and is entitled to the same benefits, including benefits under any director and officer
indemnification or insurance policy maintained by us, as any other <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Board. Dr.&nbsp;Guyer was not eligible for an annual equity award as he received a new director grant in January
2019 upon his appointment as a Board member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_6"></A>PROPOSAL 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF NINE DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board
currently consists of ten directors, G&ouml;ran Ando, David J. Mazzo, Nancy Lurker, Michael Rogers, Douglas Godshall, Jay Duker, Kristine Peterson, Ronald W. Eastman, John Landis and David Guyer. Michael Rogers will not stand for <FONT
STYLE="white-space:nowrap">re-election</FONT> to the Board but will continue to serve as a director until the expiration of his term at the Annual Meeting. At the recommendation of the Governance and Nominating Committee, the Board has <FONT
STYLE="white-space:nowrap">(i)&nbsp;re-nominated</FONT> our other current directors (excluding Mr.&nbsp;Rogers) for election at the Annual Meeting and (ii)&nbsp;reduced the size of the Board to nine directors, effective as of the conclusion of the
Annual Meeting. Each nominee, if elected, will hold office until our 2020&nbsp;Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until he or she sooner dies, resigns or is removed. Except as disclosed
below, the proposed nominees are not being nominated pursuant to any arrangement or understanding with any person. We do not anticipate that any nominee will become unavailable to serve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biographical information and the attributes, skills and experience of each nominee that led our Governance and Nominating Committee and Board to determine
that such nominee should serve as a director are discussed in the&nbsp;&#147;Directors and Executive Officers&#148;&nbsp;section of this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT YOU VOTE<U>&nbsp;FOR ALL</U>&nbsp;ON PROPOSAL NO. 1 TO ELECT G&Ouml;RAN ANDO, DAVID J. MAZZO, NANCY LURKER, DOUGLAS GODSHALL, JAY
DUKER, KRISTINE PETERSON, RONALD W. EASTMAN, JOHN LANDIS AND DAVID GUYER TO THE BOARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_7"></A>PROPOSAL 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF AMENDMENT TO 2016 PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors believes that equity
incentives are important tools in motivating the performance of our officers, key employees and directors. Through the acquisition of Icon Bioscience, Inc. in March 2018, which included its newly <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
DEXYCU product for the treatment of post-operative ocular inflammation, and the FDA approval in October 2018 of our internally developed YUTIQ product, a micro-insert providing sustained release drug for the treatment of <FONT
STYLE="white-space:nowrap">non-infectious</FONT> uveitis affecting the posterior segment of the eye for up to 36 months from a single <FONT STYLE="white-space:nowrap">in-office</FONT> injection, we have undergone a substantial transformation of our
company leading up to the direct commercial launch of both products in the first quarter of calendar 2019. The <FONT STYLE="white-space:nowrap">build-out</FONT> of our commercial and operational infrastructure in the past year has resulted in
significant headcount additions in many functional areas, including marketing and sales, medical affairs, regulatory, quality assurance, human resources, information technology and finance. As of March&nbsp;31, 2019, we had a total of 60 employees
compared to 24 employees at March&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our success depends largely upon our ability to attract, retain and motivate the highly
skilled talent and personnel we need and expect to make important contributions to our company. We accomplish this by providing our employees with meaningful equity ownership opportunities and performance-based incentives. The life sciences market
is highly competitive, and our results are largely attributable to the talents, expertise, efforts and dedication of our employees. Our compensation program, including the granting of equity compensation, is the primary means by which we attract and
recruit new employees, as well as retain our most experienced and skilled employees. As noted above, we are operating in a period of high growth in both infrastructure and headcount, and maintaining a sustainable equity program that effectively aids
in executing this growth strategy is key to our future success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this labor market, we are often competing for highly-skilled talent with many
companies that have evergreen provisions in their equity incentive plans which provide for annual additions of new shares eligible for grant to current and prospective future employees. We do not have an evergreen provision in our equity plan that
provides for annual refreshes of new shares to grant and, as such, we are required to request stockholders to approve a total share pool that will sustain the Company&#146;s equity incentive program for the next several years, and this request is
intended to do so. We project this share request, if approved, will sustain the Company&#146;s equity program for at least the next three years and this request should be viewed by stockholders in that very important context. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have carefully modeled our projected future share usage and needs for current employees and expected new hires to determine the appropriate
share request amount. We have then studied the effect this share request and its approval would have on the total overhang of the Company&#146;s equity program. We have thoughtfully compared these results to publicly disclosed share usage data from
a set of biopharmaceutical companies that are comparable to us in terms of revenue, market value, stage of development, and headcount (&#147;peer companies&#148; or &#147;peer group&#148;). Our analysis versus this set of peer companies has led to
the following key conclusions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our 2019 burn rate projects to be positioned between the
25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our issued overhang at the end of 2019 projects to approximate the peer companies&#146; 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> percentile; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our total overhang at the end of 2019 projects to be positioned between the 50<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the peer companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the above positioning demonstrates the reasonableness of this share request and that it should be supported to allow the Company to compete
successfully and create value for stockholders over the next several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, there were 1,305,278 shares available for the grant of future equity awards
under the 2016 Plan. Upon the recommendation of the Compensation Committee, the Board of Directors has approved, subject to stockholder approval, an amendment to the 2016 Plan to increase the number of shares authorized for issuance under the 2016
Plan by 11,000,000 shares. The Board believes that equity awards provide an important incentive for our employees, including our executive officers, other key employees and our directors, to remain with the Company, to motivate them to help achieve
our corporate objectives and to align their interests with those of our stockholders. The Board voted to approve the amendment to the 2016 Plan to ensure that we have sufficient capacity under the 2016 Plan to continue to provide appropriate equity
incentives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2019, the Compensation Committee approved annual grants to <FONT STYLE="white-space:nowrap">non-executive</FONT> employees under
the 2016 Plan and initial grants have been made since December&nbsp;31, 2018 to newly hired employees. These awards, net of forfeitures, have reduced the shares available for grant under the 2016 Plan to approximately 669,000 at April&nbsp;26, 2019.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2019, the closing price of our common stock on the Nasdaq Global Market was $1.77 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Material Terms of the 2016 Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following summary describes the material terms of the 2016 Plan and provides a general description of the U.S. federal income tax consequences applicable to certain transactions involving awards under the 2016 Plan. The following description of
certain features of the 2016 Plan is qualified in its entirety by reference to the full text of (x)&nbsp;Amendment No.&nbsp;1 to the 2016 Plan and (y)&nbsp;the 2016 Plan, each of which is filed as <U>Annex A</U> to this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. The 2016 Plan is administered by the Compensation Committee, which has the authority to, among other things, interpret the 2016
Plan, determine eligibility for, grant and determine, modify or waive the terms and conditions of awards under the 2016 Plan, and to do all things necessary or appropriate to carry out the purposes of the 2016 Plan. The Compensation Committee&#146;s
determinations under the 2016 Plan are conclusive and binding. The Compensation Committee may delegate certain of its duties, powers and responsibilities as it deems appropriate to one or more of its members (or one or more other members of the
Board, including the full Board), our officers or our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Term</I>. No awards will be made after the tenth anniversary of the 2016 Plan&#146;s
approval by our Board, or October&nbsp;3, 2026, but previously granted awards may continue beyond that date in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized
Shares</I>. Prior to the adoption of the amendment, the maximum number of shares of our common stock that may be delivered in satisfaction of awards under the 2016 Plan consisted of an the aggregate of 3,000,000 shares, plus up to 800,000 shares
that remain available for grant under the 2008 Plan as of the Board&#146;s adoption of the 2016 Plan (which occurred on October&nbsp;3, 2016) and any shares that would otherwise have become available for grant under the 2008 Plan after the
Board&#146;s adoption of the 2016 Plan as a result of the termination or forfeiture of awards under the 2008 Plan. As of December&nbsp;31, 2018, there were 1,305,278 shares available for the grant of future equity awards under the 2016 Plan. The
proposed amendment will increase the number of shares that may be issued under our 2016 Plan by 11,000,000 shares, for a total of 14,000,000 shares, plus 336,741 shares that remained available for grant under the 2008 Plan as of the adoption of the
2016 Plan on December&nbsp;12, 2016, and any shares that would otherwise become available for grant under the 2008 Plan thereafter as a result of the termination or forfeiture of awards under the 2008 Plan, subject to adjustment to prevent the
dilution or enlargement of rights from stock dividends, stock splits, recapitalization or similar transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock
delivered in satisfaction of awards under the 2016 Plan will be determined by (i)&nbsp;including shares withheld by us in payment of the exercise price or purchase price of the award or in satisfaction of tax withholding requirements with respect to
the award, (ii)&nbsp;including the full number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares covered by stock appreciation rights (&#147;SARs&#148;) any portion of which is settled in common stock (and not only the number of shares delivered in settlement) and (iii)&nbsp;by
excluding any shares underlying awards that expire, become unexercisable, terminate or are forfeited to or repurchased by us without the issuance of common stock. The number of shares available for delivery under the 2016 Plan will not be increased
by the amount of any shares delivered under the plan that are subsequently repurchased using proceeds directly attributable to stock option exercises.&nbsp;Shares delivered under the 2016 Plan may be authorized but unissued shares or previously
issued shares of our common stock acquired by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Individual Limits</I>. The maximum number of shares for which stock options may be granted to
any person in any calendar year is 3,000,000 shares. The maximum number of shares for which SARs may be granted to any person in any calendar year is 3,000,000 shares. The maximum number of shares subject to awards other than stock options, SARs or
cash awards that may be granted to any person in any calendar year is 3,000,000 shares. The maximum amount that may be payable to any employee in any calendar year in respect of any cash award is $5,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Limits.</I><I></I>&nbsp;The aggregate value of all compensation granted or paid to any
<FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including all awards granted under the 2016 Plan and any other fees or compensation paid to such director outside of the 2016 Plan for services as a
director, will not exceed $350,000. This limit does not apply to any award or shares of stock granted pursuant to a director&#146;s election to receive an award or shares in lieu of cash retainers or other fees. The Board may make an exception to
such limit for any director in extraordinary circumstances, as the Board may determine in its discretion, provided that any director who is granted or paid such additional compensation may not participate in the decision to grant or pay such
additional compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. The Compensation Committee selects participants from among the key employees and directors of and
consultants and advisors to us and our affiliates. Eligibility for incentive stock options (ISOs) is limited to our employees and employees of certain of our affiliates and eligibility for stock options other than ISOs is limited to individuals
providing direct services to us or a subsidiary on the date of grant or who we reasonably anticipate will begin providing direct services to us or a subsidiary of ours within twelve months following the date of grant. As of April&nbsp;26, 2019, 61
employees and nine <FONT STYLE="white-space:nowrap">non-executive</FONT> directors would be eligible to participate in the 2016 Plan. On April&nbsp;26, 2019, the closing price of a share of our common stock was $1.77. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2016 Plan provides for grants of stock options, SARs, restricted and unrestricted stock and stock units, performance awards, other
awards convertible into or otherwise based on shares of our stock and cash awards. Dividend equivalents may also be provided in connection with awards under the 2016 Plan. Awards may be settled in shares of our common stock, cash, property, other
awards or a combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options and SARs</I>. The 2016 Plan provides for the grant of ISOs,
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options (NSOs), and SARs. The exercise price of an option, and the base price against which a SAR is to be measured, may not be less than the fair market value (or, in the case of an ISO
granted to a <FONT STYLE="white-space:nowrap">10-percent</FONT> stockholder, 110% of the fair market value) of a share of our common stock on the date of grant. The Compensation Committee determines when stock options or SARs become exercisable and
the terms on which such awards remain exercisable. Stock options and SARs may have a maximum term of no more than ten years from the date of grant (or five years from the date of grant in the case of an ISO granted to a <FONT
STYLE="white-space:nowrap">10-percent</FONT> stockholder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted and Unrestricted Stock</I>: A restricted stock award is an award of our common
stock subject to restrictions requiring that it be redelivered or offered for sale to us if specified conditions are not met, while an unrestricted stock award is not subject to restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Units</I>. A stock unit award is an unfunded and unsecured promise, denominated in shares of our common stock, and entitles the participant to
receive stock or cash measured by the value of the shares in the future. The delivery of common stock or cash under a stock unit may be subject to the satisfaction of performance or other vesting conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. A performance share award is an award the vesting, settlement or exercisability
of which is subject to specified performance criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Awards</I>. A cash award is an award denominated in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vesting</I>. The Compensation Committee has the authority to determine the vesting schedule applicable to each award, and to accelerate the vesting or
exercisability of any award, provided that stock options, SARs, restricted stock, restricted stock units and cash awards granted under the 2016 Plan will be subject to a minimum vesting and exercisability period of at least one year from the award
grant date, subject to a <FONT STYLE="white-space:nowrap">carve-out</FONT> for awards that in the aggregate do not exceed five percent of the total shares of our common stock reserved for issuance under the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Employment or Service</I>. The Compensation Committee determines the effect of termination of employment or service on an award. Unless
otherwise provided by the Compensation Committee, upon a termination of employment or service, all unvested stock options and other unvested awards will be forfeited and all vested stock options and SARs will remain exercisable for the lesser of the
remaining term of the award and, in the case of a termination due to death, one year following the participant&#146;s death, or, in the case of a termination for any other reason, three months following termination. Notwithstanding the foregoing,
upon a termination of employment or service for &#147;Cause&#148; (as defined in the 2016 Plan) or in circumstances that would have constituted grounds for &#147;Cause,&#148; all stock options and SARs, whether or not exercisable, will terminate
upon cessation of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability.</I><I></I>&nbsp;Awards under the 2016 Plan generally may not be transferred except by will or by the
laws of descent and distribution. The Compensation Committee may permit the gratuitous transfer of awards other than ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions.</I><I></I>&nbsp;In the event of a consolidation, merger or similar transaction or series of related transactions, a sale or transfer of all or substantially all of our assets or a dissolution or our liquidation (a Covered Transaction),
the Compensation Committee may, among other things, provide for the continuation or assumption of outstanding awards, for new grants in substitution of outstanding awards, for the accelerated vesting or delivery of shares of common stock under
awards or for a cash out of outstanding awards, in each case on such terms and with such restrictions as it deems appropriate. Except as the Compensation Committee may otherwise determine, awards not assumed will terminate upon the consummation of
such Covered Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustment</I>. In the event of certain corporate transactions (including, but not limited to, a stock dividend, stock split
or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure that constitutes an equity restructuring within the meaning of Financial Accounting Standards Board, or FASB, ASC Topic 718), the
Compensation Committee will make appropriate adjustments to the maximum number of shares that may be issued under and the individual limits included in the 2016 Plan, and will also make appropriate adjustments to the number and kind of shares of
stock or securities underlying equity awards, the exercise or purchase prices (or base values) of awards and any other terms of awards affected by such change. The Compensation Committee may also make the types of adjustments described above to take
into account distributions to stockholders and events other than those listed above if it determines that such adjustments are appropriate to avoid distortion in the operation of the 2016 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recoupment.</I><I></I>&nbsp;The Compensation Committee may provide that outstanding awards, whether or not vested or exercisable, and the proceeds from the
exercise or disposition of awards or stock acquired under awards will be subject to forfeiture and disgorgement to us, with interest and other related earnings, if the participant to whom the award was granted violates a <FONT
STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant or any of our policies that provides for forfeiture or disgorgement with respect to incentive
compensation that includes awards under the 2016 Plan.&nbsp;In addition, the Administrator may require forfeiture and disgorgement to us of outstanding awards and the proceeds from the exercise or disposition of awards or stock acquired under
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards, with interest and other related earnings, to the extent required by law, including, without limitation, Section&nbsp;10D of the Exchange Act, or applicable stock exchange listing
standards and any of our related corporate policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. The Compensation Committee can amend the 2016 Plan or outstanding
awards issued under the 2016 Plan, or terminate the 2016 Plan as to future grants of awards, at any time except that the Compensation Committee will not be able to alter the terms of an award without a participant&#146;s consent if it would
materially and adversely affect the participant&#146;s rights under the award (unless expressly reserved by the Compensation Committee at the time of grant). Stockholder approval will be required for any amendment to the extent such approval is
required by law, including the Code and applicable stock exchange requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Repricing</I>. Except in connection with a corporate transaction
involving the Company, the Company may not, without obtaining stockholder approval, (x)&nbsp;amend the terms of outstanding stock options or SARs to reduce the exercise price or base value of such stock options or SARs, (y)&nbsp;cancel outstanding
stock options or SARs in exchange for stock options or SARs with an exercise price or base value that is less than the exercise price or base value of the original stock options or SARs, or (z)&nbsp;cancel outstanding stock options or SARs that have
an exercise price or base value greater than the fair market value of a share of the Company&#146;s common stock on the date of such cancellation in exchange for cash or other consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At its February&nbsp;21, 2019 meeting,
the Compensation Committee approved annual stock option awards to our Named Executive Officers, senior management and <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, and a restricted stock unit award to our Chief Executive Officer,
that, as a result, are subject to stockholder approval of this proposed 2016 Plan amendment. These awards are summarized in the table below. No other awards have been granted under the 2016 Plan that are subject to stockholder approval of this
proposed 2016 Plan amendment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016 Long-Term Incentive Plan</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Options </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted Stock Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Position </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Value&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Value ($) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Units (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Lurker, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">930,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,090,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Price, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dario Paggiarino, SVP and Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,090,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-Executive Director Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-Executive Officer Employee Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock options in the table above have an exercise price of $2.65 per share, the closing price on February&nbsp;21, 2019,
and (i)&nbsp;would vest ratably on a monthly basis over four years from that date for the executive officers and the <FONT STYLE="white-space:nowrap">non-executive</FONT> officer employee group and (ii)&nbsp;would vest on the first anniversary of
the date of grant for the <FONT STYLE="white-space:nowrap">non-executive</FONT> director group. Each stock option will expire no later than 10 years from the grant date. The restricted stock unit award to our Chief Executive Officer would vest
ratably on an annual basis over three years. The amounts in the &#147;Dollar Value&#148; column in the table above represent the aggregate grant date fair value of the restricted stock unit award to our Chief Executive Officer computed based on the
closing share price of $2.65 on February 21, 2019. The dollar value in accordance with FASB ASC Topic 718 will be determined based on the closing share price on June 25, 2019 following an approval of Proposal 2. We expect further additions to
headcount during 2019 to support anticipated growth in our product sales. It is not possible to predict the individuals who will receive future awards under the 2016 Plan or the number of shares of common stock covered by any future award because
such awards are wholly within the discretion of our Compensation Committee and our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences under the 2016 Plan
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of some of the material U.S. federal income tax consequences associated with the grant and exercise of awards under the
2016 Plan under current U.S. federal tax laws and certain other tax</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>considerations associated with awards under the 2016 Plan as of the date hereof. The summary does not address tax rates or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or U.S. state or
local tax consequences, nor does it address employment tax or other U.S. federal tax consequences, except as noted</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ISOs</I>. In general, a
participant realizes no taxable income upon the grant or exercise of an ISO. However, the exercise of an ISO may result in an alternative minimum tax liability to the participant. With some exceptions, a disposition of shares purchased under an ISO
within two years from the date of grant or within one year after exercise produces ordinary income to the participant (and generally a tax deduction to us) equal to the value of the shares at the time of exercise less the exercise price. Any
additional gain recognized in the disposition is treated as a capital gain for which we are not entitled to a deduction. If the participant does not dispose of the shares until after the expiration of these
<FONT STYLE="white-space:nowrap">one-</FONT> and <FONT STYLE="white-space:nowrap">two-year</FONT> holding periods, generally any gain or loss recognized upon a subsequent sale is treated as a long-term capital gain or loss for which we are not
entitled to a deduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NSOs</I>. In general, a participant has no taxable income upon the grant of an NSO but realizes taxable income in connection
with exercise of the option in an amount equal to the excess (at time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price. A corresponding tax deduction is generally available to us. Upon a subsequent
sale or exchange of the shares, any recognized gain or loss is treated as a capital gain or loss for which we are not entitled to a deduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SARs</I>. The grant of a SAR does not itself result in taxable income to a participant, nor does taxable income result merely because a SAR becomes
exercisable. In general, a participant who exercises a SAR for shares of stock or receives payment in cancellation of a SAR will have ordinary income equal to the amount of any cash and the fair market value of any stock or other property received.
A corresponding tax deduction is generally available to us at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. A participant who is awarded or purchases shares
subject to a substantial risk of forfeiture generally does not have taxable income until the risk of forfeiture lapses. When the risk of forfeiture lapses, the participant has ordinary income equal to the excess of the fair market value of the
shares at that time over the purchase price, if any, and a corresponding tax deduction is generally available to us in the same year that the participant recognizes ordinary income. However, a participant may make an election under
Section&nbsp;83(b) of the Code (83(b) election) to be taxed on restricted stock when it is acquired rather than later, when the substantial risk of forfeiture lapses. A participant who makes an effective 83(b) election will realize ordinary income
equal to the fair market value of the shares as of the time of acquisition less any price paid for the shares. A corresponding tax deduction will generally be available to us in the same year that the participant recognizes ordinary income. If a
participant makes an effective 83(b) election, no additional income results by reason of the lapsing of the restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining
capital gain or loss on a sale of shares awarded under the 2016 Plan, the holding period in the shares begins just after the participant recognizes taxable income with respect to the transfer. The participant&#146;s tax basis in the shares equals
the amount paid for the shares plus any income realized with respect to the transfer. However, if a participant makes an effective 83(b) election and later forfeits the shares, the tax loss realized as a result of the forfeiture is limited to the
excess of what the participant paid for the shares (if anything) over the amount (if any) realized in connection with the forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unrestricted
Stock.</I><I></I>&nbsp;A participant who purchases or is awarded unrestricted stock generally has ordinary income equal to the excess of the fair market value of the shares at the time of such purchase or award, as applicable, over the purchase
price, if any, and a corresponding tax deduction is generally available to us in the same year that the participant recognizes ordinary income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units</I>. The grant of a restricted stock unit does not itself generally result in taxable income. Participants are generally taxed upon
settlement (and a corresponding tax deduction is generally available to us) of a restricted stock unit, unless he or she has made a proper election to defer the receipt of the shares (or cash if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the award is cash settled) under Section&nbsp;409A of the Code. If the shares delivered are restricted for tax purposes, the participant will instead be subject to the rules described above for
restricted stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Change of Control Payments</I>. Under Section&nbsp;280G of the Code, the vesting or accelerated exercisability of stock
options or the vesting and payments of other awards in connection with a change of control of a corporation may be required to be valued and taken into account in determining whether participants have received compensatory payments, contingent on
the change in control, in excess of certain limits. If these limits are exceeded, a substantial portion of amounts payable to the participant, including income recognized by reason of the grant, vesting or exercise of awards may be subject to an
additional 20% federal tax and may be <FONT STYLE="white-space:nowrap">non-deductible</FONT> to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed Amendment to the 2016 Plan. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has approved, and recommends for adoption by our stockholders, an amendment to the 2016 Plan to increase the number of shares of common stock
reserved for issuance under the 2016 Plan from 3,000,000 shares to 14,000,000 shares, plus 336,741 shares that remained available for grant under the 2008 Plan as of the adoption of the 2016 Plan on December&nbsp;12, 2016, and any shares that would
otherwise become available for grant under the 2008 Plan thereafter as a result of the termination or forfeiture of awards under the 2008 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
effectiveness of the proposed amendment to our 2016 Plan is contingent upon stockholder approval. If our stockholders do not approve the amendment, the existing version of our 2016 Plan will remain in effect, unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT YOU VOTE <U>FOR</U> PROPOSAL NO. 2, TO APPROVE THE AMENDMENT TO THE 2016 PLAN TO INCREASE THE NUMBER OF SHARES RESERVED FOR
ISSUANCE UNDER THE 2016 PLAN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_8"></A>PROPOSAL 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF THE ADOPTION OF THE EYEPOINT PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2019, at the recommendation of
the Compensation Committee, the Board of Directors adopted the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, or the ESPP, in substantially the form attached hereto as <U>Annex B</U>. The purpose of the ESPP is to encourage and to
enable eligible employees to acquire proprietary interests in the Company through the purchase and ownership of shares of our common stock. The ESPP is intended to benefit us and our stockholders by incentivizing participants to contribute to our
success and to operate and manage our business in a manner that will provide for our long-term growth and profitability and that will benefit our stockholders and other important stakeholders. The ESPP is intended to qualify as an &#147;employee
stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Internal Revenue Code of 1986. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Reserve </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP will authorize the issuance of up to 1,100,000 shares of our common stock pursuant to purchase rights granted to our employees or to employees of any
of our participating affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP will be administered under the direction of our Board of Directors, our Compensation Committee, or any other committee designated by our Board of
Directors. Our Board of Directors has delegated full authority to administer the ESPP to its Compensation Committee. Among other things, the Compensation Committee will have the authority to determine eligibility for participation in the ESPP,
designate separate offerings under the plan, and construe, interpret and apply the terms of the plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our employees who are employed by us or our participating affiliates may be eligible to participate in the ESPP, provided that the following employees
are among those that are ineligible under the ESPP: (i)&nbsp;employees whose customary employment is 20 hours or less per week; (ii)&nbsp;employees whose customary employment is for not more than five months in any calendar year; and
(iii)&nbsp;employees who, after exercising their rights to purchase our common stock under the ESPP, would own 5% or more of our total combined voting power. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;26, 2019, a total of 61 employees would be eligible to participate in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No employee may purchase shares of our common stock in any calendar year under the ESPP and under all other employee stock purchase plans having an aggregate
fair market value in excess of $25,000, determined as of the first trading day of the offering period. In addition, unless otherwise determined by our Compensation Committee, no employee may purchase more than 50,000 shares of our common stock in
any one offering period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offering Periods </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP will be implemented through a series of offerings under which eligible employees are granted purchase rights to purchase our common stock on specified
dates during such offerings. Our Compensation Committee will determine offering periods of not more than 27 months and may permit periodic purchases of our common stock within a single offering period. Unless otherwise established by our
Compensation Committee prior to the start of an offering period, the plan will have two offering periods (with concurrent purchase periods) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that commence each calendar year, and each offering period will be of approximately six months&#146; duration, with the first such offering period beginning on the first trading day of February
and ending on the last trading day of the immediately following July, and the second such offering period beginning on the first trading day of August and ending on the last trading day of the immediately following January. Unless otherwise
established by our Compensation Committee prior to the start of the first offering period, the first offering period under the ESPP will begin on August&nbsp;1, 2019 and end on January&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payroll Deductions and Purchase Price </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally,
all employees, including executive officers, employed by us or by any of our participating affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their eligible compensation for the purchase of
our common stock under the ESPP. Unless otherwise determined by our Compensation Committee, the purchase price per share of our common stock under the ESPP will be 85% of the lesser of the average of the high and low sales price of our common stock
on (i)&nbsp;the first trading day of the relevant offering period and (ii)&nbsp;the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2019, the closing price of a share of our common stock was $1.77. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on the Sale of Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
Compensation Committee has the right to (i)&nbsp;require that an employee not request that all or a part of the shares of our common stock purchased by the employee be reissued in the employee&#146;s own name and shares be delivered to the employee
until two years have elapsed since the offering date of the offering period in which the shares of our common stock were purchased and one year has elapsed since the day the shares of our common stock were purchased, or the holding period,
(ii)&nbsp;require that any sales of our common stock during the holding period be performed through a licensed broker acceptable to us and (iii)&nbsp;limit sales or other transfers of shares of our common stock for up to two years from the date the
employee purchases shares of our common stock under the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that there occurs a change in our capital structure through such actions as a recapitalization, stock split, reverse stock split, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination of shares, exchange of shares, stock dividend or other distribution payable in capital stock, our Compensation Committee will make appropriate adjustments to the number and kind of shares that
may be purchased, and the number and kind of shares for which options are outstanding, under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of certain significant corporate
transactions, including (i)&nbsp;a dissolution or liquidation, (ii)&nbsp;a merger, consolidation or reorganization where we are not the surviving entity, (iii)&nbsp;a sale of all or substantially all of our assets, or (iv)&nbsp;a merger or
consolidation resulting in any person or entity owning more than 50% of the combined voting power of all classes of our capital stock, the ESPP and all elections outstanding under the ESPP will terminate, except for certain situations where, for
instance, the parties make arrangements for the continuation or assumption of the ESPP. In the event of any such termination of the ESPP, the offering period and the purchase period will be deemed to have ended on the last trading day prior to such
termination, and the options of each participant then outstanding will be deemed to be automatically exercised on such last trading day. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment,
Suspension, or Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP will terminate on the day before the 10th anniversary of the date of adoption of the ESPP by our Board of
Directors, unless earlier terminated. Our Compensation Committee may amend, suspend, or terminate the ESPP; however, any such amendment, suspension, or termination may not impair any vested rights without the employee&#146;s consent. Our
Compensation Committee may not increase the number of shares reserved for issuance under the ESPP without stockholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences under the ESPP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of some of the material U.S. federal income tax consequences associated with participation in the ESPP under current U.S. federal
tax laws. The summary does not address tax rates or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or U.S. state or local tax consequences, nor does it address <FONT STYLE="white-space:nowrap">employment-tax</FONT> or other U.S. federal tax
consequences, except as noted. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 of the Internal
Revenue Code, and options to make purchases under the ESPP are intended to qualify under the provisions of Section&nbsp;423 of the Internal Revenue Code. Amounts withheld from a participant&#146;s earnings under the ESPP will be taxable income to
the participant in the year in which the amounts otherwise would have been received, but the participant will not be required to recognize additional income for U.S. federal income tax purposes either at the time the participant is deemed to have
been granted an option to purchase our common stock on the grant date or when the option to purchase our common stock is exercised on the purchase date. No additional taxable income will be recognized for U.S. federal income tax purposes by a
participant until the sale or other disposition of the shares of our common stock acquired under the ESPP. Upon such sale or disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares
are held by the participant prior to selling or disposing of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a participant holds the shares of our common stock purchased under the ESPP for at
least two years after the grant date and for at least one year from the purchase date of the shares of our common stock, when the participant sells or disposes of the shares of our common stock (a &#147;qualifying disposition&#148;), the participant
will recognize as ordinary income an amount equal to the lesser of: (i)&nbsp;the excess of the fair market value of the shares of our common stock on the date of such sale or disposition over the purchase price or (ii)&nbsp;the fair market value of
the shares of our common stock on the grant date multiplied by the discount percentage for stock purchases under the ESPP. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above
but are sold for a price that is less than the purchase price, there is no ordinary income, and the participant has a long-term capital loss for the difference between the sale price and the purchase price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a participant sells or disposes of the shares of our common stock purchased under the ESPP within two years after the grant date or before one year has
elapsed since the purchase date (a &#147;disqualifying disposition&#148;), the participant will recognize as ordinary income an amount equal to the excess of the fair market value of the shares on the date the shares are purchased over the purchase
price. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to selling or disposing
of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a qualifying disposition, the Company will not receive any deduction for U.S. federal income tax purposes with respect to
those shares of our common stock or the option under which it was purchased. In connection with a disqualifying disposition, the Company will be entitled to a deduction in an amount equal to the amount that is considered ordinary income </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the number of shares of our
common stock that may be purchased under the ESPP will depend on each participant&#146;s voluntary election to participate and on the fair market value of our common stock at various future dates, the actual number of shares that may be purchased by
any individual cannot be determined in advance. No shares of our common stock have been issued under the ESPP as of the date of this proxy statement, and no shares of our common stock will be issued under the ESPP prior to approval of the ESPP by
the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT YOU VOTE <U>FOR</U> PROPOSAL NO. 3, TO APPROVE THE ADOPTION OF THE EYEPOINT
PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_9"></A>PROPOSAL 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required under Section&nbsp;14A of the Exchange Act, the Board is submitting a &#147;say on pay&#148; proposal for stockholder consideration. While the
vote on executive compensation is nonbinding and advisory, the Board and the Compensation Committee value the opinion of our stockholders, and to the extent there is any significant vote against the executive officer compensation as disclosed in
this proxy statement, we will consider our stockholders&#146; concerns and evaluate what actions may be appropriate to address those concerns. Our current policy is to provide stockholders with an opportunity to approve the compensation of our Named
Executive Officers each year at the annual meeting of stockholders. It is expected that the next such vote will occur at the 2020 annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board and the Compensation Committee value the perspectives and concerns of our stockholders regarding executive compensation. We are therefore pleased to
entertain stockholder views and receive comments about our executive compensation practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executives regularly hold meetings with stockholders,
and participate in professional investor conferences, to hear stockholder views on our financial performance, strategic business plans, corporate governance, executive compensation and related subjects. While we have not received particular
stockholder feedback that warranted significant actions be undertaken to change our executive compensation program and practices, we will continue to regularly engage with stockholders and entertain their views, and also consult with professional
advisors, regarding our Named Executive Officer compensation practices in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation of our Named Executive Officers is described
starting on page 30 of this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are asking stockholders to vote on the following resolution: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, that the Company&#146;s stockholders approve, on an advisory basis, the compensation of our Named Executive Officers as
disclosed in the proxy statement for the 2019 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT YOU VOTE, ON AN ADVISORY BASIS, <U>FOR</U> PROPOSAL NO.&nbsp;4 TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS
DISCLOSED IN THIS PROXY STATEMENT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_10"></A>PROPOSAL 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY VOTE ON FREQUENCY OF ADVISORY STOCKHOLDER VOTES ON COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the 2013 annual meeting of stockholders, the holders of a majority of our shares present and voting on the matter voted, on an advisory basis, to hold <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes, as described in the immediately preceding proposal, on an annual basis. After taking into consideration the results of this &#147;say on
frequency&#148; vote, our Board determined to include <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes in management&#146;s proxy materials on an annual basis until the next required <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-frequency&#148;</FONT></FONT> vote. Under Section&nbsp;14A of the Securities Exchange Act of 1934, as amended, we are required to solicit stockholder advisory votes on the
frequency of future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes at least once every six years. Accordingly, we are providing stockholders with the opportunity to cast an advisory vote
on whether they would prefer future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes on an annual basis, or once every two or once every three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because this proposal calls for a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote, our Board of Directors and the Compensation Committee may
determine to hold <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes more or less frequently than the option selected by our stockholders (though no less frequently than once every three
years). However, our Board of Directors and the Compensation Committee value the opinions of our stockholders and will consider the outcome of the vote when determining the frequency of future <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes. We expect that the next <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-frequency&#148;</FONT></FONT> vote will occur at the 2025 Annual Meeting of
Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful consideration, our Board of Directors has determined that an advisory vote on executive compensation that occurs every year
is the most appropriate for a company such as EyePoint, and recommends that stockholders vote for a frequency of &#147;1 YEAR&#148; for future advisory votes on executive compensation. Our Board of Directors believes that an annual advisory vote
will enable our stockholders to provide timely, direct input on our executive compensation program as disclosed in the proxy statement each year, and is consistent with our efforts to engage in an ongoing dialogue with our stockholders. The
Compensation Committee, which administers the executive compensation program, values the opinions expressed by our stockholders in these votes, and even though <FONT STYLE="white-space:nowrap">non-binding,</FONT> will continue to consider the
outcome of these votes in making its decisions on executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of Proposal No.&nbsp;5 requires the affirmative vote of a majority
of the votes properly cast on the matter. However, because stockholders have several voting choices with respect to the proposal on the frequency of future advisory votes on executive compensation, it is possible that no single choice will receive a
majority vote. In light of the foregoing, the Board of Directors will consider the outcome of the vote when determining the frequency of future advisory votes on executive compensation. Moreover, because this vote is
<FONT STYLE="white-space:nowrap">non-binding,</FONT> the Board may determine the frequency of future advisory votes on executive compensation in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT STOCKHOLDERS VOTE <U>FOR &#147;1 YEAR&#148;</U> ON THE PROPOSAL RECOMMENDING THE FREQUENCY OF ADVISORY VOTES ON NAMED EXECUTIVE
OFFICER COMPENSATION. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_11"></A>PROPOSAL 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIFICATION OF APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has appointed Deloitte&nbsp;to serve as our independent registered public accounting firm and to audit our financial statements and our
internal control over financial reporting for fiscal 2019. Although ratification is not required, we are seeking stockholder approval of the selection as a matter of good corporate practice. If stockholders do not ratify the appointment, then the
Audit Committee will consider whether it is appropriate to select a different independent registered public accounting firm or to continue Deloitte&#146;s appointment as our independent registered public accounting firm. Even if stockholders do
ratify the appointment, the Audit Committee in its discretion may select a different independent registered public accounting firm at any time during the year, if the Audit Committee determines that such a change would be in our and our
stockholders&#146; best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deloitte was our independent registered public accounting firm for the fiscal years ended June&nbsp;30, 2018 and 2017
and for the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018. Deloitte is expected to have a representative present at the Annual Meeting to answer appropriate questions and to make a statement if he
or she desires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT YOU VOTE <U>FOR</U> PROPOSAL NO. 6 TO RATIFY OUR SELECTION OF DELOITTE AS OUR INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM FOR FISCAL 2019. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the total fees paid to Deloitte and its affiliates with respect to the <FONT STYLE="white-space:nowrap">six-month</FONT>
transition period ended December&nbsp;31, 2018 and the fiscal years ended June&nbsp;30, 2018 and 2017 (in thousands): </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018&nbsp;Transition</B><br><B>Period</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees relate to professional services rendered in connection with the audit for the <FONT
STYLE="white-space:nowrap">six-month</FONT> transition period or prior fiscal years of our consolidated financial statements, reviews of the condensed consolidated financial statements performed in connection with each of our Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and the fiscal 2017 statutory audit of our wholly-owned United Kingdom subsidiary. The 2018 Transition Period fees also included $27,000 related to the consents for the incorporation by reference of
audit reports on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statements filed with the SEC. Fiscal 2018 fees also included incremental professional services related to accounting
for the acquisition of Icon Bioscience, Inc. and equity and debt transactions and issuance of a comfort letter in connection with our ATM program. Fiscal 2017 fees also include the audit of our internal controls over financial reporting, which was
not required in fiscal 2018 as we were a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer under SEC rules for that year. In addition, $48,000 of comfort letter and Form <FONT STYLE="white-space:nowrap">S-8</FONT> consent fees for fiscal
2017 previously classified as Audit-related fees have been reclassified to Audit Fees in the above table to conform to 2018 classification based on prevailing guidance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These are fees for assurance and related services that are reasonably related to performance of the audit and
review of our financial statements, and which are not reported under &#147;Audit fees&#148;. These services in fiscal 2018 were related to due diligence activities in connection with the acquisition of Icon Bioscience, Inc. and equity and debt
transactions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax fees paid to Deloitte for the 2018 transition period, fiscal 2018 and fiscal 2017 were related to the
preparation of various corporate tax returns as well as tax advice. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All other fees relate to a subscription to Deloitte&#146;s <FONT STYLE="white-space:nowrap">on-line</FONT>
accounting research database. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our policies require the Audit Committee
<FONT STYLE="white-space:nowrap">to&nbsp;pre-approve&nbsp;all</FONT> audit and <FONT STYLE="white-space:nowrap">permitted&nbsp;non-audit&nbsp;services</FONT> provided by the independent registered public accounting firm, including engagement fees
and terms. The Audit Committee may <FONT STYLE="white-space:nowrap">delegate&nbsp;pre-approval&nbsp;authority</FONT> to one or more of its members, who will report <FONT STYLE="white-space:nowrap">any&nbsp;pre-approval&nbsp;decisions</FONT> to the
full committee at its next scheduled meeting but may not <FONT STYLE="white-space:nowrap">delegate&nbsp;pre-approval&nbsp;authority</FONT> to members of management. The Audit Committee may approve only
<FONT STYLE="white-space:nowrap">those&nbsp;non-audit&nbsp;services</FONT> classified as &#147;all other services&#148; that it believes to be routine and recurring services, to be consistent with SEC rules and to not impair the auditor&#146;s
independence with respect to us. The Audit Committee reviewed <FONT STYLE="white-space:nowrap">and&nbsp;pre-approved&nbsp;all</FONT> audit services and <FONT STYLE="white-space:nowrap">permitted&nbsp;non-audit&nbsp;services</FONT> performed during
the <FONT STYLE="white-space:nowrap">six-month</FONT> transition period ended December&nbsp;31, 2018 and fiscal 2018 and 2017.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_12"></A>INFORMATION ABOUT STOCKHOLDER PROPOSALS AND DIRECTOR
NOMINATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder proposals for inclusion in our proxy statement:</I> To be eligible for inclusion in our proxy statement and form of proxy
relating to our 2020 Annual Meeting of Stockholders, or the 2020 Annual Meeting, stockholder proposals must be submitted pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> of the Securities Exchange Act of 1934, as amended, and received
at our principal executive offices no later than January&nbsp;11, 2020, which is 120 calendar days before May&nbsp;10, 2020&#151;the anniversary of the date this proxy statement was released to stockholders in connection with the Annual Meeting. If
the date of the 2020 Annual Meeting is changed by more than 30 days from the anniversary date of this year&#146;s Annual Meeting on June&nbsp;25, 2019, then the deadline is a reasonable time before we begin to print and mail proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other stockholder proposals:</I> A nomination of one or more persons for election as a director or any other stockholder proposal not included in our proxy
statement for the 2020 Annual Meeting will be ineligible for presentation at the meeting unless the stockholder gives timely notice of the proposal in writing to our Company Secretary at our principal executive offices and otherwise complies with
the provisions of our <FONT STYLE="white-space:nowrap">By-Laws.</FONT> To be timely, our <FONT STYLE="white-space:nowrap">By-Laws</FONT> provide that we must receive the stockholder&#146;s notice: (i)&nbsp;not less than 60 days in advance of the
meeting if the meeting is to be held on a day which is within 30 days preceding the anniversary of the 2019 Annual Meeting, (ii)&nbsp;not less than 90 days in advance of the meeting if the meeting is to be held on or after the anniversary of the
2019 Annual Meeting, and (iii)&nbsp;in any other cases, not more than 15 days following the date on which notice or public disclosure (as defined in our <FONT STYLE="white-space:nowrap">By-Laws)</FONT> of the date of the 2020 Annual Meeting is made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with the foregoing
requirements and with the SEC regulations regarding stockholder proposals. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_13"></A>HOUSEHOLDING OF PROXY MATERIALS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a procedure, approved by the SEC, called &#147;householding.&#148; Under this procedure, stockholders of record who have the same
address and last name may receive only one Notice of Internet Availability of Proxy Materials, unless we are notified that one or more of these stockholders wishes to continue receiving individual copies. This procedure will reduce our printing
costs and postage fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are eligible for householding, but you and other stockholders of record with whom you share an address currently receive
multiple copies of the Notice of Internet Availability of Proxy Materials, or if you hold our stock in more than one account, and in either case you wish to receive only a single copy of the Notice of Internet Availability of Proxy Materials for
your household, please contact our Company Secretary by mail, c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite A210, Watertown, MA 02472, or by phone at (617) <FONT STYLE="white-space:nowrap">926-5000.</FONT> If you participate in
householding and wish to receive a separate copy of the Notice of Internet Availability of Proxy Materials, or if you do not wish to continue to participate in householding and prefer to receive separate copies of this document in the future, please
contact our Company Secretary as indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in street name through a broker, bank or other intermediary, please contact
your broker, bank or intermediary directly if you have questions, require additional copies of our proxy materials or wish to receive a single copy of such materials in the future for all beneficial owners of shares of our common stock sharing an
address. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_14"></A>AVAILABILITY OF TRANSITION REPORT ON FORM <FONT STYLE="white-space:nowrap">10-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018 has been posted on the
Internet along with this proxy statement, each of which is accessible by following the instructions in the Notice of Internet Availability of Proxy Materials. The Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> is not
incorporated into this proxy statement and is not considered proxy-soliciting material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We filed our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC on
March&nbsp;18, 2019. We will mail without charge, upon request, a copy of our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the six months ended December&nbsp;31, 2018, excluding the exhibits thereto. We will provide
copies of the exhibits to the Form <FONT STYLE="white-space:nowrap">10-K</FONT> upon request by eligible stockholders, provided that we may impose a reasonable fee for providing such exhibits, which is limited to our reasonable expenses. Requests
for copies of the Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or such exhibits should be mailed to our Company Secretary by mail, c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite A210, Watertown, MA 02472.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc734420_15"></A>OTHER BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this Proxy Statement, we do not know of any other matter that properly may come before the Annual Meeting, and do not intend to present any
other matter. However, if any other matters properly come before the meeting or any adjournment, the persons named as proxies will be able to vote on those matters in accordance with their own judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there are insufficient votes to approve the proposals, your proxy may be voted by the persons named in the proxy to adjourn the Annual Meeting in order to
solicit additional proxies in favor of the approval of such proposals. If the Annual Meeting is adjourned or postponed for any purpose, at any subsequent reconvening of the meeting your proxy will be voted in the same manner as it would have been
voted at the original convening of the Annual Meeting unless you withdraw or revoke your proxy. Your proxy may be voted in this manner even though it may have been voted on the same or any other matter at a previous session of the Annual Meeting.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EyePoint Pharmaceuticals -
2019 Proxy Statement&nbsp;&nbsp;|&nbsp;&nbsp;56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc734420_16"></A>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EYEPOINT PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 LONG-TERM INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, EyePoint Pharmaceuticals, Inc. (the &#147;<U>Company</U>&#148;) maintains the EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive
Plan, which was effective December&nbsp;12, 2016 (the &#147;<U>Plan</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;9 of the Plan, the
Compensation Committee (&#147;<U>Compensation Committee</U>&#148;) of the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) may amend the Plan at any time; provided that, amendments to the Plan must be approved by the Company&#146;s
stockholders if and to the extent required by applicable laws or stock exchange requirements (&#147;<U>Stockholder Approval</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to terms of the Plan, the Compensation Committee has discretionary authority, subject only to the express provisions of the
Plan, to interpret and administer the plan and the Compensation Committee may delegate to the Board such of its duties, powers and responsibilities as it may determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,<B> </B>the Compensation Committee, in consultation with legal and financial advisors, has determined that it is advisable and in the
best interests of the Company and its stockholders to increase the number of shares of the Company&#146;s common stock, $0.001 par value per share, reserved for issuance under the Plan (the &#147;<U>Share Increase</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;9 of the Plan, in order to effect the Share Increase, Stockholder Approval must be obtained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Compensation Committee has approved the Share Increase and has recommended that the Board adopt and approve the Share Increase
subject to Stockholder Approval; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board desires to amend the Plan to provide for the Share Increase as set forth in this
amendment to the Plan (this &#147;<U>Amendment</U>&#148;), effective upon receipt of the Stockholder Approval; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, capitalized
terms used in this Amendment but not defined herein shall have the meaning given to them in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Board hereby
amends the Plan, effective upon receipt of the Stockholder Approval, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;4(a) of the Plan is deleted and replaced in its entirety with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;LIMITS ON AWARDS UNDER THE PLAN.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>(a) </B><B><U>Number of Shares</U></B><B>.</B> Subject to adjustment as provided in Section&nbsp;7(b), the maximum number of shares of
Stock that may be issued in satisfaction of Equity Awards under the Plan is 14,000,000, plus 336,741 shares of Stock that remained available for grant under the 2008 Plan as of the Date of Adoption, plus any shares of Stock that would otherwise have
become available for grant under the 2008 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under 2008 Plan. Up to the total number of shares of Stock set forth in the preceding sentence may be issued in
satisfaction of ISOs, but nothing in this Section&nbsp;4(a) will be construed as requiring that any, or any fixed number of, ISOs be awarded under the Plan. For purposes of this Section&nbsp;4(a), the number of shares of Stock issued in satisfaction
of Equity Awards will be determined (i)&nbsp;by including shares of Stock withheld by the Company in payment of the exercise price or purchase price of the Award or in satisfaction of tax withholding requirements with respect to the Award,
(ii)&nbsp;by including the full </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
number of shares covered by a SAR any portion of which is settled in Stock (and not only the number of shares of Stock delivered in settlement), and (iii)&nbsp;by excluding any shares of Stock
underlying Awards that expire, become unexercisable, terminate or are forfeited to or repurchased by the Company without the issuance of Stock. For the avoidance of doubt, the number of shares of Stock available for delivery under the Plan will not
be increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises. The limits set forth in this Section&nbsp;4(a) will be construed to comply with
Section&nbsp;422. To the extent consistent with the requirements of Section&nbsp;422 and the regulations thereunder, and other applicable legal requirements (including applicable stock exchange requirements), Stock issued under Substitute Awards
will not reduce the number of shares available for Awards under the Plan. The number of shares of Stock that may be delivered under Substitute Awards will be in addition to the limitations set forth in this Section&nbsp;4(a) on the number of shares
available for issuance under the Plan, and such Substitute Awards will not be subject to <FONT STYLE="white-space:nowrap">the&nbsp;per-Participant&nbsp;Award</FONT> limits described in Section&nbsp;4(c) below.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as specifically provided in and modified by this Amendment, the Plan is in all other respects hereby
ratified and confirmed and references to the Plan shall be deemed to refer to the Plan as modified by this Amendment, effective upon receipt of the Stockholder Approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EYEPOINT PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 LONG TERM INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;DEFINED</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U>, which is incorporated by reference, defines the terms used in the Plan and includes certain operational rules related to
those terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;PURPOSE</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock, Stock-based and
other incentive Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATION</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan; determine eligibility
for and grant Awards; determine, modify or waive the terms and conditions of any Award; determine the form of settlement of Awards (whether in cash, shares of Stock, or other property); prescribe forms, rules and procedures relating to the Plan and
Awards; and otherwise do all things necessary or desirable to carry out the purposes of the Plan. Determinations of the Administrator made under the Plan will be conclusive and will bind all persons. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;LIMITS</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ON AWARDS UNDER THE PLAN </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Number of Shares</U></B><B>.</B> Subject to adjustment as provided in Section&nbsp;7(b), the maximum
number of shares of Stock that may be issued in satisfaction of Equity Awards under the Plan is 3,000,000, plus up to 800,000 shares of Stock that remain available for grant under the 2008 Plan as of the Date of Adoption, plus any shares of Stock
that would otherwise have become available for grant under the 2008 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under 2008 Plan. Up to the total number of shares of Stock set forth in the preceding sentence
may be issued in satisfaction of ISOs, but nothing in this Section&nbsp;4(a) will be construed as requiring that any, or any fixed number of, ISOs be awarded under the Plan. For purposes of this Section&nbsp;4(a), the number of shares of Stock
issued in satisfaction of Equity Awards will be determined (i)&nbsp;by including shares of Stock withheld by the Company in payment of the exercise price or purchase price of the Award or in satisfaction of tax withholding requirements with respect
to the Award, (ii)&nbsp;by including the full number of shares covered by a SAR any portion of which is settled in Stock (and not only the number of shares of Stock delivered in settlement), and (iii)&nbsp;by excluding any shares of Stock underlying
Awards that expire, become unexercisable, terminate or are forfeited to or repurchased by the Company without the issuance of Stock. For the avoidance of doubt, the number of shares of Stock available for delivery under the Plan will not be
increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises. The limits set forth in this Section&nbsp;4(a) will be construed to comply with
Section&nbsp;422. To the extent consistent with the requirements of Section&nbsp;422 and the regulations thereunder, and other applicable legal requirements (including applicable stock exchange requirements), Stock issued under Substitute Awards
will not reduce the number of shares available for Awards under the Plan. The number of shares of Stock that may be delivered under Substitute Awards will be in addition to the limitations set forth in this Section&nbsp;4(a) on the number of shares
available for issuance under the Plan, and such Substitute Awards will not be subject to the <FONT STYLE="white-space:nowrap">per-Participant</FONT> Award limits described in Section&nbsp;4(c) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Type of Shares</U></B><B>.</B> Stock delivered by the Company under the Plan may be authorized but
unissued Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Section 162(m) Limits</U></B><B>.</B> Subject to Section&nbsp;4(d) below, the following additional
limits will apply to Awards of the specified type granted or, in the case of Cash Awards, payable to any person in any calendar year: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;Stock Options: 3,000,000 shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;SARs: 3,000,000 shares of Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;Awards other than Stock Options, SARs or Cash Awards: 3,000,000 shares of Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;Cash Awards: $5,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In applying the foregoing limits, (i)&nbsp;all Awards of the specified type granted to the same person in the same calendar year will be
aggregated and made subject to one limit; (ii)&nbsp;the limits applicable to Stock Options and SARs refer to the number of shares of Stock underlying those Awards; (iii)&nbsp;the share limit under clause (3)&nbsp;refers to the maximum number of
shares of Stock that may be delivered, or the value of which could be paid in cash or other property, under an Award or Awards of the type specified in clause (3)&nbsp;assuming a maximum payout; (iv)&nbsp;Awards other than Cash Awards that are
settled in cash will count against the applicable share limit under clause (1), (2) or (3)&nbsp;and not against the dollar limit under clause (4); and (v)&nbsp;the dollar limit under clause (4)&nbsp;refers to the maximum dollar amount payable under
an Award or Awards of the type specified in clause (4)&nbsp;assuming a maximum payout. The foregoing provisions will be construed in a manner consistent with Section&nbsp;162(m), including, without limitation, where applicable, the rules under
Section&nbsp;162(m) pertaining to permissible deferrals of exempt awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations on Awards to
Directors.</B> The aggregate value of all compensation granted or paid to any Director with respect to any calendar year, including all Awards granted under the Plan and any other fees or compensation paid to such Director outside of the Plan for
his or her services as a Director during such calendar year, will not exceed $350,000 in the aggregate, calculating the value of any Awards in accordance with FASB ASC Topic 718 (or any successor provision), assuming maximum performance (if
applicable). The Board may make an exception to such limit for any Director in extraordinary circumstances, as the Board may determine in its discretion, provided that any Director who is granted or paid such additional compensation may not
participate in the decision to grant or pay such additional compensation. The limitations applicable to Director Awards will not apply to any Award or shares of Stock granted pursuant to a Director&#146;s election to receive an Award or shares of
Stock in lieu of cash retainers or other fees (to the extent such Award or shares of Stock have a fair value equal to the value of such cash retainers or other fees). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Award Vesting/Exercisability/Payment/Distribution Limitations.</B> (i)&nbsp;No portion of any grant of
Restricted Stock shall be scheduled to vest prior to the date that is one (1)&nbsp;year following the date the Restricted Stock is granted; (ii)&nbsp;no portion of any grant of an Stock Option or SAR shall be scheduled to become exercisable prior to
the date that is one (1)&nbsp;year following the date the Stock Option or SAR is granted; and (iii)&nbsp;no portion of any grant of a Restricted Stock Unit or Cash Award shall be scheduled to vest or be settled, paid or distributed prior to the date
that is one (1)&nbsp;year following the date the applicable Restricted Stock Unit or Cash Award is granted; provided; however, that Awards that result in the issuance (as determined in accordance with the rules set forth in Section&nbsp;4(a)) of an
aggregate of up to five percent (5%) of the shares of Stock reserved for issuance under Section&nbsp;4(a) may be granted to eligible persons without regard to the minimum vesting, exercisability, settlement, payment and distribution provisions of
this Section&nbsp;4(e). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;ELIGIBILITY</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AND PARTICIPATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will select Participants from among key Employees and Directors of, and consultants and advisors to, the Company and its
Affiliates. Eligibility for ISOs is limited to individuals described in the first sentence of this Section&nbsp;5 who are employees of the Company or of a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; of the Company as those
terms are defined in Section&nbsp;424 of the Code. Eligibility for SARs and Stock Options other than ISOs is limited to individuals described in the first sentence of this Section&nbsp;5 who are providing direct services on the date of grant of the
Award to the Company or a subsidiary of the Company that would be described in the first sentence of Treas. Regs. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(b)(5)(iii)(E)</FONT> or to other individuals who the Company reasonably anticipates
will begin providing direct services to the Company or a subsidiary of the Company within twelve (12)&nbsp;months following an Award&#146;s date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;RULES</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPLICABLE TO AWARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>All Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Award Provisions</U></B><B>.</B> The Administrator will determine the terms of all Awards, subject to
the limitations provided herein. By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant will be deemed to have agreed to the terms of the Award and the Plan. Notwithstanding
any provision of this Plan to the contrary, Substitute Awards may contain terms and conditions that are inconsistent with the terms and conditions specified herein, as determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term of Plan</U></B><B>.</B> No Awards may be made after 10 years from the Date of Adoption, but
previously granted Awards may continue beyond that date in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Transferability</U></B><B>.</B> Neither ISOs nor, except as the Administrator otherwise expressly
provides in accordance with the third sentence of this Section&nbsp;6(a)(3), other Awards may be transferred other than by will or by the laws of descent and distribution. During a Participant&#146;s lifetime, ISOs and, except as the Administrator
otherwise expressly provides in accordance with the third sentence of this Section&nbsp;6(a)(3), SARs and NSOs may be exercised only by the Participant. The Administrator may permit the gratuitous transfer (<I>i.e.</I>, transfer not for value) of
Awards other than ISOs, subject to applicable securities and other laws and such limitations as the Administrator may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Vesting, etc</U></B><B>. </B>The Administrator will determine the time or times at which an Award will
vest or become exercisable and the terms on which a Stock Option or SAR will remain exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, regardless of any adverse or
potentially adverse tax or other consequences resulting from such acceleration. Unless the Administrator expressly provides otherwise, however, the following rules will apply if a Participant&#146;s Employment ceases: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(A)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in (B)&nbsp;and (C) below, immediately upon the cessation of the
Participant&#146;s Employment each Stock Option and SAR that is then held by the Participant or by the Participant&#146;s permitted transferees, if any, will cease to be exercisable and will terminate and all other Awards that are then held by the
Participant or by the Participant&#146;s permitted transferees, if any, to the extent not already vested will be forfeited. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(B)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to (C)&nbsp;and (D) below, all Stock Options and SARs held by the Participant or the
Participant&#146;s permitted transferees, if any, immediately prior to the cessation of the Participant&#146;s Employment, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;a period of three months or (ii)&nbsp;the
period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(C)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to (D)&nbsp;below, all Stock Options and SARs held by a Participant or the
Participant&#146;s permitted transferees, if any, immediately prior to the Participant&#146;s death, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;the one year period ending with the first anniversary of the
Participant&#146;s death or (ii)&nbsp;the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(D)</B>&nbsp;&nbsp;&nbsp;&nbsp;All Stock Options and SARs (whether or not exercisable) held by a Participant or the
Participant&#146;s permitted transferees, if any, immediately prior to the cessation of the Participant&#146;s Employment will immediately terminate upon such cessation of Employment if the termination is for Cause or occurs in circumstances that in
the sole determination of the Administrator would have constituted grounds for the Participant&#146;s Employment to be terminated for Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(5)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Recovery of Compensation</U></B>. The Administrator may provide in any case that outstanding Awards
(whether or not vested or exercisable) and the proceeds from the exercise or disposition of Awards or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock acquired under Awards will be subject to forfeiture and disgorgement to the Company, with interest and other related earnings, if the Participant to whom the Award was granted violates
(i)&nbsp;a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant by which he or she is bound, or (ii)&nbsp;any Company policy applicable to
the Participant that provides for forfeiture or disgorgement with respect to incentive compensation that includes Awards under the Plan. In addition, the Administrator may require forfeiture and disgorgement to the Company of outstanding Awards and
the proceeds from the exercise or disposition of Awards or Stock acquired under Awards, with interest and other related earnings, to the extent required by law or applicable stock exchange listing standards, including, without limitation,
Section&nbsp;10D of the Securities Exchange Act of 1934, as amended, and any related Company policy. Each Participant, by accepting or being deemed to have accepted an Award under the Plan, agrees to cooperate fully with the Administrator, and to
cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture or disgorgement required hereunder. Neither the Administrator nor the Company nor any other person, other than the
Participant and his or her permitted transferees, if any, will be responsible for any adverse tax or other consequences to a Participant or his or her permitted transferees, if any, that may arise in connection with this Section&nbsp;6(a)(5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(6)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Taxes</U></B><B>.</B> The delivery, vesting and retention of Stock, cash or other property under an
Award are conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the Award. The Administrator will prescribe such rules for the withholding of taxes with respect to any Award as it deems necessary.
The Administrator may hold back shares of Stock from an Equity Award or permit a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements (but not in excess of the maximum statutory rates for the
applicable jurisdictions or such greater amount as would not result in adverse accounting consequences to the Company under FASB ASC Topic 718 (or any successor provision)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(7)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Dividend Equivalents, Etc</U></B><B>. </B>The Administrator may provide for the payment of amounts (on
terms and subject to conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award whether or not the holder of such Award is otherwise entitled to share in the actual
dividend or distribution in respect of such Award. Any entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an exemption from, or in compliance with, the requirements of
Section&nbsp;409A. Dividends or dividend equivalent amounts payable in respect of Awards that are subject to restrictions may be subject to such limits or restrictions as the Administrator may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(8)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights Limited</U></B><B>.</B> Nothing in the Plan will be construed as giving any person the right to
be granted an Award or to continued employment or service with the Company or its Affiliates, or any rights as a shareholder except as to shares of Stock actually issued under the Plan. The loss of existing or potential profit in Awards will not
constitute an element of damages in the event of termination of Employment for any reason, even if the termination is in violation of an obligation of the Company or any Affiliate to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(9)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Section 162(m)</U></B><B>.</B> In the case of any Performance Award (other than a Stock Option or SAR)
intended to qualify for the performance-based compensation exception under Section&nbsp;162(m), the Administrator shall establish the Performance Criterion (or Criteria) applicable to the Award within the time period required under
Section&nbsp;162(m) and the grant, vesting or payment, as the case may be, of the Award will be conditioned upon the satisfaction of the Performance Criterion (or Criteria) as certified by the Administrator . The Administrator shall grant and
administer such Performance Awards pursuant to the requirements of Section&nbsp;162(m), unless the Administrator subsequently determines that such Awards are not, or are no longer, intended to qualify as &#147;performance-based compensation&#148;
under Section&nbsp;162(m). For the avoidance of doubt, in the case of an Award otherwise intended to qualify for the performance-based compensation exception under Section&nbsp;162(m), the Administrator may provide for payment or vesting under the
Award in the event of the death or disability of the Participant or a change in ownership or control of the Company without regard to the conditions that would apply to so qualify the Award, including the requirement of this Section&nbsp;6(a)(9)
that payment or vesting be conditioned upon the satisfaction of Performance Criterion (or Criteria) and including the limits set forth in Section&nbsp;4(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(10)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Coordination with Other Plans</U></B><B>.
</B>Awards under the Plan may be granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or its Affiliates. For example, but without
limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or its Affiliates may be settled in Stock (including, without limitation, Unrestricted Stock) under the Plan if the Administrator so
determines, in which case the shares delivered will be treated as awarded under the Plan (and will reduce the number of shares thereafter available under the Plan in accordance with the rules set forth in Section&nbsp;4). In any case where an award
is made under another plan or program of the Company or its Affiliates and is intended to qualify for the performance-based compensation exception under Section&nbsp;162(m), and such award is settled by the delivery of Stock or another Award under
the Plan, the applicable Section&nbsp;162(m) limitations under both the other plan or program and under the Plan will be applied to the Plan as necessary (as determined by the Administrator) to preserve the availability of the Section&nbsp;162(m)
performance-based compensation exception with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(11)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 409A</U>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(A)</B>&nbsp;&nbsp;&nbsp;&nbsp;Without limiting Section&nbsp;11(b) hereof, each Award will contain such terms as the
Administrator determines, and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section&nbsp;409A or satisfies such requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(B)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Participant is deemed on the date of the Participant&#146;s termination of Employment to
be a &#147;specified employee&#148; within the meaning of that term under Section&nbsp;409A(a)(2)(B), then, with regard to any payment that is considered nonqualified deferred compensation under Section&nbsp;409A, to the extent applicable, payable
on account of a &#147;separation from service&#148;, such payment will be made or provided on the date that is the earlier of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of such
&#147;separation from service&#148; and (b)&nbsp;the date of the Participant&#146;s death (the &#147;<U>Delay Period</U>&#148;). Upon the expiration of the Delay Period, all payments delayed pursuant to this Section&nbsp;6(a)(11) (whether they would
have otherwise been payable in a single lump sum or in installments in the absence of such delay) will be paid on the first business day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will
be paid in accordance with the normal payment dates specified for them in the applicable Award agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(C)</B>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of Section&nbsp;409A, each payment made under this Plan shall be treated as a
separate payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Options and SARs</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Time and Manner of Exercise</U></B><B>. </B>Unless the Administrator expressly provides otherwise, no
Stock Option or SAR will be deemed to have been exercised until the Administrator receives a physical or electronic notice of exercise in a form acceptable to the Administrator that is signed by the appropriate person and accompanied by any payment
required under the Award. Any attempt to exercise a Stock Option or SAR by any person other than the Participant will not be given effect unless the Administrator has received such evidence as it may require that the person exercising the Award has
the right to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercise Price</U></B><B>.</B> The exercise price (or the base value from
which appreciation is to be measured) of each Award requiring exercise will be no less than 100% (in the case of an ISO granted to a <FONT STYLE="white-space:nowrap">10-percent</FONT> shareholder within the meaning of subsection (b)(6) of
Section&nbsp;422, 110%) of the Fair Market Value of the Stock subject to the Award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment of Exercise Price</U></B><B>.</B> Where the exercise of an Award is to be accompanied by
payment, payment of the exercise price must be by cash or check acceptable to the Administrator or, if so permitted by the Administrator and if legally permissible, (i)&nbsp;through the delivery of previously acquired unrestricted shares of Stock,
or the withholding of unrestricted shares of Stock otherwise deliverable upon exercise, in either case that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a Fair Market Value equal to the exercise price, (ii)&nbsp;through a broker-assisted exercise program acceptable to the Administrator, (iii)&nbsp;by other means acceptable to the
Administrator, or (iv)&nbsp;by any combination of the foregoing permissible forms of payment. The delivery of previously acquired shares in payment of the exercise price under clause (i)&nbsp;above may be accomplished either by actual delivery or by
constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Maximum Term</U></B><B>.</B> The maximum term of Stock Options and SARs may not exceed 10 years from
the date of grant (or five years from the date of grant in the case of an ISO granted to a <FONT STYLE="white-space:nowrap">10-percent</FONT> shareholder described in Section&nbsp;6(b)(2) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(5)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Repricing</U></B><B>. </B>Except in connection with a corporate transaction involving the Company
(which term includes, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT>
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, or exchange of shares) or as otherwise contemplated by Section&nbsp;7 below, the Company may not, without obtaining shareholder approval, (A)&nbsp;amend the terms of outstanding Stock
Options or SARs to reduce the exercise price or base value of such Stock Options or SARs, (B)&nbsp;cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an exercise price or base value that is less than the exercise
price or base value of the original Stock Options or SARs, or (C)&nbsp;cancel outstanding Stock Options or SARs that have an exercise price or base value greater than the Fair Market Value of a share of Stock on the date of such cancellation in
exchange for cash or other consideration. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;EFFECT</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OF CERTAIN TRANSACTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Mergers,</U></B><B><I><U> etc</U></I></B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise
expressly provided in an Award agreement, the following provisions will apply in the event of a Covered Transaction: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Assumption or Substitution</U></B><B>.</B> If the Covered Transaction is one in which there is an
acquiring or surviving entity, the Administrator may provide for (A)&nbsp;the assumption or continuation of some or all outstanding Awards or any portion thereof or (B)&nbsp;the grant of new awards in substitution therefor by the acquiror or
survivor or an affiliate of the acquiror or survivor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U><FONT STYLE="white-space:nowrap">Cash-Out</FONT> of Awards</U></B><B>. </B>Subject to
Section&nbsp;7(a)(5), below the Administrator may provide for payment (a <FONT STYLE="white-space:nowrap">&#147;cash-out&#148;),</FONT> with respect to some or all Awards or any portion thereof, equal in the case of each affected Equity Award or
portion thereof to the excess, if any, of (A)&nbsp;the Fair Market Value of one share of Stock times the number of shares of Stock subject to the Award or such portion, over (B)&nbsp;the aggregate exercise or purchase price, if any, under the Award
or such portion (in the case of a SAR, the aggregate base value above which appreciation is measured), in each case on such payment terms (which need not be the same as the terms of payment to holders of Stock) and other terms, and subject to such
conditions, as the Administrator determines; <I>provided</I>, <I>however</I>, for the avoidance of doubt, that if the exercise or purchase price (or base value) of an Equity Award is equal to or greater than the Fair Market Value of one share of
Stock, the Award may be cancelled with no payment due hereunder or otherwise in respect of such Equity Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Acceleration of Certain Awards</U></B><B>. </B>Subject to Section&nbsp;7(a)(5) below, the
Administrator may provide that any Award requiring exercise will become exercisable, in full or in part, and/or that the delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock
Units and Performance Awards to the extent consisting of Stock Units) will be accelerated, in full or in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following
exercise of the Award or the delivery of the shares, as the case may be, to participate as a shareholder in the Covered Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination of Awards upon Consummation of Covered Transaction</U></B><B>. </B>Except as the
Administrator may otherwise determine in any case, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited) immediately upon consummation of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Covered Transaction, other than (A)&nbsp;any Award assumed pursuant to Section&nbsp;7(a)(1) above, and (B)&nbsp;any Cash Award that by its terms, or as a result of action taken by the
Administrator, continues following the Covered Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(5)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional
Limitations</U></B><B>.</B> Any share of Stock and any cash or other property delivered pursuant to Section&nbsp;7(a)(2) or Section&nbsp;7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions,
if any, as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction. For purposes of the
immediately preceding sentence, a <FONT STYLE="white-space:nowrap">cash-out</FONT> under Section&nbsp;7(a)(2) above or an acceleration under Section&nbsp;7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a
performance or other vesting condition. In the case of Restricted Stock that does not vest and is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in
respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in and Distributions with Respect to Stock</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Basic Adjustment Provisions</U></B><B>.</B> In the event of a stock dividend, stock split or
combination of shares (including a reverse stock split), recapitalization or other change in the Company&#146;s capital structure that constitutes an equity restructuring within the meaning of FASB ASC Topic 718 (or any successor provision), the
Administrator shall make appropriate adjustments to the maximum number of shares of Stock specified in Section&nbsp;4(a) that may be issued under the Plan, and shall make appropriate adjustments to the number and kind of shares of stock or
securities underlying Equity Awards then outstanding or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other provision of Awards affected by such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Certain Other Adjustments</U></B><B>.</B> The Administrator may also make adjustments of the type
described in Section&nbsp;7(b)(1) above to take into account distributions to shareholders other than those provided for in Section&nbsp;7(a) and 7(b)(1), or any other event, if the Administrator determines that adjustments are appropriate to avoid
distortion in the operation of the Plan, having due regard for the qualification of ISOs under Section&nbsp;422, the requirements of Section&nbsp;409A, and the performance-based compensation rules of Section&nbsp;162(m), to the extent applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Continuing Application of Plan Terms</U></B><B>.</B> References in the Plan to shares of Stock
will be construed to include any stock or securities resulting from an adjustment pursuant to this Section&nbsp;7. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONDITIONS ON DELIVERY OF STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock
previously delivered under the Plan until: (i)&nbsp;the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved; (ii)&nbsp;if the outstanding Stock is at the time of
delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii)&nbsp;all conditions of the Award have been
satisfied or waived. The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of
the Securities Act of 1933, as amended, or any applicable state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities law. Any Stock required to be issued to Participants under the Plan will be evidenced in such manner as the Administrator
may deem appropriate, including book-entry registration or delivery of stock certificates. In the event that the Administrator determines that stock certificates will be issued to Participants under the Plan, the Administrator may require that
certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending lapse of the applicable restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law,
and may at any time terminate the Plan as to any future grants of Awards; <I>provided</I>, <I>however</I>, that except as otherwise expressly provided in the Plan the Administrator may not, without the Participant&#146;s consent, alter the terms of
an Award so as to affect materially and adversely the Participant&#146;s rights under the Award, unless the Administrator expressly reserved the right to do so at the time the Award was granted. Any amendments to the Plan will be conditioned upon
shareholder approval only to the extent, if any, such approval is required by law (including the Code) or applicable stock exchange requirements, as determined by the Administrator. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;OTHER</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPENSATION ARRANGEMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the Plan or the grant of any Award will not affect the Company&#146;s right to award a person bonuses or other compensation in
addition to Awards under the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Waiver of Jury Trial</U></B><B>.</B> By accepting or being deemed to have accepted an Award under the
Plan, each Participant waives any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or
which in the future may be delivered in connection therewith, and agrees that any such action, proceedings or counterclaim will be tried before a court and not before a jury. By accepting or being deemed to have accepted an Award under the Plan,
each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing
waivers. Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit disputes arising under the terms of the Plan or any Award made hereunder to
binding arbitration or as limiting the ability of the Company to require any eligible individual to agree to submit such disputes to binding arbitration as a condition of receiving an Award hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Limitation of Liability</U></B><B>.</B> Notwithstanding anything to the contrary in the Plan, neither
the Company, nor any Affiliate, nor the Administrator, nor any person acting on behalf of the Company, any Affiliate, or the Administrator, will be liable to any Participant, to any permitted transferee, to the estate or beneficiary of any
Participant or any permitted transferee, or to any other holder of an Award by reason of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the
requirements of Section&nbsp;422 or Section&nbsp;409A or by reason of Section&nbsp;4999 of the Code, or otherwise asserted with respect to the Award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;ESTABLISHMENT</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OF <FONT STYLE="white-space:nowrap">SUB-PLANS</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time and from time to time establish one or more <FONT STYLE="white-space:nowrap">sub-plans</FONT> under the Plan
(for <FONT STYLE="white-space:nowrap">local-law</FONT> compliance purposes or other administrative reasons determined by the Administrator) by adopting supplements to the Plan containing, in each case, such limitations on the Administrator&#146;s
discretion under the Plan, and such additional terms and conditions, as the Administrator deems necessary or desirable. Each supplement so established will be deemed to be part of the Plan but will apply only to Participants within the group to
which the supplement applies (as determined by the Administrator). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LAW </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Certain Requirements of Corporate Law</U></B><B>.</B> Equity Awards will be granted and administered
consistent with the requirements of applicable Delaware law relating to the issuance of stock and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case as
determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Other Matters</U></B><B>.</B> Except as otherwise provided by
the express terms of an Award agreement, under a <FONT STYLE="white-space:nowrap">sub-plan</FONT> described in Section&nbsp;12 or as provided in Section&nbsp;13(a) above, the provisions of the Plan and of Awards under the Plan and all claims or
disputes arising out of our based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof will be governed by and construed in accordance with the domestic substantive laws of the Commonwealth of Massachusetts
without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Jurisdiction</U></B><B>. </B>By accepting an Award, each Participant will be deemed to (a)&nbsp;have
submitted irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other
proceeding arising out of or based upon the Plan or any Award; (b)&nbsp;agree not to commence any suit, action or other proceeding arising out of or based upon the Plan or an Award, except in the federal and state courts located within the
geographic boundaries of the United States District Court for the District of Massachusetts; and (c)&nbsp;waive, and agree not to assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that it is not
subject personally to the jurisdiction of the above-named courts that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or
proceeding is improper or that the Plan or an Award or the subject matter thereof may not be enforced in or by such court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of Terms </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;2008 Plan&#148;:</B> The pSivida Corp. 2008 Incentive Plan, as from time to time amended and in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Administrator&#148;: </B>The Compensation Committee, except that the Compensation Committee may delegate (i)&nbsp;to one or more of
its members (or one or more other members of the Board, including the full Board) such of its duties, powers and responsibilities as it may determine; (ii)&nbsp;to one or more officers of the Company the power to grant Awards to the extent permitted
by Section&nbsp;157(c) of the Delaware General Corporation Law; and (iii)&nbsp;to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. In the event of any delegation described in the preceding sentence,
the term &#147;Administrator&#148; will include the person or persons so delegated to the extent of such delegation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate&#148;: </B>Any corporation or other entity that stands in a relationship to the Company that would result in the Company
and such corporation or other entity being treated as one employer under Section&nbsp;414(b) and Section&nbsp;414(c) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Award&#148;: </B>Any or a combination of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) SARs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Restricted Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Unrestricted Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Stock Units, including Restricted Stock Units. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Performance Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Cash Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Awards (other than Awards described in (i)&nbsp;through (vii) above) that are convertible into or otherwise based on
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Board&#148;: </B>The Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Cash Award&#148;: </B>An Award denominated in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Cause&#148;: </B>In the case of any Participant who is party to an employment or severance-benefit agreement that contains a
definition of &#147;Cause,&#148; the definition set forth in such agreement will apply for Plan purposes for so long as such agreement is in effect with respect to such Participant. In every other case, &#147;Cause&#148; will mean, as determined by
the Administrator, (i)&nbsp;a substantial failure of the Participant to perform the Participant&#146;s duties and responsibilities to the Company or subsidiaries or substantial negligence in the performance of such duties and responsibilities;
(ii)&nbsp;the commission by the Participant of a felony or a crime involving moral turpitude; (iii)&nbsp;the commission by the Participant of theft, fraud, embezzlement, material breach of trust or any material act of dishonesty involving the
Company or any of its subsidiaries; (iv)&nbsp;a significant violation by the Participant of the code of conduct of the Company or its subsidiaries of any material policy of the Company or its subsidiaries, or of any statutory or common law duty of
loyalty to the Company or its subsidiaries; (v)&nbsp;material breach of any of the terms of the Plan or any Award made under the Plan, or of the terms of any other agreement between the Company or subsidiaries and the Participant; or (vi) other
conduct by the Participant that could be expected to be harmful to the business, interests or reputation of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Code&#148;: </B>The U.S. Internal Revenue Code of 1986, as from time to time
amended and in effect, or any successor statute as from time to time in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Compensation Committee&#148;: </B>The
Compensation Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company&#148;:</B> EyePoint Pharmaceuticals, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Covered Transaction&#148;: </B>Any of (i)&nbsp;a consolidation, merger, or similar transaction or series of related transactions,
including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#146;s then outstanding common stock by a single person or entity or
by a group of persons and/or entities acting in concert, (ii)&nbsp;a sale or transfer of all or substantially all the Company&#146;s assets, or (iii)&nbsp;a dissolution or liquidation of the Company. Where a Covered Transaction involves a tender
offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Date of Adoption&#148;:</B> The earlier of the date the Plan was approved by the Company&#146;s shareholders or adopted by the Board,
as determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Director&#148;:</B> A member of the Board who is not an Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employee&#148;: </B>Any person who is employed by the Company or an Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employment&#148;: </B>A Participant&#146;s employment or other service relationship with the Company and its Affiliates. Employment
will be deemed to continue, unless the Administrator expressly provides otherwise, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section&nbsp;5 to, the Company or an Affiliate. If a
Participant&#146;s employment or other service relationship is with an Affiliate and that entity ceases to be an Affiliate, the Participant&#146;s Employment will be deemed to have terminated when the entity ceases to be an Affiliate unless the
Participant transfers Employment to the Company or its remaining Affiliates. Notwithstanding the foregoing and the definition of &#147;Affiliate&#148; above, in construing the provisions of any Award relating to the payment of &#147;nonqualified
deferred compensation&#148; (subject to Section&nbsp;409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms will be construed to
require a &#147;separation from service&#148; (as that term is defined in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury Regulations) from the Company and from all other corporations and trades or businesses, if
any, that would be treated as a single &#147;service recipient&#148; with the Company under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)(3)</FONT> of the Treasury Regulations. The Company may, but need not, elect in writing, subject to
the applicable limitations under Section&nbsp;409A, any of the special elective rules prescribed in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury Regulations for purposes of determining whether a &#147;separation
from service&#148; has occurred. Any such written election will be deemed a part of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Equity Award&#148;: </B>An Award
other than a Cash Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Fair Market Value&#148;: </B>As of a particular date, (i)&nbsp;the closing price for a share of Stock
reported on the NASDAQ Global Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date on which a
closing price was reported or (ii)&nbsp;in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section&nbsp;422 and
Section&nbsp;409A to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;ISO&#148;: </B>A Stock Option intended to be an &#147;incentive stock option&#148;
within the meaning of Section&nbsp;422. Each Stock Option granted pursuant to the Plan will be treated as providing by its terms that it is to be an NSO unless, as of the date of grant, it is expressly designated as an ISO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;NSO&#148;: </B>A Stock Option that is not intended to be an &#147;incentive stock
option&#148; within the meaning of Section&nbsp;422. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Participant&#148;: </B>A person who is granted an Award under the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Award&#148;:</B> An Award subject to Performance Criteria. The Administrator may grant Performance Awards that are
intended to qualify for the performance-based compensation exception under Section&nbsp;162(m) and Performance Awards that are not intended to so qualify. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Criteria&#148;: </B>Specified criteria, other than the mere continuation of Employment or the mere passage of time, the
satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of
loss. For purposes of Awards that are intended to qualify for the performance-based compensation exception under Section&nbsp;162(m), a Performance Criterion will mean an objectively determinable measure or objectively determinable measures of
performance relating to any, or any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on
a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Committee specifies, consistent with the
requirements of Section&nbsp;162(m)) : sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per
share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; shareholder return; sales of particular
products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, <FONT STYLE="white-space:nowrap">split-ups</FONT> and the like; reorganizations; or
recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings. To the extent consistent with the requirements for satisfying the performance-based compensation exception under Section&nbsp;162(m), the Administrator may
provide in the case of any Award intended to qualify for such exception that one or more of the Performance Criteria applicable to such Award will be adjusted in an objectively determinable manner to reflect events (for example, but without
limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Plan&#148;: </B>The EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan, as from time to time amended and in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock&#148;: </B>Stock subject to restrictions requiring that it be redelivered or offered for sale to the Company if
specified service- or performance-based conditions are not satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock Unit&#148;: </B>A Stock Unit that is, or
as to which the delivery of Stock or cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;SAR&#148;: </B>A right entitling the holder upon exercise to receive an amount (payable in cash or in shares of Stock of equivalent
value) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;409A&#148;: </B>Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;422&#148;: </B>Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;162(m)&#148;: </B>Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock&#148;: </B>Common stock of the Company, par value $0.001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Option&#148;: </B>An option entitling the holder to acquire shares of Stock
upon payment of the exercise price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Unit&#148;: </B>An unfunded and unsecured promise, denominated in shares of Stock, to
deliver Stock or cash measured by the value of Stock in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Substitute Awards&#148;: </B>Equity<B> </B>Awards issued
under the Plan in substitution for equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Unrestricted Stock&#148;: </B>Stock not subject to any restrictions under the terms of the Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc734420_17"></A>Annex B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EYEPOINT PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 EMPLOYEE STOCK PURCHASE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;PURPOSE</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AND INTERPRETATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan is to encourage and to enable
Eligible Employees of the Company and its Participating Affiliates, through <FONT STYLE="white-space:nowrap">after-tax</FONT> payroll deductions or periodic cash contributions, to acquire proprietary interests in the Company through the purchase and
ownership of shares of Stock. The Plan is intended to benefit the Company and its stockholders (a)&nbsp;by incentivizing Participants to contribute to the success of the Company and to operate and manage the Company&#146;s business in a manner that
will provide for the Company&#146;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders and (b)&nbsp;by encouraging Participants to remain in the employ of the Company or its Participating
Affiliates. The Plan was adopted by the Board on April&nbsp;26, 2019 and was approved by the Company&#146;s stockholders on June&nbsp;25, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Plan and the Options granted under the Plan are intended to satisfy the requirements for an &#147;employee
stock purchase plan&#148; under Code Section&nbsp;423. Notwithstanding the foregoing, the Company makes no undertaking to, nor representation that it will, maintain the qualified status of the Plan or any Options granted under the Plan. In addition,
Options that do not satisfy the requirements for an &#147;employee stock purchase plan&#148; under Code Section&nbsp;423 may be granted under the Plan pursuant to the rules, procedures, or <FONT STYLE="white-space:nowrap">sub-plans</FONT> adopted by
the Administrator, in its sole discretion, for certain Eligible Employees. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Account</B>&#148; shall mean a bookkeeping account established and maintained to record the amount of funds
accumulated pursuant to the Plan with respect to a Participant for the purpose of purchasing shares of Stock under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Administrator</B>&#148; shall mean the Board, the Compensation Committee of the Board, or any other
committee of the Board designated by the Board to administer the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Board</B>&#148; shall mean the
Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Code</B>&#148; shall mean the Internal Revenue Code of 1986, as
amended, as now in effect or as hereafter amended, and any successor thereto. References in the Plan to any Code Section shall be deemed to include, as applicable, regulations and guidance promulgated under such Code Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Company</B>&#148; shall mean EyePoint Pharmaceuticals, Inc., a Delaware corporation, and any successor
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Custodian</B>&#148; shall mean the third-party administrator designated by the Administrator
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Effective Date</B>&#148; shall mean July&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Eligible Compensation</B>&#148; shall mean, unless otherwise established by the Administrator prior to the
start of an Offering Period, regular base compensation (including any shift differentials), but excludes any bonus, overtime payment, sales commission, incentive compensation, car allowance, advances, loans, contributions to any Code
Section&nbsp;125 or 401(k) plan, the cost of employee benefits paid for by the Company or a Participating Affiliate, education or tuition reimbursements, imputed income arising under any Company or Participating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Affiliate group insurance or benefit program, traveling expense reimbursements, business and moving expense reimbursements, income received in connection with stock options and other equity
awards, or other form of extra compensation, as determined by the Administrator at any time in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Eligible Employee</B>&#148; shall mean a natural person who has been an employee (including an officer) of
the Company or a Participating Affiliate for at least three (3)&nbsp;months as of an Offering Date, except the following, who shall not be eligible to participate under the Plan: (i)&nbsp;an employee whose customary employment is twenty
(20)&nbsp;hours or less per week, (ii)&nbsp;an employee whose customary employment is for not more than five (5)&nbsp;months in any calendar year, (iii)&nbsp;an employee who, after exercising his or her rights to purchase shares of Stock under the
Plan, would own (directly or by attribution pursuant to Code Section&nbsp;424(d)) shares of Stock (including shares that may be acquired under any outstanding Options) representing five percent (5%) or more of the total combined voting power of all
classes of stock of the Company, (iv)&nbsp;an employee who is a citizen or resident of a foreign jurisdiction (without regard to whether such employee is also a U.S. citizen or resident alien), if the grant of an Option under the Plan or an Offering
Period to such employee is prohibited under the laws of such foreign jurisdiction or compliance with the laws of such foreign jurisdiction would cause the Plan or an Offering Period to violate the requirements of Code Section&nbsp;423 and
(v)&nbsp;any other natural person whom the Administrator determines to exclude from an offering designated to satisfy the requirements of Code Section&nbsp;423, provided such exclusion is permitted by Code Section&nbsp;423 and the guidance issued
thereunder. The Administrator may, at any time in its sole discretion, if it deems it advisable to do so, exclude the participation of the employees of a particular Participating Affiliate from eligibility to participate in a future Offering Period.
Notwithstanding the foregoing, for purposes of a <FONT STYLE="white-space:nowrap">Non-423(b)</FONT> Offering under the Plan, if any, the Administrator shall have the authority, in its sole discretion, to establish a different definition of Eligible
Employee as it may deem advisable or necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Enrollment Form</B>&#148; shall mean the agreement(s)
between the Company and an Eligible Employee, in such written, electronic, or other format and/or pursuant to such written, electronic, or other process as may be established by the Administrator from time to time, pursuant to which an Eligible
Employee elects to participate in the Plan or to which a Participant elects to make changes with respect to the Participant&#146;s participation as permitted by the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Enrollment Period</B>&#148; shall mean that period of time prescribed by the Administrator, which period
shall conclude prior to the Offering Date, during which Eligible Employees may elect to participate in an Offering Period. The duration and timing of Enrollment Periods may be changed or modified by the Administrator from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fair Market Value</B>&#148; shall mean the value of each share of Stock subject to the Plan on a given
date determined as follows: (i)&nbsp;if on such date the shares of Stock are listed on an established national or regional stock exchange or are publicly traded on an established securities market, the Fair Market Value of the shares of Stock shall
be the closing price of the shares of Stock on such exchange or in such market (the exchange or market selected by the Administrator if there is more than one such exchange or market) on such date or, if such date is not a Trading Day, on the
Trading Day immediately preceding such date, or, if no sale of the shares of Stock is reported for such Trading Day, on the next preceding day on which any sale shall have been reported; or (ii)&nbsp;if the shares of Stock are not listed on such an
exchange or traded on such a market, the Fair Market Value of the shares of Stock shall be determined by the Administrator in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Holding Period</B>&#148; shall have the meaning set forth in Section&nbsp;10(c)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NGM</B>&#148; shall mean the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Non-423(b)</FONT> Offering</B>&#148; shall mean the rules, procedures, or
<FONT STYLE="white-space:nowrap">sub-plans,</FONT> if any, adopted by the Administrator, in its sole discretion, as a part of the Plan, pursuant to which Options that do not satisfy the requirements for &#147;employee stock purchase plans&#148; that
are set forth under Code Section&nbsp;423 may be granted to Eligible Employees as a separate offering under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Offering Date</B>&#148; shall mean the first day of any
Offering Period under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Offering Period</B>&#148; shall mean the period determined by the
Administrator pursuant to Section&nbsp;7, which period shall not exceed twenty-seven (27)&nbsp;months, during which payroll deductions or periodic cash contributions are accumulated for the purpose of purchasing Stock under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option</B>&#148; shall mean the right granted to Participants to purchase shares of Stock pursuant to an
offering under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Outstanding Election</B>&#148; shall mean a Participant&#146;s then-current
election to purchase shares of Stock in an Offering Period, or that part of such an election which has not been cancelled (including any voluntary cancellation under <U>Section&nbsp;6(c)</U> and deemed cancellation under <U>Section&nbsp;11</U>)
prior to the close of business on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period) or such other date as determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Participating Affiliate</B>&#148; shall mean any Subsidiary designated by the Administrator from time to
time, in its sole discretion, whose employees may participate in the Plan or in a specific Offering Period under the Plan, if such employees otherwise qualify as Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Participant</B>&#148; shall mean an Eligible Employee who has elected to participate in the Plan pursuant
to <U>Section&nbsp;5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Plan</B>&#148; shall mean this EyePoint Pharmaceuticals, Inc. 2019 Employee
Stock Purchase Plan, as it may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Period</B>&#148; shall mean the
period during an Offering Period designated by the Administrator on the last Trading Day of which purchases of Stock are made under the Plan. An Offering Period may have one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Price</B>&#148; shall mean the purchase price at which shares of Stock may be purchased under the
Plan, which shall be set by the Administrator from time to time;<I> provided, however</I>, that except as set forth in Section&nbsp;7(b) of the Plan, the Purchase Price shall not be less than the lesser of eighty-five percent (85%) of the average of
the high and low sales price of the Stock on the NGM (or, if the Stock ceases to trade on the NGM, on the principal national securities exchange on which the Stock is then trading) on the Offering Date or the last Trading Day of the Offering Period
(or, if an Offering Period has multiple Purchase Periods, on the last Trading Day of the Purchase Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Stock</B>&#148; shall mean the common stock, par value $0.001 per share, of the Company, or any security
into which shares of Stock may be changed or for which shares of Stock may be exchanged as provided in <U>Section&nbsp;12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subsidiary</B>&#148; shall mean any corporation (other than the Company) in an unbroken chain of
corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the
other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the Effective Date shall be considered a Subsidiary commencing as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Termination of Employment</B>&#148; shall mean, with respect to a Participant, a cessation of the
employee-employer relationship between the Participant and the Company or a Participating Affiliate for any reason, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;including, without limitation, (A)&nbsp;a termination by resignation, discharge, death, disability, retirement, or
the disaffiliation of a Subsidiary, (B)&nbsp;unless otherwise determined or provided by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrator, a transfer of employment to a Subsidiary that is not a Participating Affiliate as of the first day immediately following the expiration of the then-current Offering Period (or, if
an Offering Period has multiple Purchase Periods, the then-current Purchase Period), and (C)&nbsp;a termination of employment where the individual continues to provide certain services to the Company or a Subsidiary in a <FONT
STYLE="white-space:nowrap">non-employee</FONT> role, but </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;excluding (A)&nbsp;such termination of employment
where there is a simultaneous reemployment of the Participant by the Company or a Participating Affiliate and (B)&nbsp;any bona fide and Company-approved or Participating Affiliate-approved leave of absence, such as family leave, medical leave,
personal leave, and military leave, or such other leave that meets the requirements of Treasury Regulations section <FONT STYLE="white-space:nowrap">1.421-1(h)(2);</FONT> <I>provided</I>, <I>however</I>, where the period of leave exceeds three
(3)&nbsp;months and the employee&#146;s right to reemployment is not guaranteed either by statute or by contract, the employee-employer relationship will be deemed to have terminated on the first day immediately following such three (3)-month
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Trading Day</B>&#148; shall mean a day on which the NGM (or, if the Stock ceases to trade on
the NGM, the principal national securities exchange on which the Stock is then trading) is open for trading. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;SHARES</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBJECT TO THE PLAN </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Share Reserve</U>. Subject to adjustment as provided in<B> </B><U>Section&nbsp;12</U>, the maximum number of
shares of Stock that may be issued pursuant to Options granted under the Plan (including any <FONT STYLE="white-space:nowrap">Non-423(b)</FONT> Offering established hereunder) is One Million One Hundred Thousand (1,100,000) shares. The shares of
Stock reserved for issuance under the Plan may be authorized but unissued shares, treasury shares, or shares purchased on the open market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation Adjustment as a Result of the Share Reserve</U>. If the Administrator determines that the total
number of shares of Stock remaining available under the Plan is insufficient to permit the number of shares of Stock to be purchased by all Participants on the last Trading Day of an Offering Period (or if an Offering Period has multiple Purchase
Periods, on the last Trading Day of the Purchase Period) pursuant to <U>Section&nbsp;9</U>, the Administrator shall make a participation adjustment, where the number of shares of Stock purchasable by all Participants shall be reduced proportionately
in as uniform and equitable a manner as is reasonably practicable, as determined in the Administrator&#146;s sole discretion. After such adjustment, the Administrator shall refund in cash all affected Participants&#146; Account balances for such
Offering Period as soon as practicable thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable Law Limitations on the Share Reserve</U>. If
the Administrator determines that some or all of the shares of Stock to be purchased by Participants on the last Trading Day of an Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period)
would not be issued in accordance with applicable laws or any approval by any regulatory body as may be required or the shares of Stock would not be issued pursuant to an effective Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration
statement or that the issuance of some or all of such shares of Stock pursuant to a Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statement is not advisable due to the risk that such issuance will violate applicable laws, the
Administrator may, without Participants&#146; consent, terminate any outstanding Offering Period and the Options granted thereunder and refund in cash all affected Participants&#146; Account balances for such Offering Period as soon as practicable
thereafter. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATION</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Generally</U>. The Plan shall be administered under the direction of the Administrator. Subject to the express
provisions of the Plan, the Administrator shall have full authority, in its sole discretion, to take any actions it deems necessary or advisable for the administration of the Plan, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Interpreting and construing the Plan and Options granted under the Plan and the rules and regulations thereunder;
prescribing, adopting, amending, suspending, waiving, and rescinding such rules and regulations as it deems appropriate to administer and implement the Plan, including amending any outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option, as it may deem advisable or necessary to comply with applicable laws; correcting any defect or supplying any omission or reconciling any inconsistency in the Plan or Options granted under
the Plan or any Enrollment Form; and making all other decisions and determinations necessary and advisable in administering the Plan, including, without limitation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Making determinations relating to eligibility; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Determining the Purchase Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Establishing the timing and length of Offering Periods and Purchase Periods; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Establishing minimum and maximum contribution rates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Establishing new or changing existing limits on the number of shares of Stock a Participant may elect to purchase
with respect to any Offering Period, if such limits are announced prior to the first Offering Period to be affected; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Adopting such rules, procedures, or <FONT STYLE="white-space:nowrap">sub-plans</FONT> as may be deemed advisable
or necessary to comply with the laws of countries other than the United States, to allow for <FONT STYLE="white-space:nowrap">tax-preferred</FONT> treatment of the Options or otherwise to provide for the participation by Eligible Employees who
reside outside of the United States, including determining which Eligible Employees are eligible to participate in the <FONT STYLE="white-space:nowrap">Non-423(b)</FONT> Offering or other <FONT STYLE="white-space:nowrap">sub-plans</FONT> established
by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;Establishing the exchange ratio applicable to amounts withheld in a currency other
than U.S. dollars and permitting payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the processing of properly completed Enrollment Forms; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;Furnishing to the Custodian such information as the Custodian may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determinations under the Plan shall be final, binding, and conclusive upon all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Custodian</U>. If the Administrator designates a Custodian for the Plan, the Custodian shall act as custodian
under the Plan and shall perform such duties as requested by the Administrator in accordance with any agreement between the Company and the Custodian.&nbsp;The Custodian shall establish and maintain, as agent for each Participant, an Account and any
subaccounts as may be necessary or desirable for the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Administrative
Provisions</U>. The Company will furnish information to the Custodian from its records as directed by the Administrator, and such records will be conclusive on all persons unless determined by the Administrator to be incorrect.&nbsp;Each Participant
and other person claiming benefits under the Plan must furnish to the Company in writing an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> mailing address and any other information as the Administrator or
Custodian may reasonably request.&nbsp;The Plan will be administered on a reasonable and nondiscriminatory basis, and Plan provisions and rules&nbsp;thereunder will apply in a uniform manner to all persons similarly situated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Liability</U>. Neither the Board, the Compensation Committee of the Board, any other committee of the Board,
the Administrator or the Custodian, nor any of their respective agents or designees, shall be liable to any person (i)&nbsp;for any act, failure to act, or determination made in good faith with respect to the Plan or Options granted under the Plan
or (ii)&nbsp;for any tax (including any interest and penalties) by reason of the failure of the Plan, an Option, or an Offering Period to satisfy the requirements of Code Section&nbsp;423, the failure of the Participant to satisfy the requirements
of Code Section&nbsp;423, or otherwise asserted with respect to the Plan, Options granted under the Plan, or shares of Stock purchased or deemed purchased under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;PARTICIPATION</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IN THE PLAN IN AN OFFERING PERIOD </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Generally</U>. An Eligible Employee may become a Participant for an Offering Period under the Plan by completing
the prescribed Enrollment Form and submitting such Enrollment Form to the Company (or the Company&#146;s designee), in the format and pursuant to the process as prescribed by the Administrator, during the Enrollment Period prior to the commencement
of the Offering Period to which it relates. If properly completed and timely submitted, the Enrollment Form will become effective for the first Offering Period following submission of the Enrollment Form and all subsequent Offering Periods as
provided by <U>Section&nbsp;5</U>(b) until (i)&nbsp;it is terminated in accordance with <U>Section&nbsp;11</U>, (ii) it is modified by filing another Enrollment Form in accordance with this <U>Section&nbsp;5(a)</U> (including an election is made to
cease payroll deductions or periodic cash contributions in accordance with <U>Section&nbsp;6(c)</U>), or (iii)&nbsp;the Participant is otherwise ineligible to participate in the Plan or in a subsequent Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Automatic <FONT STYLE="white-space:nowrap">Re-Enrollment</FONT></U>. Following the end of each Offering Period,
each Participant shall automatically be <FONT STYLE="white-space:nowrap">re-enrolled</FONT> in the next Offering Period at the applicable rate of payroll deductions or periodic cash contributions in effect on the last Trading Day of the prior
Offering Period or otherwise as provided under <U>Section&nbsp;6</U>, unless (i)&nbsp;the Participant has experienced a Termination of Employment, or (ii)&nbsp;the Participant is otherwise ineligible to participate in the Plan or in the next
Offering Period. Notwithstanding the foregoing, the Administrator may require current Participants to complete and submit a new Enrollment Form at any time it deems necessary or desirable to facilitate Plan administration or for any other reason.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;PAYROLL</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEDUCTIONS OR PERIODIC CASH CONTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Generally</U>. Each Participant&#146;s Enrollment Form shall contain a payroll deduction authorization pursuant
to which he or she shall elect, unless otherwise established by the Administrator prior to the start of an Offering Period, to have a designated whole percentage of Eligible Compensation between one percent (1%) and ten percent (10%) deducted, on an
<FONT STYLE="white-space:nowrap">after-tax</FONT> basis, on each payday during the Offering Period and credited to the Participant&#146;s Account for the purchase of shares of Stock pursuant to the offering. The Administrator shall also have the
authority, but not the obligation, to permit a Participant to elect to make periodic cash contributions, in lieu of payroll deductions, for the purchase of shares of Stock pursuant to the offering. Notwithstanding the foregoing, if local law
prohibits payroll deductions, a Participant may elect to participate in an Offering Period through contributions to his or her Account in a format and pursuant to a process acceptable to the Administrator. In such event, any such Participant shall
be deemed to participate in a separate offering under the Plan, unless the Administrator otherwise expressly provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Insufficiency of Contributions</U>. Subject to <U>Section&nbsp;6(e)</U>, if in any payroll period a Participant
has no pay or his or her pay is insufficient (after other authorized deductions) to permit deduction of the full amount of his or her payroll deduction election, then (i)&nbsp;the payroll deduction election for such payroll period shall be reduced
to the amount of pay remaining, if any, after all other authorized deductions, and (ii)&nbsp;the percentage or dollar amount of Eligible Compensation shall be deemed to have been reduced by the amount of the reduction in the payroll deduction
election for such payroll period. Deductions of the full amount originally elected by the Participant will recommence as soon as his or her pay is sufficient to permit such payroll deductions; <I>provided</I>, <I>however</I>, no additional amounts
shall be deducted to satisfy the Outstanding Election. If the Administrator authorizes a Participant to elect to make periodic cash contributions in lieu of payroll deductions, the failure of a Participant to make any such contributions shall
reduce, to the extent of the deficiency in such payments, the number of shares purchasable under the Plan by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cessation after Offering Date</U>. A Participant may cease his or her payroll deductions or periodic cash
contributions during an Offering Period by properly completing and timely submitting a new Enrollment Form to the Company (or the Company&#146;s designee), in the format and pursuant to the process as prescribed by the Administrator, at any time
prior to the last day of such Offering Period (or if an Offering Period has multiple Purchase Periods, the last day of such Purchase Period). Any such cessation in payroll deductions or periodic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash contributions shall be effective as soon as administratively practicable thereafter and shall remain in effect for the duration of such Offering Period and for successive Offering Periods as
provided in <U>Section&nbsp;5(b)</U> unless the Participant submits a new Enrollment Form for a later Offering Period in accordance with <U>Section&nbsp;5(a)</U>. A Participant may only increase his or her rate of payroll deductions or periodic cash
contributions in accordance with <U>Section&nbsp;6(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification Prior to Offering Date</U>. A
Participant may increase or decrease his or her rate of payroll deductions or periodic cash contributions, to take effect on the Offering Date of the Offering Period following submission of the Enrollment Form, by properly completing and timely
submitting a new Enrollment Form in accordance with <U>Section&nbsp;5(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized Leave or
Disability after Offering Date</U>. Subject to <U>Section&nbsp;11</U>, if a Participant is absent from work due to an authorized leave of absence or disability (and has not experienced a Termination of Employment), such Participant shall have the
right to elect (i)&nbsp;to remain a Participant in the Plan for the then-current Offering Period (or if an Offering Period has multiple Purchase Periods, the then-current Purchase Period) but to cease his or her payroll deductions or periodic cash
contributions in accordance with <U>Section&nbsp;6(c)</U>, or (ii)&nbsp;to remain a Participant in the Plan for the then-current Offering Period (or if an Offering Period has multiple Purchase Periods, the then-current Purchase Period) but to
authorize payroll deductions to be made from payments made by the Company or a Participating Affiliate to the Participant during such leave of absence or disability and to undertake to make additional cash payments to the Plan at the end of each
payroll period during the Offering Period to the extent that the payroll deductions from payments made by the Company or a Participating Affiliate to such Participant are insufficient to meet such Participant&#146;s Outstanding Election. Neither the
Company nor a Participating Affiliate shall advance funds to a Participant if the Participant&#146;s payroll deductions and additional cash payments during the Participant&#146;s leave of absence or disability are insufficient to fund the
Participant&#146;s Account at his or her Outstanding Election. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;OFFERING</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PERIODS AND PURCHASE PERIODS; PURCHASE PRICE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine from time to time, in its sole discretion, the Offering Periods and Purchase
Periods under the Plan. Each Offering Period shall consist of one or more Purchase Periods, as determined by the Administrator. Unless otherwise established by the Administrator prior to the start of an Offering Period, the Plan shall have two
(2)&nbsp;Offering Periods (with concurrent Purchase Periods) that commence each calendar year, and each Offering Period shall be of approximately six (6)&nbsp;months&#146; duration, with the first such Offering Period beginning on the first Trading
Day of February and ending on the last Trading Day of the immediately following July, and the second such Offering Period beginning on the first Trading Day of August and ending on the last Trading Day of the immediately following January. For the
avoidance of doubt, unless otherwise established by the Administrator prior to the commencement thereof, the first Offering Period under the Plan shall commence on August&nbsp;1, 2019 and shall end on January&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine from time to time, in its sole discretion, the Purchase Price of each share of
Stock for each Purchase Period during an Offering Period. Unless otherwise established by the Administrator prior to the start of an Offering Period, the Purchase Price shall be the lesser of eighty-five percent (85%) of the average of the high and
low sales price of the Stock on the NGM (or, if the Stock ceases to trade on the NGM, on the principal national securities exchange on which the Stock is then trading) on the Offering Date or the last Trading Day of the Offering Period (or if an
Offering Period has multiple Purchase Periods, on the last Trading Day of the applicable Purchase Period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Illustrative Hypothetical Example of the Purchase Price calculation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Offering Period: August&nbsp;1, 2019 &#150; January&nbsp;31, 2020 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">High sales price of EYPT Stock on August&nbsp;1, 2019: $2.30 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Low sales price of EYPT Stock on August&nbsp;1, 2019: $2.20 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Average high and low sales price of EYPT Stock on August&nbsp;1, 2019: $2.25 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>85% of average high and low sales price of EYPT Stock on August&nbsp;1, 2019: $1.9125 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">High sales price of EYPT Stock on January&nbsp;31, 2020: $3.50 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Low sales price of EYPT Stock on January&nbsp;31, 2020: $3.30 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Average high and low sales price of EYPT Stock on January&nbsp;31, 2020: $3.40 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>85% of average high and low sales price of EYPT Stock on January&nbsp;31, 2020: $2.89 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The lesser of the two 85% of average high and low sales price figures is $1.9125. Thus, the Purchase Price applicable for this hypothetical Offering
Period is $1.9125 per Share of EYPT Stock. </I></B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;GRANT</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OF OPTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant of Option</U>. On each Offering Date, each Participant in such Offering Period shall automatically be
granted an Option to purchase as many whole shares of Stock as the Participant will be able to purchase with the payroll deductions or periodic cash contributions credited to the Participant&#146;s Account during the applicable Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>5% Owner Limit</U>. Notwithstanding any provisions of the Plan to the contrary, no Participant shall be granted
an Option to purchase shares of Stock under the Plan if such Participant (or any other person whose Stock would be attributed to such Participant pursuant to Code Section&nbsp;424(d)), immediately after such Option is granted, would own or hold
Options to purchase shares of Stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Limitation</U>. The Administrator may determine, as to any Offering Period, that the offering shall not be
extended to &#147;highly compensated employees&#148; within the meaning of Code Section&nbsp;414(q). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;PURCHASE</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OF SHARES OF STOCK; PURCHASE LIMITATIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase</U>. Unless the Participant&#146;s participation in the Plan has otherwise been terminated as provided
in <U>Section&nbsp;11</U>, such Participant will be deemed to have automatically exercised his or her Option to purchase Stock on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading
Day of the Purchase Period) for the maximum number of shares of Stock that may be purchased at the Purchase Price with the Participant&#146;s Account balance at that time; <I>provided</I>, <I>however</I>, the number of shares of Stock purchased is
subject to adjustment by <U>Section&nbsp;3</U>, this <U>Section&nbsp;9</U>, and <U>Section&nbsp;12</U>. The Administrator shall cause the amount credited to each Participant&#146;s Account to be applied to such purchase, and the amount applied to
purchase shares of Stock pursuant to an Option shall be deducted from the applicable Participant&#146;s Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Limit on Number of Shares Purchased</U>. Notwithstanding <U>Section&nbsp;8(a)</U> or <U>Section&nbsp;9(a)</U>,
in no event may a Participant purchase more than Fifty Thousand (50,000) shares of Stock in any one Offering Period; <I>provided</I>,<I> however</I>, that the Administrator may, in its sole discretion, prior to the start of an Offering Period, set a
different limit on the number of shares of Stock a Participant may purchase during such Offering Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Limit on Value of Shares Purchased</U>. Notwithstanding any
provisions of the Plan to the contrary, excluding Options granted pursuant to any <FONT STYLE="white-space:nowrap">Non-423(b)</FONT> Offering, no Participant shall be granted an Option to purchase shares of Stock under the Plan which permits the
Participant&#146;s rights to purchase shares under all &#147;employee stock purchase plans&#148; (described in Code Section&nbsp;423) of the Company and its Subsidiaries to accrue at a rate which exceeds twenty-five thousand dollars ($25,000) of the
aggregate Fair Market Value of such shares of Stock (determined at the time such Options are granted) for each calendar year in which such Options are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Fractional Shares</U>. Notwithstanding any provisions of the Plan to the contrary, no Participant may
exercise an Option to purchase less than one whole share of Stock, certificates representing fractional shares will not be delivered to Participants under any circumstances, and any Option to purchase less than one whole share of Stock shall be
automatically terminated on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period). Unless the Participant&#146;s participation in the Plan has otherwise been
terminated as provided in <U>Section&nbsp;11</U>, the portion of a Participant&#146;s Account balance remaining as a result of a Participant&#146;s inability to exercise an Option to purchase less than one whole share of Stock shall be transferred
to the Participant&#146;s brokerage account. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;STOCK</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ISSUANCE; STOCKHOLDER RIGHTS; AND SALES OF PLAN SHARES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Issuance and Account Statements</U>. Shares of Stock purchased under the Plan will be held by the
Custodian. The Custodian may hold the shares of Stock purchased under the Plan by book entry or in the form of stock certificates in nominee names and may commingle shares held in its custody in a single account without identification as to
individual Participants. The Company shall cause the Custodian to deliver to each Participant a statement for each Offering Period during which the Participant purchases Stock under the Plan, which statement shall reflect, for each such Participant,
(i)&nbsp;the transactions in his or her Account and the date thereof; (ii)&nbsp;the amount of payroll deductions withheld or periodic cash contributions made during the Offering Period; (iii)&nbsp;the number of shares of Stock purchased;
(iv)&nbsp;the aggregate Purchase Price of the shares of Stock purchased; (v)&nbsp;the Purchase Price per share; (vi)&nbsp;the brokerage fees and commissions paid (if any); and (vii)&nbsp;the total number of shares of Stock held by the Custodian for
the Participant as of the end of the Offering Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder Rights</U>. A Participant shall not be a
stockholder or have any rights as a stockholder with respect to shares of Stock subject to the Participant&#146;s Options under the Plan until the shares of Stock are purchased pursuant to the Options and such shares of Stock are transferred into
the Participant&#146;s name on the Company&#146;s books and records. No adjustment will be made for dividends or other rights for which the record date is prior to such time. Following purchase of shares of Stock under the Plan and transfer of such
shares of Stock into the Participant&#146;s name on the Company&#146;s books and records, a Participant shall become a stockholder with respect to the shares of Stock purchased during such Purchase Period and, except as otherwise provided in
<U>Section&nbsp;10(c)</U>, shall thereupon have all dividend, voting, and other ownership rights incident thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sales of Plan Shares</U>. The Administrator shall have the right to require any or all of the following with
respect to shares of Stock purchased under the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;that a Participant may not request that all or part of
the shares of Stock be reissued in the Participant&#146;s own name and shares be delivered to the Participant until two (2)&nbsp;years (or such shorter period of time as the Administrator may designate) have elapsed since the Offering Date of the
Offering Period in which the shares were purchased and one (1)&nbsp;year has elapsed since the day the shares were purchased (the &#147;<B>Holding Period</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;that all sales of shares of Stock during the Holding Period applicable to such purchased shares be performed
through a licensed broker acceptable to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;that Participants abstain from selling or otherwise
transferring shares of Stock purchased pursuant to the Plan for a period lasting up to two (2)&nbsp;years from the date the shares of Stock were purchased pursuant to the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;DEEMED</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CANCELLATION OR TERMINATION OF PARTICIPATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Employment Other than Death</U>. In the event a Participant who holds outstanding Options to
purchase shares of Stock under the Plan experiences a Termination of Employment for any reason other than death prior to the last Trading Day of the Offering Period, the Participant&#146;s outstanding Options to purchase shares of Stock under the
Plan shall automatically terminate, and the Administrator shall refund in cash the Participant&#146;s Account balance as soon as practicable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>. In the event of the death of a Participant while the Participant holds outstanding Options to
purchase shares of Stock under the Plan, the legal representatives of such Participant&#146;s estate (or, if the Administrator permits a beneficiary designation, the beneficiary or beneficiaries most recently designated by the Participant prior to
his or her death) may, within three (3)&nbsp;months after the Participant&#146;s death (but no later than the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the then-current
Purchase Period)) by written notice to the Company (or the Company&#146;s designee), elect one of the following alternatives. In the event the Participant&#146;s legal representatives (or, if applicable, beneficiary or beneficiaries) fail to deliver
such written notice to the Company (or the Company&#146;s designee) within the prescribed period, the alternative in <U>Section&nbsp;11(b)(ii)</U> shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Participant&#146;s outstanding Options shall be reduced to the number of shares of Stock that may be purchased,
as of the last day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the then-current Purchase Period), with the amount then credited to the Participant&#146;s Account; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Participant&#146;s Options to purchase shares of Stock under the Plan shall automatically terminate, and the
Administrator shall refund in cash, to the Participant&#146;s legal representatives, the Participant&#146;s Account balance as soon as practicable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Termination of Participation</U>. If a Participant ceases to be eligible to participate in the Plan for
any reason, the Administrator shall refund in cash the affected Participant&#146;s Account balance as soon as practicable thereafter. Once terminated, participation may not be reinstated for the then-current Offering Period, but, if otherwise
eligible, the Eligible Employee may elect to participate in a subsequent Offering Period in accordance with Section&nbsp;5. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;CHANGES</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IN CAPITALIZATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Stock</U>. If the number of outstanding shares of Stock is increased or decreased or the shares of
Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of any recapitalization, reclassification, stock split, reverse stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT>
combination of shares, exchange of shares, stock dividend, or other distribution payable in capital stock, or other increase or decrease in such shares effected without receipt of consideration by the Company occurring after the Effective Date, the
number and kinds of shares that may be purchased under the Plan shall be adjusted proportionately and accordingly by the Administrator. In addition, the number and kind of shares for which Options are outstanding shall be similarly adjusted so that
the proportionate interest of a Participant immediately following such event shall, to the extent practicable, be the same as immediately prior to such event. Any such adjustment in outstanding Options shall not change the aggregate Purchase Price
payable by a Participant with respect to shares subject to such Options but shall include a corresponding proportionate adjustment in the Purchase Price per share. Notwithstanding the foregoing, in the event of a
<FONT STYLE="white-space:nowrap">spin-off</FONT> that results in no change in the number of outstanding shares of Stock, the Company may, in such manner as the Company deems appropriate, adjust (i)&nbsp;the number and kind of shares for which
Options are outstanding under the Plan and (ii)&nbsp;the Purchase Price per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Reorganization&nbsp;in&nbsp;Which&nbsp;the&nbsp;Company&nbsp;Is the&nbsp;Surviving Corporation</U>. Subject
to<B> </B><U>Section&nbsp;12(c)</U>, if the Company shall be the surviving corporation in any reorganization, merger, or consolidation of the Company with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one or more other corporations, all outstanding Options under the Plan shall pertain to and apply to the securities to which a holder of the number of shares of Stock subject to such Options
would have been entitled immediately following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the Purchase Price per share so that the aggregate Purchase Price thereafter shall be the same as the
aggregate Purchase Price of the shares subject to such Options immediately prior to such reorganization, merger, or consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Reorganization&nbsp;in&nbsp;Which&nbsp;the&nbsp;Company&nbsp;Is&nbsp;Not&nbsp;the Surviving Corporation, Sale of
Assets or Stock, and Other Corporate Transactions</U>. Upon any dissolution or liquidation of the Company, or upon a merger, consolidation, or reorganization of the Company with one or more other corporations in which the Company is not the
surviving corporation, or upon a sale of all or substantially all of the assets of the Company to another corporation, or upon any merger or consolidation in which the Company is the surviving corporation that results in any person or entity owning
more than fifty percent (50%) of the combined voting power of all classes of stock of the Company, the Plan and all Options outstanding hereunder shall terminate, except to the extent provision is made in writing in connection with such transaction
for the continuation of the Plan and/or the assumption of the Options theretofore granted, or for the substitution for such Option of new rights covering the stock of a successor corporation, or a parent or subsidiary thereof, with appropriate
adjustments as to the number and kinds of shares and purchase prices, in which event the Plan and rights theretofore granted shall continue in the manner and under the terms so provided. In the event of any such termination of the Plan, the Offering
Period and the Purchase Period shall be deemed to have ended on the last Trading Day prior to such termination, and in accordance with <U>Section&nbsp;9</U>, the Options of each Participant then outstanding shall be deemed to be automatically
exercised on such last Trading Day. The Administrator shall send written notice of an event that will result in such a termination to all Participants at least five (5)&nbsp;days prior to the date upon which the Plan will be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments</U>. Adjustments under this <U>Section&nbsp;12</U> related to stock or securities of the Company
shall be made by the Administrator, whose determination in that respect shall be final, binding, and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>No&nbsp;Limitations&nbsp;on&nbsp;Company</U>. The grant of an Option pursuant to the Plan shall not affect or
limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of
its business or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;TERM; AMENDMENT, SUSPENSION, AND TERMINATION OF THE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The Plan shall be effective as of the Effective Date. The Plan shall, without further action of the
Board, terminate on the first to occur of (i)&nbsp;the day before the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the date of adoption of the Plan by the Board (which was April&nbsp;26, 2019), (ii) the date
determined in accordance with <U>Section&nbsp;12</U>, and (iii)&nbsp;the date determined in accordance with <U>Section&nbsp;13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment, Suspension, and Termination of the Plan</U>. The Administrator may, at any time and from time to
time, amend, suspend, or terminate the Plan or an Offering Period under the Plan; <I>provided</I>, <I>however</I>, that no amendment, suspension, or termination shall, without the consent of the Participant, materially impair any rights of a
Participant that have vested at the time of such amendment, suspension, or termination. The effectiveness of any amendment to the Plan shall be contingent on approval of such amendment by the Company&#146;s stockholders to the extent provided by the
Board or required by applicable law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;GENERAL</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROVISIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding of Taxes</U>. To the extent that a Participant recognizes ordinary income in connection with a sale
or other transfer of any shares of Stock purchased under the Plan, the Company may withhold amounts needed to cover such taxes from any payments otherwise due and owing to the Participant or from shares that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would otherwise be issued to the Participant under the Plan. Any Participant who sells or otherwise transfers shares of Stock purchased under the Plan within two (2)&nbsp;years after the
beginning of the Offering Period in which the shares were purchased or within one (1)&nbsp;year from the date the shares of Stock were purchased, must, within ten (10)&nbsp;days of such transfer, notify the Company in writing of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Options Not Transferable or Assignable</U>. A Participant&#146;s Options under the Plan may not be sold,
pledged, assigned, or transferred in any manner, whether voluntarily, by operation of law, or otherwise. If a Participant sells, pledges, assigns, or transfers his or her Options in violation of this <U>Section&nbsp;14(a)</U>, such Options shall
immediately terminate, and the Participant shall immediately receive a refund of the amount then credited to the Participant&#146;s Account. Any payment of cash or issuance of shares of Stock under the Plan may be made only to the Participant (or,
in the event of the Participant&#146;s death, to the Participant&#146;s estate or, if the Administrator permits a beneficiary designation, the beneficiary or beneficiaries most recently designated by the Participant prior to his or her death).
During a Participant&#146;s lifetime, only such Participant may exercise his or her Options under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Right to Continued Employment</U>. Neither the Plan nor any Option to purchase Stock under the Plan confers
upon any Eligible Employee or Participant any right to continued employment with the Company or any of its Subsidiaries, nor will a Participant&#146;s participation in the Plan restrict or interfere in any way with the right of the Company or any of
its Subsidiaries to terminate the Participant&#146;s employment at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Interest on Payments</U>.
No interest shall be paid on sums withheld from a Participant&#146;s pay or otherwise contributed for the purchase of shares of Stock under the Plan unless otherwise determined necessary by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governmental Regulation</U>. The Company&#146;s obligation to issue, sell, and deliver shares of Stock pursuant
to the Plan is subject to such approval of any governmental authority and any national securities exchange or other market quotation system as may be required in connection with the authorization, issuance, or sale of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></U>. Transactions under this Plan are intended to comply with
all applicable conditions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> or any successor provision under the Securities Exchange Act of 1934, as amended. If any provision of the Plan or action by the Administrator fails to so comply, it
shall be deemed null and void to the extent permitted by applicable law and deemed advisable by the Board. Moreover, in the event the Plan does not include a provision required by Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> to be stated in
the Plan, such provision (other than one relating to eligibility requirements or the price and amount of awards) shall be deemed automatically to be incorporated by reference into the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Plan Expenses</U>. The Company shall bear all costs of administering and carrying out the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Application of Funds</U>. All funds received or held by the Company under the Plan may be used for any corporate
purpose until applied to the purchase of Stock and/or refunded to Participants. Participants&#146; Accounts need not be segregated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. The validity and construction of the Plan and the Options granted hereunder shall be governed
by, and construed and interpreted in accordance with, the laws of the State of Delaware (other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of the Plan and the Options granted under
the Plan to the substantive laws of any other jurisdiction), except to the extent superseded by applicable U.S. federal laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" ROWSPAN="5">


<IMG SRC="g7344201.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g7344202.jpg" ALT="LOGO">
</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>Your vote matters - here&#146;s how to
vote!</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote online or by phone instead of mailing this card.</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g7344203.jpg" ALT="LOGO">
&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Votes submitted electronically must be received by 1:00 a.m., Eastern Time, on June 25, 2019.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Online</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g7344204.jpg" ALT="LOGO">
&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Go to <B>www.envisionreports.com/EYPT</B> or scan the QR code &#150; login details are located in the shaded bar below.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g7344205.jpg" ALT="LOGO">
&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Using&nbsp;a&nbsp;<B><U>black&nbsp;ink</U></B>&nbsp;pen,&nbsp;mark&nbsp;your&nbsp;votes&nbsp;with&nbsp;an&nbsp;<B>X</B>&nbsp;as&nbsp;shown&nbsp;in&nbsp;
this&nbsp;example.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">Please do not write outside the designated areas.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">


<IMG SRC="g7344207.jpg" ALT="LOGO">
</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">


<IMG SRC="g7344206.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Save paper, time and money!</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><B>Sign
up for electronic delivery at www.envisionreports.com/EYPT</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>


<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Annual Meeting Proxy Card</B></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g7344208.jpg" ALT="LOGO">
</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> IF VOTING BY MAIL, SIGN, DETACH AND RETURN
THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ec008c">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="93%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" BGCOLOR="#000000"><FONT COLOR="#FFFFFF"><B>&nbsp;A&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><B>The Board of Directors recommends you vote <U>FOR ALL</U> of the following nominees:</B></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Election of Directors:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g734420x_1.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">01 - G&#246;ran Ando</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">05 - Jay Duker</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">09 - David Guyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">02 - Nancy Lurker</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">06 - Kristine Peterson</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">03 - David J. Mazzo</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">07 - Ronald W.
Eastman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">04 - Douglas Godshall</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">08 - John B.
Landis</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:18pt">&nbsp;&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mark here to vote</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B><U>FOR</U> all
nomineese</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:18pt"><B>&nbsp;</B>&#9744;<B></B><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mark here to <U>WITHHOLD</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>vote from
all nominees</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:18pt">&nbsp;&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>For All <U>EXCEPT</U> -</B> To withhold authority to vote for any nominee(s),</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">write the name(s) of such nominee(s) below.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; ">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>

<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#FFFFFF"><B>&nbsp;B&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><B>The Board of Directors recommends you vote <U>FOR</U> proposals 2, 3, 4 and 6, and to vote &#147;1 Year&#148; for proposal 5.</B></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Abstain</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">2.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Approval of an amendment to the EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan to increase the number of shares authorized for issuance by 11,000,000.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">3.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:8pt">Approval of the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>2&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>3&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Abstain</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">4.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Approval on an advisory basis of compensation paid to EyePoint Pharmaceuticals, Inc.&#146;s named executive officers.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">5.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Approval on an advisory basis on the frequency of advisory stockholder votes on compensation paid to named executive officers.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">6.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Ratification of the appointment of Deloitte &amp; Touche LLP.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;</B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9744;<B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials
for the Annual Meeting to be Held on June 25, 2019: The proxy statement and the Transition Report on Form&nbsp;10-K for the six months ended December 31, 2018 are available at www.edocumentview.com/EYPT for street holders and
www.envisionreports.com/EYPT for registered holders. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#FFFFFF"><B>&nbsp;C&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><B>Authorized Signatures &#150; This section must be completed for your vote to count. Please date and sign below.</B></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator,
corporate officer, trustee, guardian, or custodian, please give full title. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Date (mm/dd/yyyy) &#150; Please print date below.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;Signature 1 &#150; Please keep signature within the box.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature 2 &#150; Please keep signature within the box.</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:25pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:25pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g7344209.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:13%; font-size:6pt; font-family:Times New Roman">0325ND </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2019 Annual Meeting Admission Ticket </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 Annual Meeting of EyePoint Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tuesday, June 25, 2019, 9 a.m. (EDT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>480 Pleasant Street, Suite A210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, Massachusetts 02472 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upon arrival, please present this admission ticket and photo identification at the registration desk. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>You may obtain directions to the Annual Meeting </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by calling our office at (617) 926-5000 or </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>e-mailing our office at rhonig@eyepointpharma.com </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be held on June 25, 2019: The proxy statement and
the Transition Report on Form 10-K for the six months ended December 31, 2018 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="78%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">


<IMG SRC="g73442010.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Small steps make an impact.</B></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="3" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">


<IMG SRC="g73442011.jpg" ALT="LOGO">
&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Help the environment by consenting to receive electronic</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">delivery, sign up at www.envisionreports.com/EYPT</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> IF VOTING BY MAIL, SIGN, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ec008c">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000" BGCOLOR="#d8d8d8"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Proxy &#150; EyePoint Pharmaceuticals, Inc.</B></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g734420x_1.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>Notice of 2019 Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Proxy Solicited by the Board of Directors for the Annual Meeting of Stockholders &#150; June 25, 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby appoints Nancy S. Lurker and Ron I. Honig, and each of them, each with the full power of substitution, as proxies to represent and vote
the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of EyePoint Pharmaceuticals, Inc. to be held on Tuesday, June 25, 2019 or at any postponement or
adjournment thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares represented by this proxy will be voted in the manner directed by the stockholder. If no such directions are indicated,
each of the Proxies will have authority to vote FOR the election of all nominees, FOR proposals 2, 3, 4 and 6, and FOR &#147;1&nbsp;Year&#148; frequency in proposal 5. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In his or her discretion, each of the Proxies is authorized to vote upon such other business as may properly come before the meeting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Items to be voted appear on reverse side.) </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" BGCOLOR="#000000"><FONT COLOR="#FFFFFF"><B>&nbsp;&nbsp;C&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;</TD>
<TD VALIGN="middle" BGCOLOR="#cccccc"><B>Non-Voting Items</B></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Change of Address</B> &#150; Please print new address below.</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Comments</B> &#150; Please print your comments below.</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:25pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>

<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:25pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:40pt">&#9726;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g734420x_1.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g7344201.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344201.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M[O[:QE/T#]#^6\^$(]9\33:I>>-_%L>J/=[[;7+[6GUS6=$AGU"X7R-5O[.
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M&VD*XC.J^$?$.D>)--#L"RH;[1KRXA#E02!OS@4 =70 4 % !0 4 % !0 4
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MVK1:3_;&OZYLU#4FC:]N/M_B35=0O3YC11G8;@HNWY%7)R;!L>HT % !0 4
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MXE_!7XD_L;?M@_$*PUCXI_'&XU.7PM^S[<^)O OB;PMXX\>>([^"*&YU?6K
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MUL=0^(BZ/+X8MO'%U9:3:6JZ;?>-%LF75)K6RL-5LA!-J>Y(8=2@$;*EPF\
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M-TM^^K&P;'T#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^(BWQ'D=%\M>E"JG[&K3]K2NI7]G4_>0^&?O)F/_ ,-?Z)_T$_\ S$?Q+_\
MDVM_[&Q/:E_X6X3_ .6'=_Q C,O^@./_ (D_#_\ \K/H[X1?$:V^)WAJZ\06
MLXN(K;6+G2MX\/:UX:(:WM+&Y*G3]>FDN7(%X#YRD1L"%491B>/&X.>"E1A4
M23JT^=<M6G55O:3A\5)N*^"W*VY==FC\GXXX5K<'9Q1RJO3]E.IA:>)Y?KV$
MS#2I5K4T_;X*,:*_A->S=YQM>3M**7J=<1\:% !0 4 % !2>S#;Y'R?H/@SQ
MA)X>\3>$=8\,?$9X;^/5X1!XCUOX7WWP]NK>Y\71W_DZ/9:3XCGUJ(SZ6\I1
M=2M(T\HW$<VV5HT;T'&@L-E3]O0<Z#RKVL4L2L33^K0H1K^_[-47&FX2_AU)
M2ERP=/F=[_M>:9_D5/-,KSW+LYR*-7#RI34LOPG$5#.Z52&5U*,9XNKBL!2R
M]^SQ*@IO!UYR]K[*I2YJ4:DXV;?P1X^\,2ZZ5\/WOBO3]#\:_#VX\(Q:5JN@
MKK>L^#?#<5R5CG;Q+KNG6Z:IID5ZM@[7E[ ;I=.6X1G><J'2JTJLL#4JU?95
MYU<PGBYRB^15*V6K!TZR5*,VXXB=.%6<80O3J5*D5!4XQD\:O$'#&<1R^/\
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M[#Y_FS^=Y,7HO*+9?6QWUC^#1H5?9^SW]OB:V'Y>;GTY?8\]^5WYN6RMS/\
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MN:Q/G#SWX9^//^%B>'[[7?[*_L?[%XJ\6^&?LOV[^T/,_P"$6\0W^@_;?/\
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M "8&6-O?VBWY?96MI?GN_@/TVAX%>VHNK_K3R\N;U<JY?[-O_"X-GQ=[>_\
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MWU;ZM]7^O3Q$?JMO;U_:^R^KW]O>GS\]O8PY=;GQL^)G_"G?ACXF^(W]B?\
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MM?VM3VW)]3Y_;6I<WM.7V4>3FEY[=_'C[)\5IOAC_P (KO\ )\>Z#X(_MO\
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MIF-JR,VV) OEYI*;J8?VF/CF$E2^.-6M5Y%[6K^[;KVE%KX^5)1M-2WE)O\
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MFRB6&KXF@X4E[2A&AS2<(W]I+-Z4E-/5N7L:D:?-H[7A\*U\OPSS#AKB+/\
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M*88[8,?+ &<,=@J?,X4G&3ECM8PBG[.O@U0HQNFG:-7F;CM%2<E=MHY)<>\
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M\ON3ZQ^].JU#X7>!=4^(6A?%6_T+S_'OAG2IM$T37O[3UB+[%I<\6LPRVO\
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M6T6SMT].A\BTDVHOF2>CM:ZZ.W2_8?2$% !0 4 % !0 4 % !0 4 % !0 4
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M5]AFV/R_,<4U*OBXJI'$9;5JX=49<MH4W)58RC4<HJ,H-_1]>*?E 4 % !0
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M?ZJY!_T-*7W\?_\ T'GT7\)=8U+6O#=U=ZG;&TN%UBY@6)E\$*PB2TL75B/
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MOJ%8'QX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.+:G.I7H<JE3C6E#V:N8^!"@ H * "@ H * "@ H * "@ H * "@ H * "@
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: "@ H * "@ H * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g73442010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73442010.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6-,MH@[_  G^/,UA=R7\=O RBV\+_%W1-(MM:T/4YG5,3>)+?Q1 [<.8 S3
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g73442011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73442011.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M/B/J=TDL9E\<6VB_V=;PQ0:))(;B6:4_0/T/9=#_ &<_V$M3TRVU;2-9\/\
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C_L9/"7_JP]5H _J*_9O_ .20^%O^N,O_ *$* /=* "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g7344202.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344202.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P "UTU?]^PG_8LR_P#]4O$)]%QY_P EIG7_ &(Z_P#Z[C,R?X@_\C!\ /\
MLCW[1O\ ZAVHUQX+_D4\3?\ 8MX9_P#4B(N%?^13XG?]EAP-_P"KFB3^#?\
MDF'PD_[%CPW_ .J,^.-;YS_O?%/^''_^D<,G/GG_ "6?'?\ V,<;_P"MSPF<
M;\?_ /D:/BG_ -F@^#/_ %86A5W8'^#5_P"RRPW_ *@GT7A7_P B/@'_ +.;
MF_\ ZH,:>UZK_P A/3/^P3XJ_P#3U^S;7EP_Y>_]C+!?^K[/S\VP/_(MQW_8
M1EG_ *JN/CQ3XD_\E1^-G_9QG[,7_IJU&O4R;_<N$O\ KYQ1_P"G&?I/"_\
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M/ MO_1E]491_%QW_ &3O$/\ ZER/ X,_W3Q*_P"S7?\ N##'%?"/_DF?A_\
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M1C!5/:M2<K"_ #P<H\>@:EXF_P"+BZMXGUG6\WFE_P"BW7BOPU/X5U&/2O\
MB3?N((]/G>2%9_M++, SM(@,9QIXZK2CET(QA;+(\M*ZEJEC</C_ -Y:2N_;
M8:G'W>7]VYKXG&<<?^(G9]S<+2^J8!/A'"Y9A,'^ZQ'[RGE6.688>6)_VKWY
MSK+EK.E[&,J7NPC3G[YHZ[\%/"OB!_"SWE_X@B/A'XD1_%#31:W6G()M?C:5
MEL[X2Z5)YFCYF;,47DS<#_2/6<-C:N$E5E3C!NM@L9@7S)Z4<;4=6K)6DK5(
MR=J;=XI?%";U./+/$'.<IIYY2PV%P4HY]D/^KN(]I3KMPP7+"'M:/+B8*.*M
M3C[\U4I7;_<;)9?AS]G[P;X9T*S\/V&I^)Y;*QU@:W%+=WFE/<FZ'CS2?B&(
MY'AT6)#;_P!M:/:P[1&K?99)4W^:RSII+,:TJM.KRP4J5"CATK2MR4,+C,)!
MM<U^9T\=5<FFDYQIM145*,^W-_$_/\YS/%9KBL'E]/$8O"SP<XTJ6)C35*>2
M5\A<HQGBIR4U@\1.HFYN/UE1GRNDG1D_6/@#X.UN\\'WMUJ7B:.7P3X;\:^%
MM*6WO-+2.XT_QWILVE:O-J"R:-(9;R&WG=K9X6@1' ,L<R@J<J6,J4</CL+&
M,73Q]# T*C:?-&&7S4Z+@U))2DU:JY*2:^!0>HLO\3\_RW#Y[A:&$R^5/B',
MLIS3$.=+$.4,1D^)CBL-"@XXJ*C1G4@HUXU%4G*%U3J4I>\GZ9\!/!^E:#X=
M\/6VI>)6LO#-A8Z?82S7FEM=30V'A3Q5X/A:[>/1TCDE.F>+]2E8QQQ SP6S
M!5C22*:\3CZV*J8^K4C",LP595%%22C[98%2Y+R=K++Z/+S.5N:K>_-#DG%>
M)>>XS,\VS6KA,!'$9Q6JUZT8TL0J<)U<UR[.)*E%XJ4HQ6)RRA3BISFU0G6B
MVZDH5:>9XO\ V;_ _C6_U_4-4U7Q7;S>(OAQIGPOO4T^^TB**'0-)UFTURWN
M[5;C0IVCUAKNSB1Y9&EA,;,%MU8AUUI9IB*,90C"FU+,X9J[J7^\4Z7L8PTF
MOW/+JX_'S:JHEH=G#_BSQ'PWA,HP>!P66U:62Y[B.(*#KT<5*4L;B<'5P52E
M5=/&4E+"QI592A"$855446ZTHIP?L/AWPW8^&;6ZM+"6[ECN[M;R1KMX7=94
ML+'3@J&&"("/R-/A;!!.]G.<$*O%5K2JVYDERRK25K[U\16Q,]V]%4KS4>T%
M%.[3D_@<SS3$9K5HUL1"G"5"DJ,534DN55*M6[4IS?-S59*Z:7*HZ73;Z"LC
MS0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@!A=%;8716^7"E@&^;(7Y<YYVMC_ '3Z4?I_P_Y#496N
MHNROK;32U]?*ZOVNNXT3P< 319W,@ D3[Z %E S]Y01D=1FC_*_R[^A7LJB_
MY=R5DG\+V>B>VSZ/J*)8B<"2,GT#J3PH?H#_ '&4_0@]#1MY6_31_<]!<DU]
MEKY/NU^::]4UT&BXMSC$\)RI9<2H<JI*EAAON@@C/3(HM;RM;_@?\ ?LJB_Y
M=R5G;X7O:Z6V]M;=A3/"%+^=$$7;EC(@4;AE,MG R,8]>U%NGR2\^P*G4ORJ
M$KZZ<KOIH]+=-GV#SH?F_>Q?(2&_>)\A4%F#<_*0H).>@%']+\%^J7S0>SJ:
M>Y+WK6T>M]%;36^RL*98EQF6-=S^6N749<?P#GE_8<T?U]V_W"4)ZV@_=5WH
M]%W\EY["">$C*S1$9P")$(SN"8R#UW$+]2!U-%OZ^_\ R?W/L-TZD='"46NG
M*UTOV[*_IJ!FA&W,L0W!F7,B#*H"69>>0H!R1TQ1^GY= 5.IK:$O=:3T>C>B
M3TT;Z(!-#@$2Q8/((D3!!#,,'/\ =5C]%)[4;>5O^!_FOO0>SFG;DDFNEGW2
M[=VEZM(&G@3(::)=JAR&D1<(2 '()X4D@9Z<BBUO*VGS[ J=1VM3D[NRM%[K
M6VVZML+YT0_Y:QC_ (&HZ;0>_;>G_?0]11;^OG;\U;U0N2?\CT\GY_Y/[GV$
M,\"DJ9HE*LJ,ID0%6;.U2">&(!P.^*$MK?+Y?Y#5.I96IRLTVO=>RW:TV75]
M!1+%D 21Y.  '7)R64 #/<HP_P" GT-']?A?\M?07)-+X6DO)]+7^ZZ^]=Q!
M/!P!-%G<R "1/OH 64#/WE!&1U&:/\K_ "[^@_95%_R[DK)/X7L]$]MGT?44
M2Q$X$D9/H'4GA0_0'^XRGZ$'H:-O*WZ:/[GH+DFOLM?)]VOS37JFN@T7%N<8
MGA.5++B1#E5)4L,-]T$$9]13L^VUOQV^_H-TJBO^[DN5V?NO1VNEMH[:V[#O
M-B ;][& @);YU 0*Q5BW/R@,"#GH012_X'X[??T%R3T7)+6UE9]KJWR::\G<
M030DX66(G"G D0G#XV' /1@1CUSQ1:WE;]/\K?@-TYI?!))7Z/IH^G3KV SP
MA2_G1!%VY8R(%&X93+9P,C&/7M1;I\DO/L"IU+\JA*^NG*[Z:/2W39]@\Z'Y
MOWL7R$AOWB?(5!9@W/RD*"3GH!1_2_!?JE\T'LZFGN2]ZUM'K?16TUOLK"F6
M)<9EC7<_EKEU&7'\ YY?V'-']?=O]PE">MH/W5=Z/1=_)>>PT7$!QB:$@[MN
M)$.=@);&&_A .?3%&WE;7Y#]E45U[.2M:ZY7UT73K=6]16G@3(::)=JAR&D1
M<(2 '()X4D@9Z<BBUO*VGS[ J=1VM3D[NRM%[K6VVZML+YT0_P"6L8_X&HZ;
M0>_;>G_?0]11;^OG;\U;U0N2?\CT\GY_Y/[GV$,\"DJ9HE*LJ,ID0%6;.U2"
M>&(!P.^*$MK?+Y?Y#5.I96IRLTVO=>RW:TV75]!1+%D 21Y.  '7)R64 #/<
MHP_X"?0T?U^%_P M?07)-+X6DO)]+7^ZZ^]=QZLK#*,&&2,J01E2589'<,"#
MZ$8H$TXNS3BUT:MYK3TU%H$% !0 4 % !0 4 % 'S/XM_P"2Y6G_ %Z_!K_T
M[_&VO0PO^Z4_^P[,_P#U2X8_7<G_ .3;5/\ K[Q5_P"FN"SXL\*_\CEX4_[.
MK_:/_P#41LJ]C$?\B:E_V0]'_P!.U#^AL]_Y$6??]F[\/?\ U;53Z9\#?\C5
M??\ 7*^_]9^^#M>5G?\ NN._[ \Y_P#5_5/QOB#_ )$N6_XL+_ZVG&!\G?"/
M_D'?"3_LV[XH_P#JU=2KZ+B+^/Q)_P!A?#7_ *1AC]OX]_WCCO\ [+_(O_65
MHG?^/_\ DU;7_P#L'?LX_P#IM\(U&7_\EGE__8]S+_U6H^;X6_Y/;@O^OO'O
M_J;G!K1_=_:D_P"Q[^,__JG-2KS\+_!X2_Z]+_UI,I//?\7P2_[$O!W_ *T\
M3K_B;_Q\?!+_ +/ MO\ T9?5&4?Q<=_V3O$/_J7(\#@S_=/$K_LUW_N##'%?
M"/\ Y)GX?_[* O\ ZT_X%KIJ_P"_83_L69?_ .J7B$^BX\_Y+3.O^Q'7_P#7
M<9F3_$'_ )&#X ?]D>_:-_\ 4.U&N/!?\BGB;_L6\,_^I$1<*_\ (I\3O^RP
MX&_]7-$G\&_\DP^$G_8L>&__ %1GQQK?.?\ >^*?\./_ /2.&3GSS_DL^._^
MQCC?_6YX3.-^/_\ R-'Q3_[-!\&?^K"T*N[ _P &K_V66&_]03Z+PK_Y$? /
M_9S<W_\ 5!C3VO5?^0GIG_8)\5?^GK]FVO+A_P O?^QE@O\ U?9^?FV!_P"1
M;CO^PC+/_55Q\>*?$G_DJ/QL_P"SC/V8O_35J->IDW^Y<)?]?.*/_3C/TGA?
M_DB_#_\ [-]XA_\ J3ACZ&T3_DHFD_\ 7UX _P#4_P#VAJ\'#_\ (ORWTG_Z
MR^7'Y1F?_))X[_NN_P#JLX"/F;PK_P CEX4_[.K_ &C_ /U$;*O5Q'_(FI?]
MD/1_].U#]DSW_D19]_V;OP]_]6U4^F? W_(U7W_7*^_]9^^#M>5G?^ZX[_L#
MSG_U?U3\;X@_Y$N6_P"+"_\ K:<8'RE\'O\ CT^#_P#V;G\3O_5KZC7U6;_\
MC+._^QCPM_[J'[9XA?Q>/O\ LO<C_P#64I'T!XH_Y)U^T+_V(_QV_P#5P?$>
MOF*7\7)O\7"/_I"/S/)/^2R\*O\ L;<(?^LGPV<A\'O^2A2?]DY_9,_]--K7
MHYY_N^:_]CKB3_U58\]GC[_DE*'_ &//$S_U8F3X_P#^35M?_P"P=^SC_P"F
MWPC77E__ "6>7_\ 8]S+_P!5J/2X6_Y/;@O^OO'O_J;G!K1_=_:D_P"Q[^,_
M_JG-2KS\+_!X2_Z]+_UI,I//?\7P2_[$O!W_ *T\3K_B;_Q\?!+_ +/ MO\
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M#M1KCP7_ "*>)O\ L6\,_P#J1$7"O_(I\3O^RPX&_P#5S1)_!O\ R3#X2?\
M8L>&_P#U1GQQK?.?][XI_P ./_\ 2.&3GSS_ )+/CO\ [&.-_P#6YX3.-^/_
M /R-'Q3_ .S0?!G_ *L+0J[L#_!J_P#998;_ -03Z+PK_P"1'P#_ -G-S?\
M]4&-/:]5_P"0GIG_ &"?%7_IZ_9MKRX?\O?^QE@O_5]GY^;8'_D6X[_L(RS_
M -57'QXI\2?^2H_&S_LXS]F+_P!-6HUZF3?[EPE_U\XH_P#3C/TGA?\ Y(OP
M_P#^S?>(?_J3ACZ&T3_DHFD_]?7@#_U/_P!H:O!P_P#R+\M])_\ K+Y<?E&9
M_P#))X[_ +KO_JLX"/F;PK_R.7A3_LZO]H__ -1&RKU<1_R)J7_9#T?_ $[4
M/V3/?^1%GW_9N_#W_P!6U4^F? W_ "-5]_UROO\ UG[X.UY6=_[KCO\ L#SG
M_P!7]4_&^(/^1+EO^+"_^MIQ@?*7P>_X]/@__P!FY_$[_P!6OJ-?59O_ ,C+
M._\ L8\+?^ZA^V>(7\7C[_LO<C_]92D?0'BC_DG7[0O_ &(_QV_]7!\1Z^8I
M?Q<F_P 7"/\ Z0C\SR3_ )++PJ_[&W"'_K)\-G(?![_DH4G_ &3G]DS_ ---
MK7HYY_N^:_\ 8ZXD_P#55CSV>/O^24H?]CSQ,_\ 5B9/C_\ Y-6U_P#[!W[.
M/_IM\(UUY?\ \EGE_P#V/<R_]5J/2X6_Y/;@O^OO'O\ ZFYP:T?W?VI/^Q[^
M,_\ ZIS4J\_"_P 'A+_KTO\ UI,I//?\7P2_[$O!W_K3Q.O^)O\ Q\?!+_L\
M"V_]&7U1E'\7'?\ 9.\0_P#J7(\#@S_=/$K_ +-=_P"X,,>0?#S_ )%;X9_]
MC'^T)_Z9?B55X_\ A9I_V3>4_P#IZ1]]Q7_R/^,_^P3@?_U,X7)OC_\ \C1\
M4_\ LT'P9_ZL+0J[\#_!J_\ 998;_P!02/"O_D1\ _\ 9S<W_P#5!C3VO5?^
M0GIG_8)\5?\ IZ_9MKRX?\O?^QE@O_5]GY^;8'_D6X[_ +",L_\ 55Q\>*?$
MG_DJ/QL_[.,_9B_]-6HUZF3?[EPE_P!?.*/_ $XS])X7_P"2+\/_ /LWWB'_
M .I.&/H;1/\ DHFD_P#7UX _]3_]H:O!P_\ R+\M])_^LOEQ^49G_P DGCO^
MZ[_ZK. CVOX _P#).#_V4'XS?^KC\>UQ5?X> _[%^6?^J_"GP?BC_P E<_\
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MZI@5S9?E59U\!A[QPJE'ZO5DY>UBU7JWY:U2I&R.GL?AYX.TVZDO;+1_(NI
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M)'V.'C;DQN,S&.L:2D[8S'XNMJW?VOLW>E3I0AR>C_ 3X3^'TT>/2/"GV1-
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MCJOB<>)T@>VT;X)>+]:T![H1DZ9J4-]%_:&MZ3)(RFUUFT\G0_+NH6CFA\Y
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MQXKCTS64\-:SK,,BM#=:]<:$WBN<3S RSC3O/=I&LHWM_0Q$JD</Q5*HO9O
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MIZ2^&?!R^*Y/$Z:'X>7QL^EK92ZXMAIX\2-HXD"+ ]\(OM9L=Z*F"^SY O\
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C151MS5*K4II\DY)]<!C@< < #C&.G%9'A[>5@H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g7344203.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344203.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M'_9._P"3?_ /_<T_^IKXCH Y?XO6-YJ?[0_PFTS3K?[7J&H?LY_M:6-A:?\
M"4Z[X&^TWEWK?[-MO:V__":^%K6YUKP=YD\B)_;>D6\]_I^[[79Q27%O&C&P
M;'F7_"C/C%_T3[_SJ/\ MU__ #LJ /I'X'?\>'Q,_P"RW?%3_P!26:@#S3]I
MK_D>_P!E#_LMOB[_ -9Q^.5 '7_LG?\ )O\ X!_[FG_U-?$= &/\8;7XAZ'\
M:_@W\2_!OPJ\3_%+1O#/P]^-OA'Q!9>$_$'PYT34]*O_ !MK?P4U/P_<2)\1
M/&OAR"[LYH? ^O*QLY[AXFAC\Q%$J$FP;%__ (73\7O^C/\ XV_^%S^S'_\
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M*_;3_:JUC2[2_DTR>Z,GPDTP)>Q06]S)"L6K_L]VLLFV&Z@;>B,GS[=VY6
M/8? OP!T[PGXIL/&OB7XD?%3XN^*="M-4L?"^I_$_7= NX?"EOK<5O!K#:%H
BG@[PMX<TB+4+RWMD@?4KG3[J_6"2>VBN8[:XFBD-@V/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g7344204.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344204.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MQ&%AF;RFO2KU/[&S.G.=&>%S>E7IUL!6H^UIQE*#<*^@:WXO\37/Q&T2VM?
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12>(J.4I2<FW)MMMMW;U9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g7344205.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344205.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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<DT@/;WEM>003PS1E7BEACD1E= 0;>5@V\K'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g7344206.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344206.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "@ *0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /VU^*?Q2\+?"'PI+XJ\427DPEN[71] T#2+9M1\2^+_ !-J
M):+1O"OA;2(B)=5UZ_G4I% F%55DFF>*W@EEC /"[/X9?&_XR9UKXS?$'Q#\
M)?"]V\SZ;\%O@SKJZ'J,.ES1+'!#\1?BU9P?VYJ>MD;I9;7PG<>'[.V=_L_V
MG441II@#I[?]D3X 6UHEI_PAVKW!6-D-_??$/XEW^M2,VXM<S:[>>,)-0EO=
MS%A<M<F56 *.I5< '+7OP)^*GPN6/5_V=?BWXCN+:P3?-\'?CAKVM?$CP'X@
MMXC+*]AH_C;6[BZ\9> M5FW)%#?)JNLZ=#M4RZ/-EF!M\@V^1Z[\'OC!IOQ7
MTO5HIM#U;P1X\\(7T6B_$/X;^)#:_P#"1>"]<DA^T0PSRV,TMIJ^BWUO_I6G
M:S82S6=_;$20R!TEBA /8* /D;P1ID?QB_:'\=?%'6X5N_#'P$U.\^$/PEL9
M_P![:0>-FTRTN_BWX_@B\QH_[5#ZG9>#[:;RQ);1Z#K:*W_$PE50#S'XV_#/
MP_\ &?\ ;,^'G@GQ+J/C#0X- _9?^)_B[0-?\!>,_$?@;Q1H?B*Y^*/PPT%=
M2L-8\.W]N[&/3Y;E!;W27-M(TP::"1H83$;!L=-9:;^U=\)[==3\!^.O#?[7
M7PYMVN8I/#WC*XT7P9\8K6.PN3;7%OX?^(?A^W3POXOU"!X+R&2VUS3=(D>>
M)8VOXF5\FWR#;Y'NOP;^/O@/XV6VLVWA]M6\/^,_",UK9^/?AEXRTZ3P]\0O
M 6I74/G06GB3P]<,SI!,@<VVHVCW5A=JC-:W,H1MH!YA^T)IO_"M/&?PZ_:9
M\/PO;W?AW7?#WPT^+T=G"6/B?X/^.]?M-!CGU*.,@33>#_%^K:3XAMKJ0C[)
M9+KR[Q%=R FP;'UW0!\J_L<@#X2^(3,H75F^/?[3+:^%V ?VP/V@?B.)<%27
M(%J+0?OB7XZ[-E &7K4/V+]O+X=W\[!(=:_91^+&BV *L/-O=*^+'PCU6ZC#
MD!6(L[I7VJ68!<L &4D \ ^'7QB\/?!#]J/Q;\-++1/B1H/P1^,GC#49=.U+
MQI\/?&GA#P=\/OC]=:B]CJ>A>&/$/B+1+72]0\(?$"XMY-1L!97DB#6&F:W1
MH=85HS8-C9^/WB_P_P"(/#?B[]K3X3:?JFE^//V2/'FL>%]0\2S);:;I?Q<\
M ^%[S2[?XP>!?M%I<SMXC\)1K>ZU%827L<'D>(_":RVQCB#7$I^@?H?0O[8\
M]G<_LA_M$7,FPVT_P3\>3P&8!09)?#%[)8_*W27[0T&P==^W'- '6_\ %9?]
M3-_Y5: /./ NHCX/_M#>/_A=KDL=EX7^.^JW?Q>^$5[.WEV]UXR72;*U^+O@
M.!_(6-=56;3+3Q?;V_FM+<PZ[K4R*1I\S V#8U/VE/"7C:.Y^&7QN^&.COXE
M\<? [Q!J^IW?@^U$":GX[^&OBS2?['^(?@[1YYY(TCUR2WM]&UG3XY7\N:^\
M+VD!4/+')";?(-OD1:CX]_9L_:P^#OB/P_-XZ\,W_A7Q#IWV+7;&\UK3]"\7
M>!M;MBE[:/JNE:G-'?>#_&6A:K:P7D/VN"*6WN=/CF3<BJS 'Y^?"7QFOQN^
M'-K_ ,$]/!$^AZI)X#U>;P[\=?BWX5US3[CPCX@^#.A>)K#5;_Q)X0N[75KJ
M[UCQA\0UO#I6H1QO(-+O;_79IY_EM6F /O#]H.[M_B-XJ^'/[+V@%YY?$FL>
M'OB%\5QI\IC3PM\&O .NVFMI;ZHT2M]G/B_Q5H^E>&K6TD %W9MKS8,=C*"?
MH'Z'U[0!YQ\4_A9X6^+OA27PKXHCO(!#=VNL:!K^D7+:=XE\'^)M-+2:-XJ\
M+:O$#+I.O6$[%XITRK*TD,R2V\\L4A^@?H>$6?Q3^-?P70Z+\</A_P"(/B=X
M8L!Y6G?&[X,>'[CQ)=ZA9"816K^/_A#I(F\0:#KBPLANKOPW;:]IDA1[D#3X
MV-O ?H'Z' >,/B)_P3T^(NL6VO?$30?A/XD\87%IYD47COX-7TOQ"N+*R,LC
MQ3Z#XC\$+XAN;:UD\Y9(9;1TAD=T=5>0JQ^@?H<GX_CO_CXG@BR_9<^$?C'X
M9:_\.]4M;KP1^T5XH\'3_!?PGX!TRYO+1?$VBZ%X)\3:+;^(?B3HVJ:,DD-S
MX>D\-6V@W;^0TFI07FGJ]H?H'Z'V+\'/@[I_PHTS5[F\UF]\:_$/QG?1:S\1
M_B3K,$4&M^,M:BC>*V+6T3O%HWA_3K>1K32]$M&%KI]M^[B#2232SFWR#;Y'
%LE '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g7344207.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344207.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( !T 'P,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /=OV*?V*?V9?BU^S+\-/B%\0OAI_P )!XO\0?\ "9?VOJ__
M  F7Q TK[7_9/Q \5Z)I_P#Q+]$\5V=E;^5I>FV4/[FVCW>3O?=([NP7*33L
MG:QZYX&_8P_8=\<>)/B;X2A^!5_H^O?"WQ7;>&M:L-1^(OQ,,EY9ZGHFGZ_H
M'B6P^S>/I,Z-J=C?2" R^7*)-.ND=!Y8+&WR%S25M3!LOV.?V-_%'Q1N? '@
M#X#VGB#1_!4\\'Q9\93?%'XL0:3X8U62PDDTOP5HA@\9R_VYXU:XEM+J^MP8
MX--LU*W,HN[N"$&WR#FDNI\W?\%&/V3?V?O@/\$O"WB[X4^ /^$5\1:C\4]$
M\-WFH?\ "5>-=<\[1;OPEXXU.XLOLGB3Q'J%M'OOM'TZ3SHX5E'V?:L@2217
M-BH2;?H??7_!.+_DS'X-_P#=0_\ U:OCF@F7Q,\K_:T\3:A\._CGX1UCX9>,
M#X0\2_$#P;I_P]^..N1:/>:S8> /AKK/C72M%\%_%?4C!=16NC>(M,US6=?T
M_2[F]5UF%Y,TG^C:8X8V^0+;TV_R/T ^'_@/PS\-/"6D>#?"-E]CT;287V-+
M*]U?:C>W4KW6I:SJU_,6FU/6=0OII[R[O9V>6>>XDD=B6HV^1/Z'YR?\%=?^
M3;?!/_9;_#?_ *@?Q*H+AO\ (])_85\2?\(=^P'X!\5_V1JVOGPWH/Q8UI-#
MT&RN-0UK6'TSXD>/[N/3-+LK6*26XOKEXEAC54;YI 3\H)!M\A2^+ML>Y?"[
MX*(_P]\8?\+AL-.\1>/?CC#<ZE\8LIOM"FJ6,ECIW@3392S/%X=\+Z'-'I%C
MY;KF2WN=0&VYOI78V^0KVVTY=BO\"=>\2^#[Z]_9\^(DNKZCXA\!:>DO@/QU
MJ-M<26WQ,^&4,@M-$U.XU<1FWD\;:1 +?3=:M7=9I)88M017BOBT9MY6!_TC
MY,_X*Z_\FV^"?^RW^&__ % _B505#?Y'YF_!3_@HQ\;?@/\ #+PS\*/"'A;X
M6:CX=\*_VS_9UYXDT3Q;=ZU-_;GB#5?$=W]LN-,\<:?;2;+[6+F./RK2'$4<
M2MO=6D=;?(MQ3?8]3_X>Z_M(_P#0D_!#_P )OQY_\\JF+D7F'_#W7]I'_H2?
M@A_X3?CS_P">50'(O,\"_:,_;I^+?[3G@C2_ 7CWP[\.=(T?2/%5CXNMKGPA
LI'B:PU)]2L-(US1H8)YM9\7:K UB;77[QF1+=)#)%"1*JJZ2+]!J*CL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g7344208.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344208.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MPOM%*O"IAX.;I)NHL/0JUJ>(Q3A9Q:PM*L^=<EN?W3TT?LJ_LX$ CX-> B"
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MG !\+9)A9QI;Q!8Y)I,% <YKOPF>5L%@J6 6#PE>A1E.:]O1E4DYSG*<I/\
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$WG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g7344209.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7344209.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZ$94J;A.A+^'&K.$ZE.'U,\#A<1BLFQ53$Y#Q?Q#&?%D,KS#+L-AJ>63Q]+
MT*F1Y1B*4L-A*=;%X?$*OBL'AZ^#>$J>UP]"A7Q-)S5+K[3Q7INH6?C3P#\/
MO$6K3> K_P")?P@\/:-J\.L:M*+70/&[6LGB_3_"_B.XN6O&TNYATS4(8+B"
MY?RI]6NEMI4"(8N6%"HY954S&A'VL:F;<]-QC&<XX#!U,5A8XFDK)-5G&\)Q
M3JX2%+G4HS][PZ^2XO!5\AXGXGRK#4^)L)PYQ/CL5A987#1Y\?E#JT\KQ&8X
M"%-8=8FC+$8>I6HU*,?:4L+1EB*<Y2J*?T%\,+4>'/%GQ.\#6-Q?2>'M O\
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M,J>64L#/!8ET7@\+C*.:8;#5)TXR4ZN(JUY9=4=H4:6%RN%ZDE7I3CZSX?\
MA[XX;^V=<^(O@I?%3>)?%&H>)=6\%V^I^&]1M(-7N_!_@K2] O;235=0M+.:
M+0Y?#U]8)-*\<Z3W(OK:(*L9CXL37I>RHX? 5G0EA\-B*6'Q+YZ<Z,Z^+JXF
M<I.GSS@ZGUB:4Z7/*G2IJC[WM)N7Q.9\4<.Q>79;PIQ"\FCDV78;+L-FT\/C
MZ%6IA*&:9U7QM*K##T:]>,LSCC\/C)THQE1E1@\%B*LI\ZG!HOPV^(.DZ1=V
M5KX;^R^,M3L=:TCQ9X_2^\.6W_"6'Q%+I&DPZU<26>JMJ&J2Z3:&^U)6U.VA
MGA6Q,%FLDESY3%:KA\1-TW-1RYSJM827M.6,?KU3%648)QIJMAU+"WIRYN;%
M1<^6%.<Z=X_BWAC&8^ABJN;>VR' U\)B\KR5TL?5_LN. HXK$2P,%6PZPN'C
MC:_L,))8.M4H5I5/;XN5.-%5%'>_ IKO2)GU3X;^%M6\2:7X8L_#5IK+:=X5
MU?4]7MM#\36]CILPU#Q#<+<7<\W@&V@M9/[5NHC)&LMI/)L?#/\ M+$\[E#%
MUJ4*]?+Z]6G&7LX>UA4KU,=4]E2:HQ52O[/$<M.*YN:G://3<87AO$AX;&TZ
M>"XNS+ 9/B\?B<?/"K$9EA,-A:F-RYUZL/88&#IT84<[J5:M-X*A/V4^3%4:
M:DDU])?#_1;?P[X3TS1[70(/#$-HU[MT:VTCPWH,%J9[^YN&=-*\(WMWI5KY
MK2F4_9IW+F0R2[97=1RXNM4Q%;VM6O+$3<8)SE.I4E[L%%)RJI3]U*R7PQ5H
MQ;BD?DO$V85LTSO&X^OF<\XJ5_8WQ=3$X_&3J<E"G32>)S*E1QM3V:@J:]M3
MCRJ*A3O2C!OLZYCP0H * "@ H * "@ H * /E?\ ;8_Y-C^)G_<F?^K \*5[
MW#'_ "/,#_W&_P#4>J?M?T=O^3Q<'_\ =5_]4F9'R_!_R5S]@+_LC'AC_P!0
M]J]6I_N?&'_89'_U*D?L=7_DAOI0?]E7CO\ U:F3_P %+O\ D(_![_KR\<?^
MC_"M=7!&V9_]R_\ [G._Z('^Z\??]?<G_P#2,S/&_P!IO_D@7[''_8C^+?\
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M_P!EQO\ _P!-OQ"KW\)_R5^9_P#8)'\L(?NF1?\ *3_&7_9(4/\ T_D1I_\
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M !0!\K_ML?\ )L?Q,_[DS_U8'A2O>X8_Y'F!_P"XW_J/5/VOZ.W_ ">+@_\
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MY80_=,B_Y2?XR_[)"A_Z?R(T_P#G'W_W5[_VM7-_S6G_ '"_]UCB_P"<IO\
MNV?_ '&?4OC#_D_C]GK_ +([>_\ IE^+]>3A/^20S;_L+C_Z5@S\8R#_ )1A
M\4_^RIH_^I?"YK?L(?\ (&^-?_97=7_])8*Y>(_CRG_L78?\YGG_ $E?]_\
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M''GP?\-?^3&OVB_^QX\#?^I%X#KZS&?\E;E/_8-4_P#2,4?TSQ=_RDEX4?\
M8GS?_P!0<Z-/X"?\FC_M2?\ <$_]%QUS9U_R4N2?]PO_ $](XO$__D^O@Q_W
M,_\ I<CU'QQ_J/\ @FC_ -?OA7_TX_!ZL,'_ ,UM_P!Q_P L8?&\-_Q/I?\
M_7K,_P#TQQ2>U?L[?\G3_M7?]A/1_P#TMU"O&S3_ )$?#WIBO_3D#\Z\5?\
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M4H^_3<9.-2,HWMSTY*4914K<T6E)K4\&A_:D\'6_@/QOXG\0Z/K'A_Q7\/\
MQ/+X'U[X8RM;7GB^X\9W5P(/"V@Z%# RIK/_  DB364^EW4($4\-T9"56WF,
M>%Y5</E-; P>,GG,O8X>BK0J1Q5-VQ>&Q',W&A+ \LZF+G)\E+#Q^L7=.4;]
M:I*GC,?A<55AA:>64EBJV(;<J+P,X\]+&4VDI3IU5^[IT^557B4\-R^T2O\
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M_P!0<>?!_P -?^3&OVB_^QX\#?\ J1> Z^LQG_)6Y3_V#5/_ $C%'],\7?\
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M+<91:E%M-,Y,/7IXFC"M2NH2OI).,H2BW&<)Q>L9TY)PG%ZQE%Q>J-ZL#8*
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MC]CJ_P#)#?2@_P"RKQW_ *M3)_X*7?\ (1^#W_7EXX_]'^%:ZN"-LS_[E_\
MW.=_T0/]UX^_Z^Y/_P"D9F>-_M-_\D"_8X_[$?Q;_P"DW@&O0X?_ .1IQ)_V
M$Q_].8D^_P#!S_DY_C]_V.,M_P#3F=GK6L?\DD_8'_[*/H?_ *D5A7D4?^1E
MQ9_V"XS\SX3+_P#DNOI._P#8AQW_ *A5C'T__D"_\%)/^QOB_P#4^^(U=6(^
M+@G_  4__2,(>CB_^1A]$;_L6/\ ]4V0GU=IO_)ADG_9 -5_]1J\KP'_ ,E3
M_P!U-?\ J2?B&+_Y29A_V6^&_P#5C2/@_P#9*_Y)M^UQ_P!D.US_ -,/BVOK
M.(?^1EPW_P!A:_\ 3N&/Z9\<O^2O\"O^ROPG_J;E9I_L.?\ -?O^R0ZK_P"W
M%<W&'_,J_P"OM3_W&<7TD?\ FV'_ &4U#_W&,\<?\H_/@[_V6+5/_0OBG71A
M/^2OS3_L$A_Z3A"^&_\ E*3C_P#[);#_ )<-GU]8?\I!=:_[)%%_Z3Z37R\O
M^25A_P!C'_W#(_!<3_RBWE__ &5,OSQ)\@_\%$/^2ZZ1_P!DXT#_ -/GBBOJ
M.#?^176_["I_^FJ)^]?12_Y-KC_^Q]C?_4++3/\ V\_^2D_#7_LAW@W_ -/W
MC"GP?_R+<3_V%U/_ $U1.KZ,G_)'\7?]E?FG_J%E1]7:U_R<I^QE_P!DNN__
M %$-8KYC"?\ (CXB_P"ON&_]/GX?EO\ R:'Z0/\ V4-#_P!6F%/C_0O^3#_&
M?_9P=K_ZBGA.OJ<3_P E;E__ &!2_/$G[WF?_*3/#O\ V1%7_P!6.9GZ!?M=
M_P#)HNL?]>'PZ_\ 4@\.5\CPU_R/L)ZU_P#TS5/Y;\"/^3ZY=_U^SW_U!QY\
M'_#7_DQK]HO_ +'CP-_ZD7@.OK,9_P E;E/_ &#5/_2,4?TSQ=_RDEX4?]B?
M-_\ U!SHT_@)_P FC_M2?]P3_P!%QUS9U_R4N2?]PO\ T](XO$__ )/KX,?]
MS/\ Z7(]1\<?ZC_@FC_U^^%?_3C\'JPP?_-;?]Q_RQA\;PW_ !/I?_\ 7K,_
M_3'%)[5^SM_R=/\ M7?]A/1__2W4*\;-/^1'P]Z8K_TY _.O%7_DRW@C_P!@
M^,_]-T#XD^/?_)[M]_V47X9_^F[P?7U66?\ ))2_[!L9_P"E5S^B_#+_ )1Q
MH?\ 8BXA_P#3^:D7[4G_ ">9X@_[&7X7_P#J)^"J>4?\DI_W+XS_ -.5S3P9
M_P"4?,L_[%_$7_JRS<^F_BU_R<?^TE_V9_XY_P#4>TZO"RS_ )%.4_\ 8[H?
M^DGXYP+_ ,FF\(_^SI9/_P"IE<\<;_DWS]B/_LKOB/\ ]67J5>A6_P"1SQ1_
MV+G_ .H]$^_?_)T_I%_]DM@O_5!ACZ2_X*/?\DB\&?\ 91[/_P!1GQ-7E\&?
M\C/$?]@L_P#T[1/R3Z)7_)><0?\ 8AK?^K#+CY'\6?\ )@OPQ_[+C?\ _IM^
M(5>_A/\ DK\S_P"P2/Y80_=,B_Y2?XR_[)"A_P"G\B-/_G'W_P!U>_\ :U<W
M_-:?]PO_ '6.+_G*;_NV?_<9]2^,/^3^/V>O^R.WO_IE^+]>3A/^20S;_L+C
M_P"E8,_&,@_Y1A\4_P#LJ:/_ *E\+FM^PA_R!OC7_P!E=U?_ -)8*Y>(_CRG
M_L78?\YGG_25_P!_\._^R6PG_IR9\2?"O_D^G_NL?Q#_ /2OQ17U68_\DC#_
M +!,'^= _HOC7_E&I?\ 9*Y#_P"F\M/?OV6O^3W/VC/^ZO?^K;\/5YN>_P#)
M,9-_W*?^HE0_,?&G_E'3PF_[MC_UF<<?JC7P9_%04 % %<6=HMR;T6MNMXT?
MDM=B",7)B!!$1G"[S'E1\I;' XXH7NW2]U2=VEI=K1-]VEIJ#UY;Z\OPWZ;[
M=MWMW?<L4 % !0 4 % !0 4 % !0 4 % !0 4 11P0PM(\4,43S-OE:.-$:5
MP,!Y&4 NV.YR:-DELE>RZ:[Z>?4N52I-0C.<I*FN6*;;45VBF_=7DK(EH((Q
M#"LK3B*-9F01M,$42LBG*HT@&XH#T!.!1LFMDW=KS6B?JEH6YSY%3YY>SBVU
M&[Y4WNU'9-]6D24$$;0PO)%*\4;2P;O)D:-6DAWC:_E.1F/<O!VD9'!H6E[:
M7T?IV+4YQC.G&<HPG;FBFU&7*[QYDM'RO57V>Q)001RPPSQM%/%'-$V-T4J+
M)&VTAEW(X(.& (R.H'I1LUT<=O+T[%PG.E)3I3E3G':46XR6EG9JS6FGH2=/
M;'X8Q00% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % ',^-=)M]>\&^+-"NWGBM-8\-:YI5U);-&EQ';ZAIE
MU:3/ \L<B),L<K%2\;J& )5AP>+,<-#%X'%86HY1IUX.$G%I22>CLVFD^UT_
M0[,OKSPF.P6)II.IAZ]*I%23Y>:G.,DI)-.UUK9IVV:/&/V5_A3X=^"_PDL/
M GA:\UJ_TBRUK6[Z*XU^XL;K4C+J-RMQ.LDVG:=8PF-7.$ MU('4L>:]G%5Y
MUJ6 A)**PV']E&R:]U8BO4O*[>MZC6EE9+2]V_)P]&-*MCZD6[XFO&K).UE)
88;#T4HV2LN6E%ZMOF<M;62^C:XSJ/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g734420g08i61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g734420g08i61.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1B(4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $G    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    B %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0
M #$ , !< $$ 6@ P #$ -0 Q "T > !E '( ;P!X "T ,@ S       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0(D            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M     #^    X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              )H   %&@         !
M          $             !1H   )H                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   )H     %)G:'1L;VYG   %&@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   ":     !29VAT;&]N9P  !1H    #=7)L5$585     $
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M!!0       0    $.$))300,      Z^     0   *    !+   !X   C*
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M_@ZZV*OU7J>+TGIN3U+,=MQ\6LV/U )CZ-=?J.8QUMK_ -%2S?\ I+5;6/\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)22H "
M  X   $$  $   #0!0   0$$  $   "Z @   @$#  ,   "V     P$#  $
M   !    !@$#  $    "    $@$#  $    !    %0$#  $    #    &@$%
M  $   "\    &P$%  $   #$    ' $#  $    !    * $#  $    "
M,0$" !X   #,    ,@$" !0   #J    :8<$  $      0  + $   @ "  (
M   2>@ 0)P   !)Z ! G  !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$V.C$P.C V(#$V.C$V.C R     P !H ,  0   /__   "H 0  0
M !H%   #H 0  0   &@"           &  ,! P !    !@   !H!!0 !
M>@$  !L!!0 !    @@$  "@! P !     @    $"!  !    B@$   ("!  !
M              !(     0   $@    !    .$))30/]       (
M  #_X0&,24DJ  @    .   !!  !    T 4   $!!  !    N@(   (! P #
M    M@    ,! P !     0    8! P !     @   !(! P !         !4!
M P !     P   !H!!0 !    O    !L!!0 !    Q    !P! P !     0
M "@! P !     @   #$! @ >    S    #(! @ 4    Z@   &F'!  !
M  $  "P!   (  @ " #  P   0   , #   !    061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-CHQ,#HP-B Q-CHQ-CHP,@    ,  : #  $
M  #__P   J $  $    :!0   Z $  $   !H @          !@ # 0,  0
M  8    : 04  0   'H!   ; 04  0   ((!   H 0,  0    (    ! @0
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M 0$! 0$! 0$! 0$! 0'_P  1" !* )T# 1$  A$! Q$!_\0 &P !  (# 0$
M              <)! @*!0;_Q  I$  !! ,! 0 " @(" P$    $ P4&!P$"
M"  )$1(4%1,A%B(7&#$C_\0 % $!                     /_$ !01 0
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MDK4?5FKR(!M8<*KAI7PB/#JFAD-C*>-!6)//@@3Y3D2.V:RO+MZ7J:KG=W]
MRR[:VQE)8=1HY>B[0PT]RRRX'W&$131<:DKYJLI=5!';#D]62]/"A*ZCEG_&
M%IW@>!X'@T7[_HV=VQ4,;G]*KC!=%\N6(S=(T,JNVBG8D,M@[2^MLEJHI9;<
M<D!FNZN)!,ZE>"PS@]A4)<DX+[+H@;#JAK%\IK6C71=@_2?IRN3GHBI;UZVI
MB2U\A((DM&G9--J^<_$+-)\GJ&IZ'JNC3)4#X-(F3;<@&,RJ$OP(Q*I:[EG
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M^D_*(G2UE4)QP\6;0]NF(<=<@5)5+E-FA\3@;0HT-;L(E%7F#M,Z>8 5T%+
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M16;%3&68-!X_DDV8.NXMG]((YG@A8MC&,8QC&,8QC&,8QC'XQC&/]8QC&/\
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5D>!X'@>!X'@>!X'@>!X'@>!X/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g734420g33q91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g734420g33q91.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1:24&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :"(U0         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  !R   "*@         !                          $
M BH   !R                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   !R     %)G:'1L;VYG   "*@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    <@    !29VAT
M;&]N9P   BH    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     $X0DE-! P     # (    !    H    "$   '@   ]X   "^8
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M;X1O75&E;/\ _]"]U"A^/GY-#Q!98_0]VN.]G^?6Y8.?@>C-U(_0_G-_<_\
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MBWU_LK-GJENS=J73LW/V_2_>6BDE9JD/_]'U5)?*J22GZJ27RJDDI^JE0O\
M^6L/_P +Y/\ U>(OF1)$?Q4'Z)L_GK/_ $Y6?^V;U6_P?2__  K@?^W6&OG]
M)/[?1<_171O^4?\ KG4__;K'6?5_R+D?^%^F_DK7@J277[/^DI]<S/Z=]??^
M(J_ZERGC_P!%^H'_ !COR,7D"2DZ#^7^33_+_FOT;U/_ +WO_3>S_J,Q<UU'
M_P 7O4?_ $U5?^W&(O%TDR'7R_[U ?9?\9/_ "3U/_P]B_\ GA:/U4_\77UH
M_K4_D7A*2/\ D_I_WB?T7ZJ27RJDH5C]5)+Y5224_P#_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ '77"   G$  ==<(  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-#HR-B Q,#HT
M-#HR- !R<C(Y-#8R,0       Z !  ,    !__\  * "  0    !   "*J #
M  0    !    <@         & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C(V(#$P.C0T.C(T ')R,CDT
M-C(Q       #H $  P    '__P  H ( !     $   (JH , !     $   !R
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ .0$4 P$1  (1 0,1 ?_$ !\
M  $$ P # 0            D !@@*! 4' @,+ ?_$ %T0   & 0," P(%"PL-
M$0    $" P0%!@< "!$)$A,4(0HQ%2(X05$6(SEA<79W>+6VMQ<9)S(W.D)U
ML;+P)3,V1%)7<X:1EK/1U2@T0T5367)Y@9*3H:?!Q]+A_\0 '0$  00# 0$
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MP)D-C&W3?F1TV&.95N734?I'WR$FRRKROMLUK@$]-S>V"_ZJ^(_"T8,+1@Q
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M>FK8F!MI<$[\T-UMW#4I87W ZWWOR'.^&_=C(^*^$LPC#+79/5RP^BKJM91
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M>#C#)4SFB51G%"@2MA4C7*J ZA:P.P.N [ZD+K_9QBH1,TI!4PK_ $F%0)5
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MKY%<6 CB;B(,+GW<S=2+D;+7U %^O6W.]Q;G>_V^X-(/"'"K)?2>'<E(-_\
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MAMA'LI?]7)_P-_ECLY#D4(11,Y5$U"E.0Y# 8AR& #%.0Q1$IBF*("4P"("
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M!T=FJZO'0I'UW]GCBW?YMJ/]LM__ !D__MKF.*YCVD435 134(H #P(D,4X
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M^%R?/M]_%?[V68>8[?#^%"L^GW$9SC^35U\HVQR;?_1Y.7BZ?LO?Z-L3&?\
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M$0#AYF.;YAFIA-?/V_FZ%(O01-"L02+(%&Y WM?;G8 !6>JGJ=';/K[-=*[
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M( 1W-E7<@DW[N7+GC002M$\P7WN-E5SW%C8=-_'NZXU=WW68-QUG#'.W:VW
M(S*V4VBCRHP7P;)+M5B?U0*P2DIA%L>+B',XK$2J$"WD'2"LNXC7J+,ISHB
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M)MRQ,14JRO6XY-"0L$O:I8Y">?G9H[<';Q4  #"FU8HM8]BAR')&S-LF0O\
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@3Y ^QL7=M<BQ6,+1@PM&#"T8,+1@PM&#"T8,+1@Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g734420g85m10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g734420g85m10.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1:X4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(S,S,Q-C@< @4
M0$UI8W)O<V]F="!7;W)D("T@15E05" M(%1R86YS:71I;VX@4&5R:6]D(%!R
M;WAY(%-T871E;65N="!$<F%F=%\ .$))300E       0<@E4W,H"F0 ;0)8O
MS2*;?3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _0      !( -0    $ +0
M  8       $X0DE- _<      !P  /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              ""   !G0         !
M                      $              9T   ""
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   ""     %)G:'1L;VYG
M   !G0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    @@    !29VAT;&]N9P   9T    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M#)0    !    H    #(   '@  !=P   #'@ &  !_]C_[0 ,061O8F5?0TT
M __N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( #( H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ /4ZZZZF-KK:&5L :QC0  T:-:UH^BUJDF6?D=8;
M]I?@]/J.=FU_SK&NVU4S]'[9E0]E'YOZ"ME^;L_2LQ'U>])3HI+#ZA=US$Z;
M?GY.9BX[J&.L;572][-W^"H?;9;ZN1ZC_P!#^@HQKKO4_1?I%7'4^L]<<<?I
MK#@5-&W)R'@N+':-LI:_VL?E5V>K4_'Q_P"9_P"U6;@9E/[/O2G<?U#"9G,Z
M>ZYGVVQAL;C@S9Z8G],YC?<RG<W9ZK_T?J?HT=4NE]&P.EML^RU_IKR'9.0^
M#;<X?X2^W\_G_BZ_\$KR2E))+/R^KMKR#@X-1SL\1OI80UE0<)99G9!W-QJW
M?N;;LNW^<Q\6_98DIT$EDW=/MNI?=UG.<VEC7.LJQWNQ:&- W.=;>Q[<NSTV
M[_4L?DU8[_\ N+6J73<7IKLAO6J,:OI?3,&JST;7,&.ZYKA^FRLB178S K8W
M?4W*_I%OZY95^@Q+K4IZ-!R<O%Q*3?EW5X]+>;+7!C1\7O+6K#SNOYES6-PZ
MK,9N3(Q-U<YE\']*_$P+_39AT,8YO^4.J?HJ+/Y_!]*RGUK>-T[IV!0WJ74M
MIRZV[[LS+L]9U9/\X*LBUM=>/7O_ ,'BU8M'_ I*2MZYC71]BIR,P&2'U5.;
M60.[,G)^SXUG_6KGH_3>I4]1H?=2RQ@KMLHL;8V"+*G&FYK7-W56M;8W;ZE%
MEM7]O>LO,ZG9?4+\E]G2>EEXK:7M<S,RG'Z%&+CM'VK%];_!L97^U;_\%3A>
MFRVZ=/3LKJ=+&9M?[.Z4QNRKI-4-<^L#:QN?;0=M=7_FOPW^EL_I61DU6_9:
MDI-;UFS*L?B]$K&7:PEEN6XQBTN&AWW-]V5<QW_:7#W_ *3]%E787\XK.#@7
M4.-V5E69>2\0YQ]E30==F/BL_1UUM_,]3U\G_2Y-JM5554U,II8VNJMH976P
M!K6M:-K6,8WVM:UJFDI2228I*4G5+I]O4<D'(RZQB5ND5XAAUK0#&[(N8Y]6
MYW^CQ_97_P!R+U=24__0],SL:W+H]!E[\9KS%ME6EA9^<RJW_ .?]'UF?I6?
MX'TKO3NKJY69TCZN=/97M;10P$4T,@$GZ=A]Y:WZ3M]U]S_YRS]+9ZEJ/U3J
M3.GX_J;/6OL.S'H!#2]\%T;W>VNMC&^K?=_@:=]JY2GHG5NNYUN>[*:,>QE?
MH=2#'!X@EU[>DT/?L]!V[;A]6N_2U5_I<&BRS+MZI<E)\7%R/K3>^[K%8'2\
M=W\T2YK76M/\S4UPJLJ9B.;^M9-FS-NR/U2ROIM?[2Z2M7'^LO1FV/Q\?;7T
MW#:VK[<"QF+ZOM;5T_#<'?K-[6?X/&K].K^9_GOT2R/^:F;U*R["SV&GI# :
M:VVN8^QS&^RMV)B8H;TSIU/I;JZ/2Q_MC/9;=8^W^8Z'IWU?Z+TMM8P,.JDT
MM+*GANY[6D[G,;=9OMV.<[=]-)2NG];QNH9=V+CU7M..QK[++:S6T%^K*7,M
MV7UW^G^F]&ZFNST;*K?\+6M!865]5,>S#./CY6178VQMM3[;;K6-(N;F6;J6
MWT>KZ[O4KLN]3[3LNL_3K3ZB>I#$>>F-H?FQ%7VESFU G\^ST6V6.V_Z-OT_
M]+6DI!U;,O9;C=/Q'>GDYI>77:'T:*@#E9;6O#JW6,]2C'H]1KZ_M&339;5=
M3794J./USH.&7=,Z'79U+(K.ZRG"!N]]A>YUF9U"UPQ&7V.98^VS-S?M%O\
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M\,^E_P!V/])_UM;*^54DE/U4DOE5))3_ /_9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  D   "PAVD !     $   "\    Z  AD<   "<0 "&1P   )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C T.C(W(# X.C(W.C U ')R
M,S,S,38X       #H $  P    '__P  H ( !     $   &=H , !     $
M  ""          8! P #     0 &   !&@ %     0   38!&P %     0
M 3X!*  #     0 "   " 0 $     0   48" @ $     0
M2     $   !(     3A"24T#_0      "           _^$!2$U- "H    (
M  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3DZ,#0Z,C<@,#@Z,C<Z,#4 <G(S,S,Q-C@
M  .@ 0 #     ?__  "@ @ $     0   9V@ P $     0   ((
M!@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !
M  (   (!  0    !   !1@("  0    !              /      0   \
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MFSC'3E@W:I2)&Y&CA=$$P364*(2Z'A !_=#;;8  !#?;X@&V_?C?MT!@ "
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MOT!<;>7W^>_W?YZ= D W$=RE -@V'GQ"&XB)>WR'??;??H%% =Q$-@[COO\
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MSCH%\;"!=M^?3UY_OT"##Y;>'U  X'X\<^7Q[!SOT!\"'D&WD/F/W;>GES\
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M"'KL'GST#8E,81W*/?N/;;@!W >>.^P;=N.>@3X% [!P//\ *'Z_X'0.>?\
MM_Z= 0=A^7ZAT"R_P&^_\N@)/^ /F7_KT"%/],O_ ,O_ += 0_R?(O\ PZ O
MY1_W?F/0+'L'R_4>@+H"'L/R'\N@ =@^0?ET#Q^WW_H/08Y>YOG^H] ?\H?[
L?S#H&ENWW!^?0*#^(/D'_'H,LO;^G_$.@:4_T#?+_MT#_0#H!T Z =!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g734420x_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g734420x_1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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%ZRD(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
